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Abstract
In the UK approximately 12,000 new cases of bladder cancer are diagnosed every year. 
Approximately 80% of these cases are non muscle invasive bladder cancer (NMIBC) defined 
as stage Ta-Tl, grade 1-3 and carcinoma in situ. Despite current operative and postoperative 
treatment options there is recurrence rate of 15-61% and significant risk of progression (1- 
17%). Gene therapy strategies have been developed as a therapeutic approach for a number of 
malignances. Gene transfer by viral vectors takes the advantage of the natural ability of 
viruses to enter cells and express transgenes by the infected cells.
OncoVex^^^^^^ is a modified oncolytic herpes simplex virus, where the virus is deleted for 
ICP34,5 region to provide tumour selective replication and also deleted for the ICP47 region 
to increase antigen presentation and the antitumor immune response. The OncoVex^^^^^^ 
virus carries a highly potent prodrug activating gene for suicide gene therapy (Fcyifur gene = 
yeast cytosine deaminase / uracil phospho-ribosyltransferase enzyme gene, the enzyme which 
converts 5-fluorocytosine (5-FC) to active 5-fluorouracil (5-FU)) and a fusogenic 
glycoprotein gene from gibbon ape leukaemia virus (GALV). OncoVex^^^^^^ has shown 
enhanced local tumour control by combining its oncolytic activity with the effect of the 
carried pro-drug activating and a fusogenic gene. Effective use (enhanced cell killing and 
tumour shrinkage) of OncoVex^^^^^^ vector has been previously described in vitro and in 
vivo other tumour sites but not the bladder. A version of this virus expressing GM-CSF has 
shown promising results in Phase I and II clinical trials.
The present thesis aimed to test in vitro and in vivo the OncoVex^"^^^^^ as an intravesical 
therapy for NMIBC and to test the efficacy of the virus in combination with current 
chemotherapies.
In vitro tumour cell killing by OncoVex^^^^^^ was assessed by Fusion/Prodrug MTS assays 
and staining by Crystal Violet. Treatment of seven human bladder carcinoma cell lines with
II
the virus resulted in higher tumour cell killing through oncolysis, pro-drug activation and 
glycoprotein fusion. For the in vivo tests we have developed a rat orthotopic bladder tumour 
model using acid and alkali to damage the bladder mucosa and using AY-27 HVEM cells for 
implantation. We decided to determine the presence of tumour by quantitative reverse 
transcription polymerase chain reaction (QRT-PCR). However while we obtained positive 
signals on bladder tissue, signals using urine samples were insignificant. In vivo efficacy of 
the O n c o t r e a t m e n t  was studied on the orthotopic bladder tumour model, where the 
results showed enhanced local tumour control and higher body weights in the presence of 
both OncoVex^^^^^^ and prodrug when compared to control (No virus + prodrug) or virus 
alone. The effect of O n c o V t r e a t m e n t  in combination with chemotherapies 
(mitomycin, cisplatin, gemcitabine) on cell proliferation was assessed by calculating 
combination index values using CalcuSyn software. The coadministration of OncoVex^'^^^^^ 
and mitomycin showed synergistic, whereas the coadministration Avith cisplatin or 
gemcitabine showed antagonistic effect in vitro.
In conclusion our results on human bladder carcinoma cell lines and rat ortotopic bladder 
tumour model indicate that OncoVex^"^^^^^ may improve local tumour control within the 
bladder and it can be used in combination wdth mitomycin. It is hoped that this Avill lead to 
new therapeutic options for bladder cancer.
Ill
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Chapter 1
Introduction
1 Introduction
1.1 Bladder cancer
1.1.1 Incidence
In the UK approximately 12,000 new cases of bladder cancer are diagnosed every 
year making it the fifth commonest cancer in men and the eleventh commonest cancer 
in women. Bladder cancer causes around 4,700 deaths each year in the UK (Figure 
1.1). Bladder cancer is a heterogeneous disease with a variable natural history. At one 
end of the spectrum, low grade Ta tumors have a low progression rate and require 
initial endoscopic treatment and surveillance, but rarely present a threat to the patient. 
At the other extreme, high grade tumors have a high malignant potential associated 
with significant progression and cancer death rates. The incidence of the disease 
increases by age and it occurs most commonly in people between 50 and 70 years of 
age. The average age at diagnosis is 65 years. Bladder cancer is 3 to 4 times more 
common among males than females. On the other hand, it has been suggested that the 
stage-adjusted survival of bladder cancer among women is worse than among men 
(Mungan, Aben et al. 2000).
The incidence is higher in Caucasians than in African Americans and these 
differences may be partly due to genes, as studies have shown that certain genetic 
polymorphisms linked to an increased risk of bladder cancer (for example, the N- 
acetyltransferase 2 (NAT2 ) slow acetylator polymorphism) are much more prevalent 
in Caucasian than non-white populations (Garcia-Closas, Malats et al. 2005). There is 
a positive social class gradient for bladder cancer in both sexes. Surveys of cancer 
incidence and mortality suggest that parous women have a lower risk of bladder
cancer than nulliparous women, probably due to hormonal changes related to 
pregnancy, and that the risk may decrease with increasing parity (Miller, Barclay et al. 
1980; Plesko, Preston-Martin et al. 1985; Green, Beral et al. 1988; Cantor, Lynch et 
al. 1992)
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Figure 1.1 Number of new cases and age specific incidence rates, by sex, bladder 
cancer, UK 2005 (info.cancerresearchuk.org)
1.1.2 Risk factors
Cigarette smoking is the principal preventable risk factor for bladder cancer in both 
men and women. In Europe it is estimated that up to half the bladder cancer cases in 
men and a third in women are caused by cigarette smoking. Current smokers have 
around three times the risk of developing bladder cancer compared to non-smokers 
while ex-smokers have double the risk of non-smokers. Risk is positively associated 
with both increasing dose and duration of smoking (Brennan, Bogillot et al. 2000; 
Brennan, Bogillot et al. 2001; NICE 2002). The causative agents amongst others are 
thought to be alpha- and beta- naphtylamine, which are secreted into the urine of 
smokers.
Bladder cancer was one of the first cancers shown to be industrially associated. In 
1895 Rehn reported cases of bladder cancer in a German aniline dye factory (Rehn 
1895). Altogether it is estimated that between 5 and 10% of male bladder cancer cases 
in Europe are caused by occupational exposure (Kogevinas, Mannetje et al. 2003). 
This proportion may be higher in countries with less-regulated industrial processes. 
Workers in chemical, dye, rubber, petroleum, leather and printing industries are at 
increased risk. Excess risks have been frequently observed among painters, which is 
thought to be due to exposure to possible carcinogenic constituents of paints like 
benzidine, polychlorinated biphenyls, formaldehyde, and asbestos and solvents like 
benzene, dioxane, and methylene chloride (Steenland and Palu 1999). The latency 
period between exposure and tumour development may be prolonged. A moderately 
increased risk is also found among leather workers and shoe makers, although the 
responsible agent is still un-known (Marrett, Hartge et al. 1986). An excess risk of 
bladder cancer is also observed in aluminum, iron, and steelworkers, which may be 
the result of exposure to aromatic amines and polycyclic aromatic hydrocarbons in 
coal-tar pitch volatiles (Theriault, Tremblay et al. 1984; Romundstad, Haldorsen et al. 
2000; Gaertner and Theriault 2002). Several studies have been performed on 
chlorinated drinking water and bladder cancer, and all of these reported increased 
risks (King and Marrett 1996; Koivusalo, Hakulinen et al. 1998). Other studies have 
evaluated the association between ingestion of arsenic in drinking water and the risk 
of bladder cancer.
Chronic urinary tract infection is associated with the development of bladder cancer, 
especially invasive squamous cell carcinoma (Kantor, Hartge et al. 1984). 
Cyclophosphamide, an alkylating agent used in the treatment of malignant neoplasms, 
particularly lymphoproliferative and myeloproliferative diseases, increases the risk of
bladder cancer (mainly urothelial carcinoma) with a clear dose-response relationship 
(Fairchild, Spence et al. 1979; Travis, Curtis et al. 1995). A chelating agent is now 
given with cyclophosphamide to reduce this risk. Treatment with radiotherapy to the 
pelvic area for cancers such as cervical cancer, prostate cancer, kidney cancer, 
fallopian tube cancer and testicular cancer can increase the risk of bladder cancer 
(Kaldor, Day et al. 1995).
Ingestion of artificial sweeteners has been proposed to be a risk factor, but several, 
studies have failed to confirm any association (Howe, Burch et al. 1977; Elcock and 
Morgan 1993). Physical trauma to the urothelium induced by infection, 
instrumentation, and calculi increases the risk of malignancy (Hicks, Ismail et al. 
1982). Most studies show a two-six-fold increased risk of bladder cancer in first- 
degree relatives of bladder cancer patients, with a higher risk if the relative was 
diagnosed before the age of 45. (Randi, Pelucchi et al. 2007).
Squamous cell carcinoma of the urinary bladder has been known to be associated with 
Schistosoma haematobium infection for many years. The epidemiologic association is 
based both on case-control studies and on the close correlation of bladder cancer 
incidence with the prevalence of S. haematobium infection 'within different 
geographic areas (Gelfand 1967; Lucas 1982; Bedwani, Renganathan et al. 1998).
1.1.3 Pathogenesis
Although many environmental risk factors have been implicated in the etiology of 
bladder cancer, only occupation and smoking are responsible for a considerable part 
of all new cases. Without any doubt, genetic susceptibility will prove to be 
responsible for another considerable part, most importantly by gene-environment 
interactions. The exact genetic events leading to the development of bladder cancer 
are unknown, but they are likely to be multiple and may involve the activation of
oncogenes and inactivation or loss of tumor supressor genes (Olumi, Skinner et al. 
1990). Deletions on chromosome 9 appears to be consistent finding in patients with 
both low-grade, low-stage and high-grade, high-stage disease (Tsai, Nichols et al. 
1990; Miyao, Tsai et al. 1993), which suggest that this may be an early event in 
bladder cancer development. Additional genetic changes have been described that are 
specific for invasive bladder tumours. Chromosome 1 Ip, which contains the c-H-ras 
proto-oncogene, is deleted in approximately 40% of bladder cancers (Olumi, Skinner 
et al. 1990). Increased expression of the c-H-ras protein product, p21, has been 
detected in dysplastic and high grade tumours but not in low-grade bladder cancers. 
Deletions of chromosome 17p have also been detected in over 60% of all invasive 
bladder cancers, but 17 p deletions have not been described in superficial tumours. 
This finding is noteworthy because the p53 tumor supressor gene maps to 
chromosome 17p. p53 alterations represents the most commonly identified genetic 
abnormality in human cancers, making deletion of this chromosome an important 
finding in muscle invasive bladder cancer. The role of NAT2 slow acétylation 
phenotype or genotype and bladder cancer is most fi*equently studied. In a meta­
analysis of 22 studies, it appeared that slow acetylators have a 40% (95% Cl 1.2 to 
1.6) increased risk of bladder cancer. This increased risk, however, may be different 
in different populations (higher in Asians and lower or even absent in United States 
Caucasians) (Marcus, Hayes et al. 2000).
Schoenberg and Sidransky et al. discovered a new bladder cancer gene at 20ql 1. This 
gene, CDC91L1, encoding CDC91L1, which is also called phosphatidylinositol 
glycan class U (PIG-U), has a role in the glycosylphosphatidylinositol (GPI) 
anchoring pathway. Further research suggested that the gene is amplified and
overexpressed in as many as one-third of bladder cancers and primary tumors. 
CDC91L1 should therefore be regarded as an oncogene (Guo, Linn et al. 2004).
1.1.4 Staging
The stage of a cancer describes its size and whether it has spread. The most 
appropriate treatment depends on the stage of the cancer. The most commonly used 
staging system for bladder cancer is the TNM system of the European Association of 
Urology (EAU), in which T is the size of the tumour, N is whether it has spread to the 
nearby lymph nodes, M is whether the cancer has spread to other parts of the body 
(métastasés) (Figure 1.2).
Tumour size (T):
Superficial bladder cancer
CIS CIS (carcinoma in situ) is a high -grade (anaplastic) carcinoma confined to the 
urothelium, but with flat non-papillary configurations. CIS appears as reddened and 
velvety mucosa and is slightly elevated but sometimes not visible.
Ta These tumours are confined to the urothelium, have a papillary configuration of 
their exophytic part and do not penetrate from the urothelium into the lamina propria 
or detrusor muscle.
T1 tumours generate from the urothelium but penetrate the basement membrane 
which separates the urothelium from the deeper layers. T 1 tumours invade the lamina 
propria but not so deep that they reach the detrusor muscle.
Invasive bladder cancer
T2 The cancer has started to grow into the muscle of the bladder wall under the 
connective tissue layer.
T2a The tumour invades the superficial muscle.
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T2b The tumour invades the deep muscle.
T3 The cancer invades the perivesical tissue.
T3a microscopically 
T3b macroscopically 
Locally advanced bladder cancer
T4 The cancer has spread outside the bladder to any of the following: the prostate, 
uterus, vagina, pelvic or abdominal wall.
T4a The cancer has spread to the prostate, uterus or vagina.
T4b The cancer has spread to the pelvic or abdominal wall.
Fat
Muscle
Connective tissue 
Bladder lining
CIS
Figure 1.2 T stages of bladder cancer 
Lvmph nodes (N):
The N refers to whether the cancer cells have spread into the lymph nodes.
NO There are no cancer cells in any lymph nodes.
NI There are cancer cells in one lymph node smaller than 2cm across.
N2 There are cancer cells in one affected lymph node larger than 2cm, but smaller 
than 5cm, or more than one node affected, but all of them smaller than 5cm across.
N3 There are cancer cells in at least one affected lymph node larger than 5cm across.
Métastasés (M):
MO if the cancer cells have not spread.
M l is when the cancer cells have spread to other parts of the body. If bladder cancer 
spreads, it’s most likely to go to the bones, the lungs or the liver.
1.1.5 Grading
The grading system is also very important in the classification of bladder cancer. The 
grading system describes the anaplastic degree of the cancer cells.
Grade 1 is well differentiated tumour.
Grade 2 is moderately differentiated tumour.
Grade 3 is poorly differentiated tumour.
1.1.6 Histopathology
The normal urothelium is composed of 3-7 layers of transitional cell epithelium 
resting on a basement membrane composed of extracellular matrix (collagen, 
adhesive glycoproteins, glycosaminoglycans). The epithelial cells vary in appearance. 
The basal cells are actively proliferating cells resting on the basal membrane; the 
luminal cells, perhaps the most important feature of normal bladder epithelium, are 
larger umbrella-like cells that are bound together by tight junctions. Beyond the
basement membrane is loose connective tissue, the lamina propria, in which 
occasionally smooth-muscle fibres can be identified. The fibres should be 
distinguished from deeper, more extensive muscle elements defining the true 
muscularis propria. The muscle wall of the bladder is composed of muscle bundles 
coursing in multiple directions. As these converge near the bladder neck, 3 layers can 
be recognized: inner and outer longitudinally oriented layers and a middle, circularly 
oriented layer.
According to the WHO/ISUP system all bladder tumour cases are devided into four 
groups.
1.1.6.1 WHO/ISUP system
1.1.6.1.1 Papilloma
The WHO/ISUP system has very restrictive histologic features for the diagnosis of 
papilloma, where normal appearing urothelium lines papillary fi*onds. Defined as 
such, it is a rare benign condition typically occurring as a small, isolated growth seen 
primarily in younger patients. The majority of these lesions once excised will not 
recur (McKenney, Amin et al. 2003).
1.1.6.1.2 Papillary Urothelial Neoplasms of Low Malingnant Potential 
(PUNLMP)
The category of PUNLMP was derived to describe lesions that do not have cytologic 
features of malignancy, yet have thickened urothelium as compared to papilloma. 
There is no or very little variation of nuclear features or the pattern of organization. 
Having a category of PUNLMP avoids labeling a patient as having cancer with its 
psychosocial and financial implications, although they are not diagnosed as having a 
benign lesion, whereby they might not be followed as closely. The current 
classification system allows for designation of a lesion (papillary urothelial neoplasm
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of low malignant potential), that biologically has a very low risk of progression, yet is 
not entirely benign.
1.1.6.13 Low and High grade papillary carcinoma
The WHO/ISUP system classifies papillary urothelial carcinoma into only 2 grades. 
Low grade papillary urothelial carcinoma exhibits an overall orderly appearance but 
has minimal variability in architecture and/or cytologic features, which are easily 
recognizable at scanning magnification. High grade papillary urothelial carcinomas 
are characterized by a disorderly appearance due to marked architectural and 
cytologic abnormalities, recognizable at low magnification. It is important to 
remember that a single papillary urothelial neoplasm may contain a spectrum of 
cytologic and architectural abnormalities.
Bladder cancer can be classified by the histopathological type.
1.1.6.2 Histopathological type
1.1.6.2.1 Transitional cell carcinoma
Approximately 90% of all bladder cancers are transitional cell carcinomas. These 
tumours most commonly appear as papillary, exophytic lesions, less commonly they 
may be sessile or ulcerated. Whereas the former group are usually superficial in 
nature, sessile growths are often invasive.
1.1.6.2.2 Nontransitional cell carcinomas
1.1.6.2.2.1 Adenocarcinoma
Adenocarcinomas account for less than 2% of all blader cancer. Primary 
adenocarcinomas of the bladder may be preceded by cystitis and metaplasia. 
Histologically adenocarcinomas are mucus secreting and may have glandular, colloid 
or signet-ring patterns. Whereas primary adenocarcinomas often arise along the floor
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of the bladder, adenocarcinomas arising from the urachus occur at the dome. Both 
tumour types are often localized at the time of diagnosis, but muscle invasion is 
usually present. Five-year survival is usually less than 40%, despite aggressive 
surgical management (Kramer, Bredael et al. 1979; Malek, Rosen et al. 1983; 
Abenoza, Manivel et al. 1987; Wright, Bernstein et al. 1988).
1.1.6.2.2.2 Squamous cell carcinoma
Squamous cell carcinoma account for between 5% and 10% of all bladder cancers and 
is often associated with a history of chronic infection, vesical calculi, or chronic 
catheter use. It may also be associated with bilharzial infection owing to Schistosoma 
haematobium, because squamous cell carcinoma accounts for approximately 60% of 
all bladder cancers in Egypt, parts of Africa and Middle East, where this infection is 
prevalent (El-Bolkainy, Mokhtar et al. 1981). These tumours are often nodular and 
invasive at the time of diagnosis. Histologically they appear as poorly differentiated 
neoplasms composed of polygonal cells with characteristic intercellular bridges.
1.1.6.2.2.3 Undifferentiated carcinomas
Undifferentiated bladder carcinomas, which are rare (accounting for less than 2%), 
have no mature epithelial elements. A small cell type has been described that 
histologically resembles similar lesions of the lung (Mills, Wolfe et al. 1987).
1.1.6.2.2.4 Mixed carcinoma
Mixed carcinomas constitute 4-6% of all bladder cancers and are composed of 
transitional, glandular, squamous or undifferentiated patterns. The most common type 
comprises transitional and squamous cell elements (Murphy 1989). Most mixed 
carcinomas are large and infiltrating at the time of diagnosis.
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1.1.6.2.2.5 Rare epithelial and nonepithelial cancers
Rare epithelial carcinomas identified in the bladder include villous adenomas, 
carcinoid tumours, carcinosarcomas and melanomas. Rare nonepithelial cancers of the 
urinary bladder include pheochromocytomas, lymphomas, choriocarcinomas and 
various mesenchymal tumours (hemangioma, osteogenic sarcoma and myosarcoma) 
(Murphy 1989). Cancers of the prostate, cervix and rectum may involve the bladder 
by direct extension. The most common tumours metastatic to the bladder include (in 
order of incidence) melanoma, lymphoma, stomach, breast, kidney and lung 
(Goldstein 1967; Murphy 1989).
1.2 Non-muscle invasive (superficial) bladder cancer
1.2.1 Non-muscle invasive bladder cancer
Approximately 80% of all bladder cancer cases are non muscle invasive bladder 
cancer (NMIBC) defined as stage Ta-Tl, grade 1-3 and carcinoma in situ (CIS). 
Historically these tumours were viewed as a homogeneous group, referred to as 
‘superficial’ bladder cancer and treatment was based at reducing recurrences. In the 
1980’s it was recognised that a subgroup of these patients with TI 03 tumour and/or 
CIS had a significant rate of progression to muscle invasive disease and a poor long 
term survival (Cookson, Herr et al. 1997) which led to the concept of ‘high risk’ 
NMIBC. Further studies have now shown that these ‘superficial’ tumours in fact form 
a heterogenous group of tumours whose 1 year recurrence and progression rates vary 
from 15-61% and <1-17% respectively (Table 1.1) (Sylvester, van der Meijden et al. 
2006). As it is shown in this table low and intermediate risk patients have much less 
risk of recurrence and progression compared to the high risk group.
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% of
total
Recurrence 
1 year
Recurrence 
5 year
Progression 
1 year
Progression 
5 year
Low risk 
TaG l
50 15-24 31-46 <1 1-6
Intermediate risk 
Ta-1 GI-2
35 24-38 46-62 <1-5 1-17
High risk 
Ta-I G3
15 24-61 46-78 1-17 6-45
Table 1.1 EORTC risk tables Sylvester 2006
Based on the developing understanding of the pathological behaviour of NMIBC, the 
therapeutic options for the management of NMIBC have evolved over the last half 
century. Initially, treatment was transurethral resection (TURBT) alone until Jones 
and Swinney first described the use of intravesical chemotherapy using Thiotepa in 
1961 (Jones and Swinney 1961). After TURBT the use of Bacille Calmette-Guerin as 
intravesical immunotherapy in NMIBC was first reported by Morales in 1976 
(Morales, Eidinger et al. 1976). and refined with the introduction of a maintenance 
regime by Lamm (Lamm, Blumenstein et al. 2000). Radical cystectomy was 
advocated as a treatment for ‘high risk’ NMIBC (Malkowicz, Nichols et al. 1990). A 
single immediate instillation of intravesical chemotherapy has been shown to be of 
benefit (in terms of recurrence and progression) immediately following transurethral 
resection of bladder tumour (TURBT) (Sylvester, Oosterlinck et al. 2004).
The wide spectrum of pathological behaviour of NMIBC has led to the realisation that 
in some cases eg a solitary pTa TCC, the main therapeutic goal should be to prevent 
recurrences with minimal morbidity (Hall, Parmar et al. 1994), whilst in other cases 
relatively high morbidity is acceptable in order to prevent progression to muscle 
invasive disease. Out of this has been borne the concept of NMIBC risk groups. 
Whilst the exact definition of each risk category varies (Hall, Parmar et al. 1994; EAU 
April 2008), two groups are clearly defined, i.e. low and high risk NMIBC.
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1.2.2 Current therapeutical options for NMIBC
Current guidelines suggest that all patients with non muscle invasive bladder cancer 
should receive one immediate post operative instillation of chemotherapy within 6 
hours after TURBT. Further treatment depends on the patients' risk of recurrence and 
progression to muscle invasive disease (Sylvester, van der Meijden et al. 2006). Low 
risk group patients have single, small (<3cm), histologically Ta, low grade tumour. 
For these patients no further treatment is recommended prior to a subsequent 
recurrence (Hall, Parmar et al. 1994; EAU April 2008). Patients with Ta-Tl, high 
grade tumour, or with carcinoma in situ, or with combination of these are in the high 
risk group. For this group a further transurethral resection (re-TURBT) and 1-3 years 
of maintenance BCG (bacillus Calmette-Guerin) intravesical immunotherapy is 
recommended (EAU April 2008).
1.2.3 Intermediate risk NMBC
The remaining group with intermediate risk forms approximately 35% of all NMIBC 
and is by definition made up of patients excluded from the other risk categories. 
(Patients with Ta-Tl, low and intermediate grade, multifocal, >3cm tumours attend to 
this group). Intermediate risk group patients form a heterogeneous group of patients 
e.g. from solitary but recurrent GlpTa to multiple recurrent G2pTa. These patients 
have a significant risk of recurrence of between 24% at 1 year and 62% at 5 years, and 
a single instillation of intravesical chemotherapy is inadequate treatment. On the other 
hand, the relatively high morbidity of intravesical BCG, particularly during 
maintenance treatment, has meant that the use of BCG in this group has not been 
popular, at least in Europe. The current popular therapeutic option is weekly 
instillation of intravesical chemotherapy for 6 weeks (induction course) with or 
without maintenance therapy. However, the EORTC risk tables suggest a risk of
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progression as high as 17% at 5 years, which suggests that some patients within the 
intermediate group may have a significant risk of progression, and would therefore 
benefit from a more intensive treatment than is currently used even if this results in 
higher morbidity. Unfortunately we currently cannot identify such patients 
individually, and so efforts are focused on new approaches to the therapy of these 
patients as a group, with the ultimate aim of reducing recurrences, preventing 
progression with acceptable morbidity.
1.2.4 Current therapeutic options for intermediate risk NMIBC
Four national and international urological association guidelines are available for 
NMIBC (Oosterlinck, Solsona et al. 2005; Hall, Chang et al. 2007; BAUS 2008; EAU 
April 2008). All four guidelines recommend that all patients with intermediate risk 
(IR) NMIBC should receive one immediate instillation of chemotherapy after 
TURBT.
1.2.4.1 Induction course of intravesical chemotherapy
Whilst all the guidelines agree that further treatment is required, no clear consensus 
emerges as to the optimal dose, regimen and duration of treatment. The summary of 
product characteristics for mitomycin-C (Kyowa Hakko UK, Slough, UK) suggests 
that 20-40 mg of mitomycin-C in 2 0 ^ 0  mL of diluent is given weekly or three times 
a week for a total of 20 doses (Kyowa). Many urologists seem to prefer a 6-week 
course of weekly intravesical chemotherapy, often called an ‘induction’ course, 
perhaps because this regimen is similar to the induction regimen for intravesical BCG.
1.2.4.2 Maintenance intravesical chemotherapy
Maintenance regimens of intravesical chemotherapy are based on the hypothesis that 
a prolonged course of intravesical chemotherapy will reduce the recurrence rate of
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bladder cancer by more than one immediate instillation or an induction course, with 
acceptable morbidity. It is not known whether maintenance chemotherapy is 
necessary if one dose of intravesical chemotherapy was given immediately after 
TURBT, and vice versa, i.e. that if a maintenance course of intravesical chemotherapy 
is given for in intermediate risk NMIBC, then an immediate instillation may not be 
necessary. If one immediate instillation is not given, then a prolonged course of 
intravesical chemotherapy of 1 year might be required to achieve the same magnitude 
of reduction in the recurrence rate (EAU April 2008). Given the simplicity and safety 
of an immediate instillation, it would seem sensible to pursue the former approach 
rather than the latter. Finally, there is a theoretical risk of carcinogenesis with 
prolonged use of any chemotherapeutic agent.
1.2.4.3 Optimizing intravesical chemotherapy
It was postulated that the variable response of patients to intravesical chemotherapy 
has two components; lack of sensitivity of the tumour to intravesical chemotherapy 
and inadequate drug delivery to the tumour (Au, Badalament et al. 2001). The latter 
might be improved by optimizing intravesical chemotherapy. Au et al. (Au, 
Badalament et al. 2001) assessed, in a randomized phase III trial, four approaches 
combined to optimize the efficacy of intravesical mitomycin C. Patients were 
randomized into either standard intervention and received 20 mg mitomycin C in 20 
mL of sterile water, or optimized intervention, and were asked to refrain from 
drinking for 8 h before treatment, given a total of 3.9 g of sodium bicarbonate orally, 
and had any residual urine drained from the bladder before receiving 40 mg 
mitomycin C in 20 mL of sterile water. The optimized arm showed a longer median 
(95% Cl) time to recurrence of 29.1 (14.0^4.2) months and a greater 5-year 
recurrence-free fraction of 41.0 (30.9-51.1)% than the standard arm, of 11.8 (7.2-
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16.4) months and 24.6 (14.9-34.3)% respectively (P =0.005, log-rank test for time to 
recurrence). Despite the relative simplicity of the optimization schedule and the 
improved efficacy, optimized intravesical regimens have not been widely adopted. 
Another simple way to increase the time of residence in the bladder is prolonged drug 
infusion into the bladder. Other methods have included triblock copolymers which 
release drug over time and in response to temperature.
1.2.4.4 BCG: Reducing side -effects
BCG therapy remains the reference standard non-surgical treatment for high-risk 
NMIBC and might therefore be, theoretically at least, the optimum therapy for 
intermediate risk NMIBC. In practice, BCG is associated with relatively high 
morbidity, with up to 25% of patients failing to complete a full maintenance course of 
BCG. To avoid this, recent studies have assessed various means of reducing the 
toxicity of BCG therapy whilst maintaining its therapeutic effects. The Spanish 
CUETO group have examined this issue. In a series of methodical trials they showed 
that 27 mg of BCG Connaught strain (one-third dose) had lower toxicity than 81 mg 
(full dose) but was as effective as a full dose for high-risk disease; 13.5 mg BCG was 
not as effective as 27 mg but produced the same toxicity, so 27 mg of BCG seems to 
be the minimum effective dose (Femandez-Gomez, Solsona et al. 2008). A further 
study suggested that monthly single instillations of 120 mg BCG for 1 year was as 
effective as 3-week courses of maintenance BCG at 3, 6, 12, 18 and 24 months, in 
terms of recurrence and progression rates, and with less toxicity (Ali-El-Dein 2007). 
The EORTC 30962 study assessed at the one-third vs full-dose BCG over 1 or 3 years 
of maintenance. The study closed in 2005 and the results are eagerly awaited. Finally, 
a randomized double-blind placebocontrolled multicentre trial showed that
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prophylaxis with 200 mg ofloxacin after each BCG instillation reduced the incidence 
of BCG-induced side-effects (Colombel, Saint et al. 2006).
1.2.4.5 Device-assisted therapy
Another approach to improving the delivery of intravesical chemotherapy drugs to the 
tumour is with device-assisted therapy. The two main methods are with microwave 
hyperthermia to heat the bladder wall, or electromotive drug administration (EMDA). 
The theoretical base of EMDA (Di Stasi, Giannantoni et al. 2006) and 
thermochemotherapy (Gofrit, Shapiro et al. 2004; van der Heijden, Kiemeney et al. 
2004) is to increase the permeability of the bladder mucosa (with BCG induced 
inflammation and with hyperthermia in the bladder) before administering 
chemotherapy eg. Mitomycin. A very small electric current increases the permeation 
of charged and neutral compounds through the process of electromigration and elecro- 
osmosis. Microwave hyperthermia was designed to be used exclusively in the setting 
of high-risk NMIBC and patients in whom intravesical BCG failed. The use of 
EMDA-potentiated mitomycin C alone has been described but it appears to be 
particularly effective when used in conjunction with BCG (Di Stasi, Giannantoni et al. 
2006). In this randomized trial specifically in patients with stage pTl disease (i.e. 
high-risk NMIBC) the combination of EMDA, mitomycin C and BCG when used 
sequentially showed a higher mean (95% Cl) disease-free interval than BCG alone, at 
69 (55-86) vs 21 (15-54) months, respectively. That study was also unique in that it 
was the first study of intravesical therapy to show a reduction in disease specific 
mortality and overall mortality. The authors hypothesised that the mode of action in 
sequential BCG/EMDA mitomycin C is that BCG-induced inflammation increases the 
permeability of the bladder wall and improves the delivery of the mitomycin C to the 
tumour site. Thus sequential BCG/EMDA/mitomycin C might have a role in
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intermediate risk NMIBC in the future, particularly in patients thought to be at high 
risk of progression.
1.3 Gene therapy
Gene therapy is the treatment of disease by the introduction of normal genes into the 
patient to overcome the effects of those defective genes. Cancer gene therapy is the 
introduction of DNA or RNA which cause cellular changes that inhibit the 
uncontrolled growth of tumour cells. Several viral and nonviral vectors have been 
developed to achieve the delivery of the transgene to the tumour cells. Gene transfer 
by viral vectors takes advantage of the natural ability of viruses to enter cells and 
express transgenes by the infected cells. The success of these strategies depends on 
the high level transfer of therapeutic genetic material to the cells of interest (ie. 
tumour, immune cell, endothelial cell).
This approach was first applied to cancer patients using non-replicating adenoviruses 
or retroviruses to deliver copies of the wild type tumour suppressor gene p53 to 
tumours with the aim of preventing uncontrolled cell division (Roth 1996; Spitz, 
Nguyen et al. 1996). This technology uses our understanding of cancer at the 
molecular level and has been exploited to develop new strategies for killing cells 
selectively or arresting their growth (McCormick 2001). Gene therapy for the 
treatment of cancer was initiated with high levels of optimism and enthusiasm. 
Recently however, this perception has been tempered by the realisation that efficiency 
of gene delivery remains the most significant barrier to success (Vile, Russell et al. 
2000).
The field of molecular cancer therapy embraces a range of technologies including 
direct attack on tumour cells using oncolytic viruses or prodrug activating systems, , 
and viral fusiogenic envelopes. These fields are illustrated in Figure 1.3. However the
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categorisation of such therapies is somewhat artificial for two reasons. Firstly, one 
single therapy is unlikely to cure a particular cancer since evidence from conventional 
therapies suggests that a combination of therapies is much more likely to work in the 
clinic. Secondly, a particular therapy may have multiple modes of action. For 
example, the prodrug activating system of HSV-TK combined with ganciclovir 
promotes tumour reduction by directly killing tumour cells and also stimulates an 
immune response against the tumour (Vile, Castleden et al. 1997).
21
Cancer Gene 
Therapy
r
Cytokine
Therapy
Immune-
therapy ^
<
Cell Death 
Therapy
aiicer Vaccines
Cellular 
Gene Therapy
Viral
Molecular
Therapy
Prodrug
Activating
Therapy
Viral Fusogenic 
Envelopes
Oncolytic Therapy
Figure 1.3 An outline of the areas of cancer gene therapy being developed. The 
approaches highlighted in blue are discussed in this thesis.
1.4 Gene therapy in bladder cancer
In the following part we aim to review bladder cancer gene therapy by analyzing the 
stages which are key to its success: route of delivery, anti-tumour approaches and 
vectors used.
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1.4.1 Route of delivery
1.4.1.1 Systemic administration
This route often fails in the treatment of bladder cancer due to loss of the therapeutic 
agent from metabolism in the liver and poor tumour penetration. There is a need for a 
sufficient level and an appropriate amount of time for the therapeutic agent to come 
into contact with the tumour cells in the bladder mucosa in order to achieve its effect 
which is not achieved via this route.
1.4.1.2 Intravesical administration
The bladder represents an ideal target for intravesical gene therapy in the management 
of bladder cancer. The vectors are in direct local tumour contact, eliminating the 
difficulties associated with systemic administration and ensuring a low risk of gene 
transfer to other organs. Easy external access is achieved through the urethra which 
avoids losses from the first pass metabolism in the liver and minimizes the clearance 
of the vector by the immune system allowing minimal systemic side effects.
The inside of the bladder consists of 6-7 layers of cells which form a permeable 
transitional epithelium known as the urothelium (Figure 1.4). The urothelium acts as a 
barrier and in healthy circumstances it is almost impermeable. The main part of this 
barrier is the superficial cell layer of the transitional epithelium made up of umbrella 
cells. The umbrella cells join to each other with tight junctions and constitute a 
watertight barrier (Hohlbrugger 1995). The apical surface of the umbrella cells is 
covered by uroplakins (UPIa, UPIb, UPII, UPIII), which make up the rigid plaques. In 
addition the umbrella cells are covered by a hydrophilic glycosaminoglycan (GAG) 
layer. The GAG layer physically blocks the adhesion of foreign substances such as 
drugs and viruses (Parsons 1994; Lande, Donovan et al. 1995). Together these layers 
erect a tough bladder barrier that maintains a high electrochemical gradient between
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the urine and the blood. The impermeability of the urothelium is frequently exploited 
for instilling potentially toxic agents into the bladder to achieve localized 
pharmalogical effect.
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Figure 1.4 Structure of the transitional epithelium of the bladder 
Several strategies have been developed to improve the intravesical delivery of drugs 
in the bladder. This includes helping them cross the permeability barrier of the 
urothelium by both physical and chemical enhancement methods and increasing 
residence time in the bladder. These approaches may also improve the efficacy of 
some gene therapy vectors.
1.4.1.2.1 Improving permeability using physical methods.
The permeability of bladder cells can be improved with physical approaches like 
electromotive drug administration (EMDA), thermotherapy or iontophoresis which 
was further discussed in section 1.2.4.5.
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1.4.1.2.2 Improving permeability using chemical approaches.
Several chemical approaches that improve the permeability of the urothelium have 
been investigated in the literature. Protamine sulfate interacts with the GAG layer to 
increase the permeability of the urothelium (Tzan, Berg et al. 1994; Cetinel, Ercan et 
al. 2003) whilst administration of dimethyl sulfoxide has been described to enhance 
the absorption of paclitaxel and pirarubicin (Hashimoto, Tokunaka et al. 1992; Chen, 
Song et al. 2003). The administration of 22% ethanol prior to the instillation of an 
adenoviral vector causes damage of the GAG layer and makes the treatment more 
effective (Engler, Anderson et al. 1999). In addition a polyamide containing 
formulation, syn3, when used as a pre-treatment prior to intravesically administered 
adenovirus has been reported to enhance viral uptake (Yamashita, Rosser et al. 2002). 
Recent studies in preclinical models with the syn3/adenoviral-based strategy have also 
shown an improved therapeutic effect (Benedict, Tao et al. 2004; Connor, Anderson 
et al. 2005). A phase I study of the Big CHAP polyamide and an adenovirus 
coadministered intravesically led to increased transduction compared to adenovirus 
alone (Kuball, Wen et al. 2002). Although the use of Syn3 appears to be non toxic to 
the bladder tissue the use of other transducing agents has been shown to have adverse 
effects on the urothelium (Benedict, Tao et al. 2004).
1.4.1.2.3 Increasing residence time in the bladder
Increasing the time of residence in the bladder is an obvious strategy to increase the 
efficacy of a drug or therapy by increasing the duration of direct contact between drug 
and abnormal urothelium and ensuring constant drug concentration. This method was 
further discussed in section 1.2.4.3.
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1.4.1.2.4 Bioadhesion
This defines the interaction between a biological surface, such as the urothelium and 
a polymer such as algin, chitosan, fibrinogen, gelatin, polyethhylene glycol (Ye, Chen 
et al. 2001; Ozturk, Eroglu et al. 2004; Tyagi, Wu et al. 2006) . The efficiency of drug 
absorption is increased after bioadhesion properties are coupled to microspheres, 
liposomes or nanoparticles. For example microspheres based on chitosan are strongly 
mucoadhesive and their instillation was able to increase the residence time and 
decrease the frequency of administration of acyclovir (Genta, Conti et al. 1997).
The residual urine in the bladder before instillation and the accumulated urine during 
instillation can cause dilution in the concentration of the administered therapeutic 
agent. Restricted fluid intake before and during instillation and the complete emptying 
of bladder is required in any kind of intravesical treatment (Au, Badalament et al. 
2001). Significant differences in gene expression are achieved by varying physical 
parameters during intravesical instillation. Increased gene expression associated with 
larger volume instillation may be responsible for some reported variability of gene 
transfer to the bladder. Significantly more gene expression was detected in bladders 
instilled with a higher volume of viral vectors (p <0.05). Likewise, higher instillation 
pressures resulted in higher transgene expression in distant organs (Siemens, Austin et 
al. 2001).
1.4.2 Therapeutic genes used against bladder cancer
1.4.2.1 Tumour suppressor genes
Mutations in tumour suppressor genes are prevalent in many cancers and mutation of 
the p53 gene is common in muscle-invasive bladder cancer (Smith, Rubenstein et al. 
2003). Réintroduction of a functional copy of the p53 gene is one route taken by 
scientists. Miyake et al (Miyake, Hara et al. 1998) introduced a functional copy of the
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p53 gene into the bladder cancer cell line (HT1376) in vitro and found it became 
resensitised to cisplatin. Further in vivo studies used an adenoviral vector carrying the 
p53 gene which was injected directly into HT1372 tumours established in nude mice. 
Intraperitoneal administration of cisplatin then led to massive apoptotic destruction of 
the tumour. Adenoviral vectors carrying the p53 gene, INGN201 and SCH58500, 
have been tested in phase I clinical trials for bladder cancer (Table 1.2) (Barnard 
2000).
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1.4.2.2 Suicide gene therapy.
The delivery of genes encoding prodrug-converting enzymes into cancer cells results in a 
local conversion of a nontoxic prodrug into an active chemotherapy agent in high local 
concentration thus causing limited systemic toxicity. A number of suicide genes have been 
examined in different types of cancer including thymidine kinase, rat p450 CYP2B1, human 
intestinal carboxylesterase, yeast cytosine deaminase.
1.4.2.2.1 Thymidine kinase
The thymidine kinase gene system is based on the metabolism of certain purine nucleosides. 
Thymidine kinase catalyses the phosphorylation of the purine nucleoside analogues 
Ganciclovir (GCV), Acyclovir (ACV) and l-(2’-deoxy-2’-fluoro-/5-D-arabinofuranosyl)-5- 
iodouracyl (FIAU) converting them to their corresponding nucleoside monophosphates, 
which are catalysed to nucleoside diphosphates by mammalian nucleoside monophosphate 
kinases and are subsequently converted to the tri phosphate form by nucleoside diphosphate 
kinase (Miller and Miller 1980). The phosphorylation of these substrates by thymidine kinase 
into a monophosphate form (eg GCV-MP) is the rate-limiting step in the generation of a 
cytotoxic drug (Nishiyama and Rapp 1979; Field 1983; Oliver, Bubley et al. 1985). These 
prodrug metabolites are able to stall DNA synthesis by inhibiting DNA polymerase and by 
incorporation into DNA causing chain termination (Elion 1980; Davidson, Kaufman et al. 
1981) thus killing dividing cells. It has been shown that therapeutic concentrations of these 
drugs are non-toxic to cells that lack thymidine kinase, and conversely expression of 
thymidine kinase is non toxic to cells in the absence of these drugs (Elion 1980; Field 1983). 
It was tested in retrovirus, adenovirus and has been shown effective in tumour killing in vitro 
and in vivo (Yazawa, Fisher et al. 2002). Viral-mediated transfer of the herpes simplex virus 
thymidine kinase gene has been demonstrated by several investigators to confer sensitivity to 
nucleoside analogues such as ganciclovir in brain, prostate, liver, kidney, ovary, head and
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neck, lung, pancreas, and bladder cancers (Nasu, Kusaka et al. 2000). Oncolytic HSV-1 
vectors with intact thymidine kinase should also activate these prodrugs such that infected 
cells are killed by both the activated prodrug active and oncolysis. This may of course be 
counterproductive as replication of the oncolytic HSV may also be inhibited. Most studies 
have shown very little or no synergy between oncolytic HSV vectors and TK mediated 
prodrug activation, due to the inhibition of virus replication, which occurs. Suicide gene 
therapy using adenoviral-mediated herpes simplex virus thymidine kinase and the prodrug 
ganciclovir in an orthotopic murine bladder cancer model demonstrated a greater than 
threefold reduction in tumor growth. Long-term survival results suggested a survival benefit 
for the treated animals compared to the control group. (Sutton, Berkman et al. 1997; Sutton, 
Freund et al. 2000; Cheon, Moon et al. 2002). An adenovirus-mediated thymidine kinase 
suicide gene therapy was tested with different promoters in the treatment of experimental 
bladder cancer. Cytomegalovirus-immediate-early promoter and the Rous-sarcoma-virus 
promoters expressing thymidine kinase were both effective (Freund, Tong et al. 2000). A 
retroviral vector was also tested with thymidine kinase gene plus ganciclovir on human 
bladder cancer cells and on a nude mouse model and effective transduction and reduction of 
tumour volume was shown (He, Chen et al. 2004).
1.4.2.2.2 E. coli/yeast cytosine deaminase enzyme
A commonly used enzyme-prodrug combination is the E. coli/yeast cytosine deaminase 
enzyme and 5-fluorocytosine. The CD enzyme converts 5-fluorocytosine (5-FC) to active 5- 
fluorouracil (5-FU), which is a highly toxic compound (Zhang, Turner et al. 2009). This 
method will be further discussed in details in chapter 4.
1.4.2.2.3 Rat p450 enzyme and cyclophosphamide
Expression of the rat p450 enzyme from hrR3 (rRp450), in the presence of 
cyclophosphamide, has also shown oncolysis and prodrug activation in vitro without
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inhibiting virus replication in both colon carcinoma and glioma cells (Chase, Chung et al. 
1998; Aghi, Chou et al. 1999; Ichikawa, Petros et al. 2001; Pawlik, Nakamura et al. 2002; 
Tyminski, Leroy et al. 2005). In vivo studies on liver métastasés and glioma models revealed 
a substantial decrease in the tumour burden in all animals treated with rRp450 
(+cyclophosphamide) compared to controls (Chase, Chung et al. 1998; Aghi, Chou et al. 
1999; Ichikawa, Petros et al. 2001; Pawlik, Nakamura et al. 2002).
1.4.2.2.4 Human intestinal carboxylesterase
Recently p450 has been co-expressed from an ICP34.5- and ICP6- mutant HSV with another 
prodrug activating gene, intestinal carboxylesterase (Tyminski, Leroy et al. 2005). This new 
oncolytic herpes virus (MGH2) displays increased anti-tumour efficacy against human glioma 
cell lines (U251, T98G) when combined with the prodrugs, cyclophosphamide and CPT-11 
(Tyminski, Leroy et al. 2005). In vivo studies using MGH2 in glioma models have indicated 
an additive benefit of each of the pro-drugs (Tyminski, Leroy et al. 2005).
1.4.2.2.5 Sweet almond beta-glucosidase
Amygdalin as a prodrug is a naturally occurring cyanogenic glycoside, which can be cleaved 
by sweet almond beta-glucosidase to yield free cyanide. If amygdalin is activated specifically 
at the tumour site, then malignant cells are killed without the systemic toxicity usually 
associated with chemotherapy. Beta-glucosidase was conjugated to a tumour-associated 
monoclonal antibody (MAb) (HMFGl) and the conjugate has been tested in vitro. The 
combination of amygdalin with HMFGl-beta-glucosidase enhanced the cytotoxic effect of 
amygdalin by 36-fold on HT1376 bladder cancer cells (Syrigos, Rowlinson-Busza et al. 
1998).
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1.4.2.2.6 Escherichia coli purine nucleoside phosphorylase
In another in vivo model intratumoral injection of a replication-competent retroviral vectors 
delivering Escherichia coli purine nucleoside phosphorylase (PNP) followed by systemically 
administered fludarabine phosphate, significantly inhibited the growth of pre-established KU- 
19-19 tumours (Kikuchi, Menendez et al. 2007).
1.4.2.2.7 Horseradish peroxidase
The plant enzyme horseradish peroxidase (HRP) and the plant hormone indole-3-acetic acid 
(lAA) have also been used effectively as an enzyme/prodrug combination killing T24 bladder 
carcinoma. The activated drug is a long-lived species able to cross cell membranes, and cell 
contact appears not to be required for a bystander effect to take place (Greco, Folkes et al. 
2000)
1.4.2.3 Fusogenic membrane glycoproteins
Using viral fusogenic membrane glycoproteins is a new approach for cancer therapy 
(Bateman, Bullough et al. 2000). The virus kills the target cells by causing fusion between 
infected and non-infected cells, which also provides a bystander effect. Several membrane 
glycoproteins have been investigated previously (rhabdoviral VZV-G gene, F and H genes 
from measles virus, a mutated version of the retroviral gibbon ape leukaemia virus (GALV)). 
The GALV gene showed the best results in cell killing. Several immune stimulatory 
molecules associated with a stress response, such as heat shock proteins (Melcher, Todryk et 
al. 1998), the NK cell receptor (Groh, Steinle et al. 1998) and murine IFN-y were detected in 
treated mice, suggesting that the immune system may partly contribute to the mode of action 
of GALV env R-.
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1.4.2.4 Immunotherapy
The current therapy for some high risk patients with non-muscle invasive bladder cancer is 
intravesical BCG therapy. The bacteria are taken up into the bladder mucosa and this leads to 
an early immune response resulting in the release of several cytokines including TNFa, ILl, 
IL2, IL l2 and interferon y. These cytokines may exert their effects though the humoural or 
cellular immunity or through direct tumour cytotoxicity (Poppas, Pavlovich et al. 1998). Some 
groups have sought to recreate this immune stimulation through gene therapy (Kausch, Ardelt 
et al. 2002). One such approach was to use the innate immunogenicity of an adenovirus which 
was engineered to carry an immunostimulatory gene IFNa. This was then used in combination 
with Syn3 to improve adenoviral transduction to human bladder cancer cells forming a 
tumour in nude mice (Benedict, Tao et al. 2004). High local concentrations of IFNa were 
achieved together with marked tumour regression and little toxicity to normal cells.
1.4.2.5 Antiangiogenesis
Inhibition of the process by which tumours develop a new blood supply, angiogenesis, is 
another potential approach to bladder cancer gene therapy. Work carried out by Shichionhe et 
al (Shichinohe, Bochner et al. 2001) used a vector based on vesicular stomatitis virus (VSVG) 
to efficiently transduce bladder cancer cells with endostatin and angiostatin in vitro. The 
vector demonstrated preferential transduction of the tumour cells over the endothelial cells.
1.4.2.6 RNAi and antisense technology
Most oncogenes can be targeted by antisense oligonucleotides in bladder cancer and it is a 
relatively established technique (Goodchild 2004). Antisense oligonucleotides have also been 
used before chemotherapy to help sensitize the tumour cells (Duggan, Gray et al. 2002). Hong 
et al. observed that certain cisplatin resistant cells fines which had elevated levels of BCL-2 
became sensitive to cisplatin after treatment with an antisense BCL2 oligonucleotide (Hong, 
Lee et al. 2002).
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The use of RNAi technology in bladder cancer is still relatively novel but is an exciting 
technology for gene therapy of bladder cancer (Bartz and Jackson 2005). RNAi is a process 
whereby double-stranded RNA molecules known as siRNAs promote specific and potent gene 
silencing by binding to the target gene and initiating degradation of the message before 
translation can occur. One study used siRNA to silence Cdc42 in two human bladder cancer 
cell lines, EJ and T24. RNAi mediated silencing led to a marked decrease in Cdc42 mRNA 
and protein expression but moreover induced apoptosis of EJ cells (Wu, Chen et al. 2008).
1.4.2.7 Combination therapies
Ionizing radiation and chemotherapy approaches to cancer therapy destroy dividing cells 
because tumour cells divide more rapidly than normal cells. These therapies have to be 
balanced between causing maximum damage to the cancer cells, while keeping toxicity in 
normal host cells within acceptable levels. The combination of conventional therapies and the 
gene therapy may further improve the efficacy. The combination of the oncolytic replication 
competent herpes simplex virus type-1 (HSV) and mitomycin C as a chemotherapeutic agent 
demonstrated synergistic effect with about 90% estimated cell killing in an orthotopic murine 
model (Mullerad, Bochner et al. 2005). In vitro treatment with an adeno-associated virus-2 
vector encoding p53 gene treatment in combination with cisplatin showed a synergistic killing 
effect on the 5637 bladder cell line (Ruifa, Liwei et al. 2006). The systemic administration of 
recombinant IL-2 in combination with ADV/RSV-HSV-tk gene therapy with acyclovir was 
tested in a murine bladder tumor model and exhibited an enhanced antitumor effect (Terao, 
Shirakawa et al. 2005). The combination of adenoviral vector containing wild-type human 
p53 gene (Ad5CMV-p53) and cisplatin revealed synergy which is a potential method for 
overcoming resistance (Pagliaro, Keyhani et al. 2003).
Gene therapy combined with radiation represents a new approach to cancer treatment. An 
adenovirally directed, cytosine deaminase plus 5-fluorocytosine gene therapy was tested in
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combination with radiotherapy. This combination resulted in enhanced tumour cell killing of 
human bladder-cancer cells in vitro and enhanced tumour-growth inhibition in the KK47 
subcutaneous tumour model (Zhang, Shirakawa et al. 2003).
1.4.3 Vectors for bladder cancer gene therapy
1.4.3.1 Plasmids
The potential problem of inadvertent systemic release of viral vectors from the bladder has 
driven the search for non-viral vectors for gene transfer (Table 1.3). Plasmid vectors 
overcome this but have low efficiency of gene transfer. In vitro electroporation of HSVTK 
plasmid into chemically induced rat urinary bladder carcinomas cells results in between 50- 
70% cell death after administration of ganciclovir (GCV) (Shibata, Horiguchi et al. 2003). A 
significant increase in apoptosis was also observed after a single electroporation in vivo 
followed by GCV i.p. administration (Shibata, Horiguchi et al. 2003). BC-819 is a DNA 
plasmid that contains HI 9 gene regulatory sequences that drive the expression of an 
intracellular toxin. In patients with low grade superficial bladder cancer which expresses HI 9 
intravesical BC-819 caused tumour ablation following intravesical administration (Sidi, 
Ghana et al. 2008). The polycation poly(ethylenimine) was used to deliver plasmids coding 
for various combinations of caspases to Cox-2 overexpressing bladder and colon cancer cell 
lines. The combination of caspase 3 plus caspase 9 was the most effective and produced 
phosphatidylserine flipping in addition to fragmentation of genomic DNA (Zhang, Turner et 
al. 2009). In a recent study the authors used a nanocomplex consisting of the RB94 plasmid 
encapsulated by a cationic liposome. The potent tumor suppressor RB94 was delivered 
efficiently and it was effective for genitourinary and other cancers (Pirollo, Rait et al. 2008). 
Electroporation has also been tested as a method for gene transfer in a rat bladder model. For 
example a plasmid encoding the neuronal nitric oxide synthase gene was injected into the 
bladder and electroporation was applied. The authors found a marked neuronal nitric oxide
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synthase immunoreactivity, and the released nitric oxide was significantly greater than in the 
control groups (Yoshida, Iwashita et al. 2008).
Plasmid
vectors
Therapeutic
gene
Permeability
and
Bioadhesion
Agents
In vivo model References
pHSV?^ HSV TK + 
GCV
electrogene transfer Chemically induced 
orthotopic tumour model
(Shibata, 
Horiguchi et 
al. 2003)
Caspase
plasmisds
combination of 
caspase genes
poly(ethylenimine) In vitro only work (Zhang, 
Turner et al. 
2009)
RB94 RBI 10 tumour 
suppression
cationic liposome Orthotopic bladder tumour 
model
(Pirollo, Rait 
et al. 2008)
pcDNAS.l- 
mouse nNOS
neuronal nitric 
oxide synthase 
gene
Electroporation Orthotopic bladder model 
(smooth muscles)
(Yoshida, 
Iwashita et al. 
2008)
Table 1.3 DNA plasmid vectors using within bladder cancer models 
1.4.3.2 Viral vectors for bladder cancer
A range of viral vectors have been used for gene therapy of bladder cancer. Within each 
subset of viral vectors work has been carried out on both non-replicating vectors (Table 1.4), 
which offer strong therapeutic gene expression, and on replication competent/oncolytic 
vectors (Table 1.5) which offer tumour selective kill due to viral replication and even stronger 
therapeutic gene expression due to multiple rounds of replication and promoter up regulation 
(Ring 2002).
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Viral vectors Therapeutic gene In vivo model References
NRC retrovirus CD40 ligand Subcutaneously inoculated preinfected 
tumours (MBT2-CD40L) as vaccine.
(Kimura, 
Ohashi et al. 
2003)
NRC retrovirus prothymosiu alpha (ProT) Subcutaneously inoculated pre-infected 
tumours with and without prothymosin alpha 
(ProT)
(Shiau, Lin et 
al. 2001)
NRC retrovirus interferon-gamma (IFN- 
gamma)
Subcutaneously inoculated pre-infected 
tumours with and without interferon-gamma 
(IFN-gamma)
(Shiau, Lin et 
al. 2001)
NRC Lentivirus angiostatin and endostatm In vitro only (Shichinohe, 
Bochner et al. 
2001)
NRC Lentivirus endostatin Orthotopic bladder tumor model (Kikuchi, 
Menendez et 
al. 2004)
NRC Lentivirus Mutant human telomerase Kidney capsule athymic nude mouse model (Li,
Rosenberg et 
al. 2004)
Adeno-
associated
virus-2
p53 In vitro only (Ruifa, Liwei 
et al. 2006)
NRC
Adenovirus
p53 Orthotopic bladder tumor model (Werthman, 
Drazan et al. 
1990
NRC
Adenovirus
Rb Subcutaneously inoculated of pre-infected 
tumours with and without Rb (xenograph 
model)
(Xu, Zhou et 
al. 1996)
NRC
Adenovirus
p21 In vitro only (Hall, Li et al. 
2000)
NRC
Adenovirus
p53 Orthotopic bladder model 
Biosafety
(Perrotte, 
Wood et al. 
2000)
NRC
Adenovirus
p53 In vitro only (Irie, Uchida 
etal. 2001)
NRC
Adenovirus
MMACl/PTEN + doxorubicm In vitro only (Tanaka, Koul 
et al. 2000)
NRC
Adenovirus
p l6 In vitro only (Lee, Seol et 
al. 2001)
NRC
Adenovirus
p53 + cisplatin Subcutaneous and orthotopic tumor models. (Miyake, Kara 
et al. 2000)
NRC
Adenovirus
p53 + cisplatin 
or doxorubicm
In vitro only (Shirakawa, 
Sasaki et al. 
2001)
NRC
Adenovirus
thymidine kinase gene +GCV Orthotopic bladder tumor model (Sutton, 
Berkman et al. 
1997; Sutton, 
Freund et al. 
2000)
NRC
Adenovirus
thymidine kinase gene +GCV Chemical induction of a orthotopic rat model (Akasaka, 
Suzuki et al. 
2001)
NRC
Adenovirus
thymidine kinase gene +GCV 
+doxorubicin, cisplatin or 
mitomycin C or or 
methotrexate
In vitro only (Freund, Tong 
et al. 2003)
NRC thymidine kinase gene +GCV Subcutaneous tumors model (Freund, Tong
37
Adenovirus et al. 2000)
NRC
Adenovirus
interferon-a2b + Syn 3 Intravesical rat non tumour model (Connor, 
Anderson et 
al. 2005)
NRC
Adenovirus
interferon-o2b + Syn 3 Intravesical rat tumour model (Tao, Connor 
et al. 2006)
NRC
Adenovirus
interferon-o2b Intravesical murine tumour model (Adam, Black 
et al. 2007)
NRC
Adenovirus
TRAIL gene In vitro only (Griffith, 
Anderson et 
al. 2000)
NRC
Adenovirus
TRAIL gene + Trichostatin A In vitro only (El-Zawahry, 
Lu et al. 2006)
NRC
Adenovirus
connexin 26 (Cx26) gene 
+ cisplatin
Subcutaneous nude mice models. (Tanaka and 
Grossman 
2001)
NRC
Adenovirus
wild-type gelsolin Orthotopic bladder cancer nude mouse model (Sazawa, 
Watanabe et 
al. 2002)
NRC
Adenovirus
anti-sense to IL-8 Subcutaneous nude mice models. (Inoue, 
Perrotte et al. 
2000)
NRC
Adenovirus
anti-sense to IL-8 Subcutaneous nude mice models. (Inoue, Wood 
et al. 2001)
NRC
Adenovirus
human CD40 ligand 
+fluorouracil, cis-platin and 
mitomycin C
Subcutaneous nude mice models (Vardouli, 
Lindqvist et 
al. 2009)
NRC
Adenovirus
Fas ligand gene fused to GFP In vitro only (Sudarshan, 
Holman et al. 
2005)
ALVAC,
NYVAC 
NRC vaccinia 
virus
beta-galactosidase and firefly 
luciferase
Mouse orthotopic bladder tumour model. (Siemens, 
Crist et al. 
2003)
Table 1.4 Non replication competent (NRC) viral vectors used within bladder cancer models
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Viral vectors Therapeutic gene In vivo model Reference
s
RC retroviral 
(RCR) vector
cytosine deaminase gene +5- 
FC
Orthotopic bladder tumor model (Kikuchi, 
Menendez et 
al. 2007)
RC retroviral 
(RCR) vector
Escherichia coli purine 
nucleoside phosphorylase 
(PNP)
Orthotopic bladder tumor model (Kikuchi, 
Menendez et 
al. 2007)
RC Adenovirus - Mouse orthotopic bladder tumour model. (Wang, Satoh 
et al. 2006)
wild-type VSV 
or a mutant 
Deltas IM 
variant (AV3)
Orthotopic bladder cancer nude mouse model, 
tumor growth was quantified using 
bioluminescence imaging
(Hadaschik, 
Zhang et al. 
2008)
Wild type 
Reovirus
- Intravesical rat tumour model (Hanel, Xiao 
et al. 2004)
RC vaccinia 
virus
p53 Mouse orthotopic bladder tumour model. (Fodor, 
Timiryasova 
et al. 2005)
RC
pseudorabies
virus
Mouse orthotopic bladder tumour model. (Shiau, Lin et 
al. 2001)
RC HSV-1 
G207 and 
Nvl020
Mouse orthotopic bladder tumour model. (Cozzi, 
Malhotra et 
al. 2001)
RC HSV-1 
mutant HF10
- Mouse orthotopic bladder tumour model. (Kohno, Luo 
et al. 2005)
RC HSV-1 cytosine deaminase + 
fiisogenic glycoprotein from 
gibbon ape leukaemia virus 
(GALV)
Rat orthotopic bladder tumour model. See in this 
thesis.
Table 1.5 Replication competent (RC) viral vectors used within bladder cancer models 
1.4.3.2.1 Retroviral vectors
In a recent study murine leukemia virus (MuLV)- based replication competent retroviral 
(RCR) vector was able to transduce a wide range of bladder cancer cells in a subcutaneous 
bladder tumour model (Bochner 2008). However the same group also found that intravesical 
administration of a replication competent retroviral vector in an orthotopic murine bladder 
tumour model led to low transduction efficiencies (20-60%). In contrast highly efficient 
transduction was observed (85%) in a KU-19-19 human tumour model using intravesically 
instilled replication competent retroviral vectors (Kikuchi, Menendez et al. 2007). Mice
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treated with replication competent retroviral vector containing cytosine deaminase gene plus 
5-fluorocytosine showed a 50% survival rate compare to 0% survival rate in control groups 
over a 70 day period (Kikuchi, Menendez et al. 2007). In another in vivo model intratumoral 
injection of a replication-competent retroviral vector delivering Escherichia coli purine 
nucleoside phosphorylase (PNP) followed by systemically administered fludarabine 
phosphate, significantly inhibited the growth of pre-established KU-19-19 tumours (Kikuchi, 
Menendez et al. 2007). Antitumor immunity induced by a retroviral vector expressing CD40L 
was effective in a mouse vaccination model and suggested that immunogene therapy using 
CD40L may be a new strategy in the treatment of bladder cancer (Kimura, Ohashi et al. 
2003). A replication-defective recombinant retroviral vector encoding prothymosin alpha 
(ProT), a putative thymic hormone, exhibited smaller tumour mass, lower tumor incidence 
and higher survival rates, as well as higher antitumor cytotoxic activities in a mouse model. 
ProT exerts antitumor effects through its immunomodulatory activities (Shiau, Lin et al.
2001). Gene therapy based on the delivery of interferon-gamma (IFN-gamma) was also tested 
using retroviral vectors. A recombinant retroviral vector showed lower tumor incidence, lower 
tumor mass, and higher survival rate, as well as higher antitumor responses in a mouse model 
(Shiau, Lin et al. 2001).
1.4.3.2.2 Lentiviral vectors
These have been shown to be capable of efficient and stable gene transfer to a variety of 
human bladder tumor cell lines. Using self-inactivating lentiviral vectors containing green 
fluorescent protein in combination with endostatin sustained long-term expression of 
endostatin was achieved in an orthotopic bladder tumour model and it was associated with 
decreased vascularisation and inhibition of tumor growth (Kikuchi, Menendez et al. 2004). 
Long-term expression and secretion of angiostatin and endostatin was also found in lentivirus 
transduced T24 cells, which resulted in significant inhibition of cellular proliferation on co
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culture with endothelial cells (Shichinohe, Bochner et al. 2001). These reports suggest the 
potential utility of antiangiogenic gene therapy with lentiviral vectors for the treatment of 
cancer. In a recent study a lentiviral system was used to efficiently overexpress a mutant- 
template human telomerase RNA to add mutant DNA to telomeres in cancer cells. The 
overexpression of this mutant-template human telomerase RNA inhibited cell growth and 
induced apoptosis in telomerase-positive precancerous or cancer cells but not in telomerase- 
negative cells (Li, Rosenberg et al. 2004).
1.4.3.2.3 Adeno-associated virus-2
Mutations in the p53 tumor suppressor gene are the most common molecular genetic 
abnormalities in bladder cancer and p53 gene transfer in the human bladder cancer cell line by 
adenoviral or other vectors has been demonstrated to be cytotoxic. AAV encoding the p53 
gene has been shown to enter bladder cancer cells and express its gene products which are 
cytotoxic to bladder cancer cells. Additionally in vitro treatment with a adeno-associated 
virus- 2  vector encoding p53 gene treatment in combination with cisplatin showed synergistic 
killing effect on the 5637 bladder cell line (Ruifa, Liwei et al. 2006).
1.4.3.2.4 Adenoviral vectors
It was first shown in the 1990’s that replication-defective adenoviral vector can infect and 
express transgenes within bladder cells, offering possibility for therapeutic gene transfer (Morris, 
Drazan et al. 1994; Bass, Cabrera et al. 1995; Werthman, Drazan et al. 1996; Watanabe, Shinohara et 
al. 2000) . Using adenoviral vectors cell cycle related genes, including wild type p53, p21, 
MMACl/PTEN, p i 6  and N-terminal truncated retinoblastoma (RB) protein, were strongly 
expressed in bladder cancer models in vitro and in vivo but with limited efficacy (Werthman, 
Drazan et al. 1996; Xu, Zhou et al. 1996; Hall, Li et al. 2000; Perrotte, Wood et al. 2000; 
Tanaka, Koul et al. 2000; Irie, Uchida et al. 2001; Lee, Seol et al. 2001). Efficacy of such cell 
cycle related genes within adeno vectors has been shown to improve in the presence of chemo
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agents such as cisplatin or doxorubicin (Miyake, Hara et al. 1998; Miyake, Hara et al. 2000; 
Tanaka, Koul et al. 2000; Shirakawa, Sasaki et al. 2001). Phase 1 studies using replication 
deficient adenovirus containing wild type p53 gene showed safe administration in locally 
advanced bladder cancer patients (Kuball, Wen et al. 2002; Pagliaro, Keyhani et al. 2003).
A wide range of suicide genes have also been expressed by replication-defective adenoviral 
vectors within bladder cancer. These include the thymidine kinase gene (Sutton, Berkman et 
al. 1997; Freund, Sutton et al. 2000; Freund, Tong et al. 2000; Akasaka, Suzuki et al. 2001; 
Freund, Tong et al. 2003). The interferon alpha protein has antitumour effect through 
prolongation of the cell cycle, inhibition of biosynthetic enzymes and apoptosis. The 
intravesical delivery of the interferon-a2 b gene with a replication deficient adenoviral vector 
led to a strong increase in interferon concentration in the bladder (Connor, Anderson et al. 
2005). In interferon-alpha infected cells vascular endothelial growth factor was decreased and 
anti-angiogenic interferon-gamma inducible protein 10 was up-regulated. This led to an 
increased angiostatic activity of the bladder cancer microenvironment (Adam, Black et al.
2007). Using a mouse superficial bladder cancer model it was shown that the efficacy of a 
single intravesical treatment with an adenovirus encoding human interferon alpha plus Syn 3 
(gene transfer enhancing agent) is dose dependent and the efficacy was also correlated with 
the level of interferon produced in the urine after treatment (Tao, Connor et al. 2006). 
TNF-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily of 
cytokines that induces apoptosis in a variety of cancer cells. Introduction of the human 
TRAIL gene into TRAIL-sensitive tumor cells using an adenoviral vector led to the rapid 
production and expression of TRAIL protein, and subsequent death of the bladder tumor cells 
in vitro (Griffith, Anderson et al. 2000). In a recent study a histone deacetylase inhibitor 
trichostatin A treatment enhanced the efficacy of an adenovirus that expresses TNF-related 
apoptosis-inducing ligand (AdTRAIL). Trichostatin A enchances the adenovirus efficacy by
42
restoring CAR expression and by generating a more pro-apoptotic phenotype that would 
facilitate bystander activity of TRAIL (El-Zawahry, Lu et al. 2006). The modulation of CAR 
expression by inhibition of histone deacetylation (ie. valproic acid) has proved useful in 
improving the efficacy of adenoviral therapy (Bochner 2008). Ipriflavone and plant 
isoflavones were also found to exhibit the ability to induce the CAR gene in combination with 
a histone deacetylase inhibitor (FK228)(Pong, Roark et al. 2006). The addition of butyrate 
was found to increase the transduction rate of adenovirus and increase the antitumour effect of 
adenovirus-pl6  in bladder cancer cell lines with little CAR expression. (Lee, Seol et al. 2001) 
The connexin 26 (Cx26) gene encodes a protein involved in gap junctional intercellular 
communication and is a putative tumour suppressor. Infection with a Cx26 expressing 
adenoviral vector suppressed the growth of human bladder cancer cell lines such as UM-UC- 
3, UM-UC-6 , UM-UC-14, and T24 in vitro and prevented tumour formation in vivo (Tanaka 
and Grossman 2001). This adenoviral vector was also shown to have dramatic synergy in vivo 
with cisplatin (Tanaka and Grossman 2001). Gelsolin is an actin regulatory protein that is 
undetectable or reduced in human bladder tumours compared with normal epithelial cells. 
Over expression of wild-type gelsolin from an adenoviral vector inhibits tumour growth in an 
orthotopic bladder cancer nude mouse model by causing cells to arrest or delay at the G2/M 
phase of the cell cycle (Sazawa, Watanabe et al. 2002).
Replication-defective adenoviral vectors offer a stable platform for anti-sense expression to 
target genes within bladder cancer cells. Down regulation of basic fibroblast growth factor or 
IL- 8  has been shown resulting in endothelial cell apoptosis and significant tumour growth 
inhibition in vivo within a bladder model A replication defective recombinant adenoviral 
vector expressing human CD40 ligand (RAd-hCD40L), (a tumour necrosis factor receptor) 
caused anti-proliferative and pro-apoptotic effects on human bladder carcinoma cell lines in 
vitro and suppressed cancer growth in a mouse xenograft tumour model (Vardouli, Lindqvist
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et al. 2009). A replication-deficient adenovirus containing a modified Fas ligand gene fused to 
green fluorescent protein (AdGFPFasL) was cytotoxic to bladder cancer cells that would 
otherwise be considered Fas resistant (Sudarshan, Holman et al. 2005). A recent study 
investigated the therapeutic effect of a double-restricted oncolytic adenovirus (AxdAdB-3 
containing a mutant El A and an E1B-55KD deletion) on human bladder cancer cell lines and 
on a mouse orthotopic bladder tumour model. AxdAdB-3 was found to be effective in tumour 
growth inhibition, leading to significantly prolonged survival (Wang, Satoh et al. 2006).
1.4.3.2.5 Vesicular stomatitis virus (VSV)
VSV is an oncolytic, enveloped, negative-sense RNA virus that selectively replicates in IFN- 
resistant cells, but is strongly suppressed in IFN-responsive normal tissues. Human bladder 
cancer cell lines were treated with either wild-type VSV or a mutant Delta51M variant (AV3). 
Both viruses could kill the more aggressive IFN-nonresponsive bladder cancer cell lines, 
whereas IFN-responsive cells were less susceptible. In a mice bladder tumour model VSV 
instillation therapy showed promising antitumor activity and safety (Hadaschik, Zhang et al.
2008). 
1.4.3.2.6 Reovirus
Reovirus is a non-pathogenic virus in humans, which is found in the respiratory and enteric 
tracts. Reovirus causes oncolysis through the overactivation of Ras signalling cascade of 
target cells (Coffey, Strong et al. 1998; Strong, Coffey et al. 1998). In untransformed cells the 
reovirus activated protein kinase blocks viral protein translation. In tumours with activated 
Ras this protein kinase activation is inhibited, allowing viral replication and oncolysis (Hanel, 
Xiao et al. 2004). In an in vitro co-culture spheroid bladder cancer model reovirus selectively 
destroyed the transformed cells by lysis or induction of apoptosis (Kilani, Tamimi et al.
2003). In a rat orthotopic bladder tumour model AY-27 cells were susceptible to reovirus 
oncolyis. The animal survival was dose dependent and a survival rate of 90% was found in the
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reovirus group compared to 50% survival rate in the BCG treated group (in a 100 day period) 
(Hanel, Xiao et al. 2004). Systemic administration of reovirus in immunocompetent animals 
provokes an antiviral immunity that limits the efficacy of reovirus efficacy (Hirasawa, 
Nishikawa et al. 2003), but intravesical administration of reovirus may avoid this limitation.
1.4.3.2.7 Poxviruses
Poxviruses have several advantages as potential agents for cancer therapy. They can be used 
as an oncolytic vector and as vectors for gene delivery. The vaccinia virus can replicate in 
mammalian cells, is highly cytolytic for a broad range of tumour types, and is genetically 
stable and safe. The vaccinia virus can be genetically modified and has a large capacity for the 
delivered genes (Harrington, Vile et al. 2008). Recombinant vaccinia virus is effective in 
introducing foreign antigens locally into tumors in vivo, supporting its use in clinical 
immunotherapy (Lee, Eisenlohr et al. 1994). A recombinant vaccinia virus expressing human 
p53 can induce the death of MB-49 bladder tumor cells in vivo, not only through the lytic 
effect of the virus, but also through expression of the death inducing p53 transgene (Fodor, 
Timiryasova et al. 2005). The avipox virus is not able to replicate in mammalian cells 
although they have been used as a means of delivering immunogenic genes. The canarypox 
virus (ALVAC) can infect mammalian cells, but it is restricted to avian species for 
replication. It has been shown to be a safe and effective vector in humans (Taylor, Trimarchi 
et al. 1991). The attenuated vaccinia virus (NYVAC) is made nonlytic in mammalian cells. 
The efficacy of gene transfer by ALVAC, NYVAC and replication competent adenovirus was 
compared and the ALVAC and NYVAC was found better than adenovirus in vitro and in an 
orthotopic murine bladder cancer model (Siemens, Crist et al. 2003). A phase I trial using 
intravesical vaccinia virus in patients with muscle invasive transitional cell carcinoma has 
been conducted. Bladder histology samples after cystectomy showed evidence of viral 
infection in tumor and normal urothelial cells and there were no signs of vaccinia related
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toxicity except mild dysuria. This study demonstrates that vaccinia virus can be administered 
safely into the bladder (Gomella, Mastrangelo et al. 2001).
1.4.3.2.8 Pseudorabies virus
A mutant pseudorabies virus (YP2) which was carrying glycoprotein D and herpes simplex 
virus type 1 thymidine kinase genes was recently studied on human bladder, mouse bladder, 
and hamster oral cancer cells in vitro. The aim of this study was to target HER-2/neu- 
overexpressing cancer cells. YP2 replicated selectively in and lysed the HER-2/neu- 
overexpressing cells. In a mouse orthotopic bladder tumour model YP2 retarded MBT-2 
bladder tumour growth by more than 50% and more than half of the treated mice survived for 
over 50 days whereas control mice survived less than 30 days (Shiau, Lin et al. 2007).
1.4.3.2.9 Herpes simplex virus
Herpes simplex virus will be discussed later in section 1.6 .
1.5 Oncolytic viruses
1.5.1 Historical background of oncolytic viruses
It is likely that the use of viruses in the treatment of cancer was the result of the observation 
that clinical remission was occasionally seen in patients who contracted an infectious disease. 
These early reports were almost exclusively related to haematological malignancies which are 
associated with significant immune suppression. As early as 1904 there were reports of the 
beneficial effects seen in patients with leukaemia who developed influenza (Dock 1904). 
More recent clinical reports have described the regression of leukaemia, Hodgkins’s disease, 
and Burkitt’s lymphoma in association with measles infection (Bluming and Ziegler 1971; 
Gross 1971; Pasquinucci 1971; Zygiert 1971; Taqi, Abdurrahman et al. 1981). From these 
reports investigators have deduced the following: occasionally, certain viruses can destroy 
cancer cells without causing undue harm to the patient, this is most often seen in patients with
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a suppressed immune system, and these virally-induced remissions are short-lived and 
incomplete (Kelly and Russell 2007).
Formal evaluation of viral therapy began in 1949 with a study looking at hepatitis in 22 
patients suffering from Hodgkin’s disease (Hoster, Zanes et al. 1949). 7 of 13 patients, who 
developed hepatitis, showed improvement lasting over a month or more. Over the next twenty 
years a large number of different human pathogens were assessed in clinical trials. Early trials 
focused on West Nile virus, but limited responses and concerns regarding neurological side 
effects meant that its development was dropped (Southam and Moore 1952). Attention then 
turned to adenoviruses and herpes viruses. Adenoviruses were initially viewed with 
enthusiasm having limited side-effects and dramatic responses after intra-tumoural injection. 
However, it became clear that adenoviral infection was rapidly cleared by the immune system, 
especially in those with pre-existing exposure to adenovirus (Kelly and Russell 2007). The 
lack of significant efficacy coupled with the risks of using non-attenuated human pathogens 
led to a temporary hiatus in oncolytic virotherapy research.
Methods to limit the pathogenicity of oncolytic viruses were attempted as early as the 1950s. 
The concept of viral adaptation, whereby the oncolytic potential of a virus was enhanced by 
numerous passages in a given tumour, had been proven by Moore et al (Moore 1952). They 
rightly assumed that viruses would develop mutations that would enhance replication in the 
cells in which they were propagated. However, it was not until the advent of recombinant 
DNA technology in the early 1990s that the prospect of altering the selectivity of viruses 
became possible. The first studies to use this approach was published in 1991 by Martuza et 
al. and Maclean et al. using a genetically modified Herpes Simplex virus (HSV) (MacLean, 
ul-Fareed et al. 1991; Martuza, Malick et al. 1991). They developed HSV mutants that lack 
thymidine kinase or ICP 34.5 and these viruses were only able to replicate in dividing cells. 
When these modified viruses were used in a nude mouse glioma model they caused tumour
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growth inhibition and improved survival. Since then a large number of human pathogens have 
been genetically modified to increase their specificity for cancer cells and enhance their 
oncolytic capability.
1.5.2 Properties of oncolytic viruses
Viruses can transfer their genes from one host cell to another very efficiently and this has led 
to the widespread use of viruses as genetic vectors. For safety reasons, such virus vectors are 
generally rendered replication deficient but, unfortunately, this has limited the efficiency of 
treatment by restricting the number of cells to which the therapeutic gene is delivered. 
Therefore, the use of replication-competent viruses has been proposed, since virus replication 
would be expected to lead to amplification and spread of the therapeutic genes in vivo, 
however such replicating virus vectors must have some kind of tumour selectivity in their 
growth. They are dependent upon the host for replication, and differences in the cellular 
processes of normal host cells and tumour cells provide the potential for tumour targeting 
while sparing normal cells.
Recent advances in molecular biology and cell biology and a better understanding of cancer 
and the replication and pathogenesis of viruses have allowed the production of new agents 
that have been engineered to enhance their anti-tumour potential. Herpesviruses and 
adenoviruses are among the vectors that have been genetically engineered and developed as 
new agents against cancer, but there are many inherited tumour selective viruses that have 
been characterised including reovirus, Newcastle disease virus and vesicular stomatitis virus. 
Each of these agents has shown tumour selectivity in vitro and in vivo. Different viral vectors 
used for bladder cancer were discussed in detail above in this thesis.
The most important factor in defining oncolytic vectors is whether they can replicate in and 
destroy human tumour cells. Receptors for viral entry must be expressed on the target tumour 
cells. Ideally the wild-type virus should cause no disease or a mild, well characterised human
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or animal disease. The availability of drug treatment is also an advantage. Recombination 
with wild type viruses in the environment should not lead to a new pathogen. It has been 
suggested that non-integrating vectors are potentially safer. A genetically stable virus is 
desirable from the point of view of safety and manufacture. Finally, the virus vector must be 
amenable to high titre production and purification under good manufacturing practice.
1.6 Herpes simplex virus
The Herpesviridae consist of three sub families, the a, p, and y herpes viruses, differing in 
their pathology, tropisms and characteristics of latent infection. Human pathogen members 
include: the herpes simplex viruses HSV-1, HSV-2 and varicella-zoster virus (VZV) that 
represent the alphaherpesvirinae. Cytomegalovirus (CMV) is the prototype for 
betaherpesvirinae and also includes, both human herpes virus 6  and 7 (HHV-6 , HHV-7). 
Epstein Barr virus (EBV) and Kaposi’s Sarcoma associated virus (human herpes 8 , HHV-8 ) 
are examples of gammaherpesvirinae. All viruses within herpesviridae have one characteristic 
that links them together, their ability to establish and maintain latent infection for the lifetime 
of the host, from which they can re-activate and cause disease long after the primary infection. 
HSV-1 virus infection is highly prevalent worldwide, serum studies having also shown that 
antibody prevalence increases with age (Nahmias, Lee et al. 1990). The natural route of HSV- 
1 infection involves uptake of the virus by skin epithelial cells, whereupon the virus lytic 
cycle genes are expressed and the virus replicates (Roizman 2001). Following lytic replication 
the virus infects sensory nerve terminals and is transported retrogradely to the nerve cell body. 
The virus can then either undergo a further round of replication or the virus can enter latency. 
Sensory neurons are the natural site of herpes latency and as such the virus is thought of as 
neurotropic. However, in vitro and in vivo HSV-1 has been shown to infect a broad range of 
cell types as well as neurons. The lytic, replicative cycles of HSV-1 and HSV-2 are 
responsible for the symptoms of oral and genital herpes, respectively (Whitley 2001). HSV-1
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can also infect the central nervous system to cause encephalitis, but this is very rare, only 
occurring in approximately 1-2 cases per million, per year (Kennedy 1984).
1.6.1 Herpes Simplex Virus-1
HSV-1 is a double stranded DNA virus with a genome of 152kb, encoding over 80 
polypeptides (Roizman 2001). The HSV genome comprises two unique regions, short and 
long, each of which is flanked by inverted terminal repeats. The genes contained within the 
inverted repeats are present in two copies per viral genome. The unique segments can invert 
relative to each other, thus yielding four possible isomers. Approximately half of the 80 
proteins encoded by HSV are essential for virus replication in vitro, the rest being necessary 
for full pathogenesis in the host.
1.6.2 Properties of Herpes Simplex virus 1, relevant to oncolytic virus 
therapy
1. Mutation of a number of individual genes allows tumour selective virus 
replication and blocks virulence. Because wild type HSV-1 can infect replicating or 
quiescent cells, certain genes can be deleted to render the virus non-virulent, which 
also results in selective replication in tumour cells. (MacLean, ul-Fareed et al. 1991; 
Martuza, Malick et al. 1991; McKie, MacLean et al. 1996; Rampling, Cruickshank et 
al. 2000; Todo, Martuza et al. 2001).
2. Ease of manipulation. Foreign DNA can be inserted into the HSV genome by 
homologous recombination techniques (Roizman and Jenkins 1985). This property is 
not exclusive to HSV, but the lytic nature of HSV-1 aids fast plaque purification. An 
alternative method used by some groups is to employ the bacterial artificial 
chromosome (BAG), a single-copy plasmid that can stably retain a large size (300kb) 
DNA as an insert (Shizuya, Birren et al. 1992).
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3. Oncolytic HSV can infect a broad range of human tumour cell types. This 
replication competent virus can replicate and spread in situ and exhibit oncolytic 
activity through a direct cytopathic effect (Ring 2002). The following studies have 
shown that oncolytic HSV infects and replicates in vitro and in vivo in a wide range of 
human tumour cell types: glioma (Chambers, Gillespie et al. 1995; Andreansky, He et 
al. 1996; Andreansky, Soroceanu et al. 1997; Samoto, Ehtesham et al. 2002; Detta, 
Harland et al. 2003), colon carcinoma (Carroll, Chiocca et al. 1996), retinoblastoma 
(Nicolo and Chiocca 1998), epithelial ovarian cancer (Coukos, Makrigiannakis et al. 
1999), colorectal cancer (Kooby, Carew et al. 1999; Reinblatt, Pin et al. 2004), 
prostate cancer (Walker, McGeagh et al. 1999; Cozzi, Burke et al. 2002), non-small 
cell lung cancer (Toyoizumi, Mick et al. 1999), gallbladder carcinoma (Nakano, Todo 
et al. 2001), head and neck squamous cell carcinoma (Wong, Kim et al. 2001), 
esophageal adenocarcinoma (Stiles, Bhargava et al. 2003), breast cancer (Pin, 
Reinblatt et al. 2004; Teshigahara, Goshima et al. 2004; Liu and Rabkin 2005), thyroid 
cancers (Yu, Eisenberg et al. 2004), hepatocellular carcinoma (Pin, Reinblatt et al.
2004) and rhabdomyosracoma (Currier, Adams et al. 2005).
4. HSV-1 is a highly lytic virus, resulting in tumour cell death. Viral plaques can be 
detected in less than 16 hours.
5. HSV does not integrate into the host genome. By not integrating, use of HSV avoids 
the possibility of activating proto-oncogenes in the host genome, as has recently been 
described with integrating vectors (Fischer, Hacein-Bey et al. 2002).
6. Ease of production. Oncolytic HSV can easily be grown in culture to the titres 
required for clinical use.
7. Large insert capacity. HSV allows the insertion of up to 30 kb of exogenous DNA 
(Longnecker 1988). This capacity allows the insertion of multiple therapeutic genes
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such as prodrug activating genes, immune-stimulatory genes and fiisogenic membrane 
glycoprotein genes to increase tumour killing.
8 . Viral replication control. Most versions of oncolytic HSV ((1716, (MacLean, ul- 
Fareed et al. 1991))(G207, (Mineta, Rabkin et al. 1995))(OncoVex, (Liu, Robinson et 
al. 2003))) retain an intact thymidine kinase gene. As a result, many anti-herpes 
drugs, which require the thymidine kinase gene for activity, [e.g. Ganciclovir (GCV), 
Acyclovir (ACV), 1 -(2’ -deoxy-2’ -fluoro-/?-D-arabinofuranosyl)-5-iodouracyl (FIAU)) 
are available to prevent virus replication if this were thought to be necessary in a 
patient.
1.6.3 HSV-1 mutations giving tumour selective replication
During development of different oncolytic HSV vectors several types of mutations were 
investigated (nucleotide metabolism mutants, ICP34.5 mutant, ICP34.5+ICP6 mutant, HSV- 
1/HSV-2 intertypic recombinants, ICP34.5+US2 mutant, ICP34.5+US12 mutant, 
ICP34.7+ICP47 mutant). In this thesis we discuss the role of those mutations that are found in 
the Oncovex GALV/CD virus, which was tested by our group.
1.6.3.1 Single mutation to the ICP34.5 neurovirulence gene
The existence of a neurovirulence locus in the long repeat region of the HSV genome is well 
documented (Taha 1989; MacLean, ul-Fareed et al. 1991). This phenotype has been 
specifically assigned to the RL-1 gene (Chou, Kern et al. 1990; Dolan, McKie et al. 1992) and 
its encoded protein ICP34.5 (Chou, Kern et al. 1990). Expression of this protein facilitates 
viral replication in non-dividing cells, such as adult neurons (Robertson, MacLean et al. 1992; 
Whitley, Kern et al. 1993). ICP34.5- mutant viruses are also avirulent (Taha 1989; Chou, 
Kern et al. 1990; MacLean, ul-Fareed et al. 1991). The LD50 of many strains of wild type 
HSV-1 is less than 300 pfu following intracranial delivery. In contrast upwards of 10^-10^ pfu 
of ICP34.5 mutant viruses have been safely injected intracranially into mouse, rat, non-human
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primate, and human brains (Chou, Kern et al. 1990; MacLean, ul-Fareed et al. 1991; Mineta, 
Rabkin et al. 1995; Hunter, Martuza et al. 1999; Markert, Medlock et al. 2000; Rampling, 
Cruickshank et al. 2000; Sundaresan, Hunter et al. 2000; Simpson, Han et al. 2006). An 
ICP34.5- mutant (1714) was identified in studies of spontaneous mutants of wild type HSV 
that had lost their neurovirulence properties. The 1714 virus had a number of deletions and 
mutations, including a 759bp deletion in ICP34.5. When this particular deletion was 
introduced into 17syn+ backbone, creating virus strain 1716, a loss in neurovirulence was 
observed (MacLean, ul-Fareed et al. 1991) demonstrating the RLl gene to be responsible.
The fimction of HSV ICP34.5 is to disrupt the host anti-viral defence mechanisms. However, 
ICP34.5 doesn’t target protein kinase R (PKR) itself but instead forms a complex with protein 
phosphatase 1 which is then directed to dephosphorylate eIF-2a, promoting translation of 
viral transcripts and subsequently inhibiting the induction of apoptosis and promoting 
infection (He, Gross et al. 1997; Roizman and Markovitz 1997). The carboxyl-terminal 
domain of ICP34.5 is homologous to the corresponding domain of a conserved mammalian 
protein called growth arrest and DNA damage 34 protein (GADD34). GADD34 can substitute 
for the corresponding domain in ICP34.5 blocking the effects of the PKR/ eIF-2a pathway 
(Brown, MacLean et al. 1997).
ICP34.5- mutants in which both copies of the gene are mutated are incapable of replicating in 
neurons, but can replicate in and destroy glioma cells in vitro and in vivo (Andreansky, He et 
al. 1996). This suggests that deletion of the ICP34.5 gene somehow allows the virus to 
specifically target cancer cells while sparing normal tissue (Andreansky, He et al. 1996; 
Rampling, Cruickshank et al. 2000). The precise mechanism for growth of ICP34.5 mutants in 
each tumour type is not fully understood, but it is known from knockout mouse studies that 
deletions and mutations in PKR and the IFN receptors allow ICP34.5 mutant growth (Leib, 
Harrison et al. 1999; Leib, Machalek et al. 2000), and that these mutations and deletions have
53
been found in a number of tumour types (Haus 2000). Work from 2001 hypothesized that the 
higher levels of Ras activation found in transformed cells as compared to normal cells inhibits 
or reverses eIF-2a phosphorylation, thereby allowing viral protein synthesis and virus 
replication (Farassati, Yang et al. 2001). However, more recently this hypothesis has been 
disproved as no correlation has been found between Ras status and virus susceptibility in 
various panels of tumour cells (Mahller, Rangwala et al. 2006; Sarinella, Calistri et al. 2006). 
The early work leading to the Ras hypothesis was carried out in mouse cells over-expressing 
the Ras oncogene, a phenotype which does not accurately model human tumour cells and 
probably explains the misleading results obtained. Smith et al (Smith, Mezhir et al. 2006) 
went on to show a correlation between viral growth and activation of MEK which together 
suggests that the deregulation of different and/or multiple pathways in different tumour types 
allows tumour selective growth of ICP34.5 mutants.
It is important to note that oncolytic HSV containing only a deletion in both copies of the 
ICP34.5 gene such as R3616 (Chou, Kern et al. 1990) and 1716 (MacLean, ul-Fareed et al. 
1991) are now considered relatively primitive oncolytic viruses because they fail to replicate 
in a number of tumour cell types (Mohr 2005), unlike more advanced multiply mutated 
viruses in development now. The reason for this is that 34.5 mutants cannot take advantage of 
the other HSV-1 genes that also act on the IFN/ PKR/ eIF-2a pathway, US 11 (Mohr 2005). 
1716, a single deletion oncolytic HSV vector, showed clinical safety, as well as indications of 
efficacy, in human phase I trials (Rampling, Cruickshank et al. 2000; MacKie, Stewart et al. 
2001; Papanastassiou, Rampling et al. 2002).
1.6.3.2 ICP34.5-, ICP47 double mutants
When an ICP34.5 deleted virus was serially passaged in tumour cells a novel mutant 
appeared, which exhibited dramatically improved growth properties in tumour cells (Mohr 
1996). This so called suppressor mutant virus (SUP) contained an additional mutation that
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overcomes the protein synthesis block by altering the expression profile of U S ll, which 
encodes a viral RNA binding protein, from a late gene to an immediate early gene (Mohr 
1996; Cassady, Gross et al. 1998; Mulvey, Poppers et al. 1999). The altered regulation of 
U S ll in the SUP mutant takes place because of a deletion in the US 12 gene encoding ICP47, 
which places U S ll under the control of the ICP47 immediate early promoter. Accumulation 
of US 11 at early times during infection inhibits the activation of the cellular PKR kinase and 
allows protein synthesis to proceed in the absence of the ICP34.5 gene product (Cassady, 
Gross et al. 1998; Mulvey, Poppers et al. 1999). A physical complex between U S ll and PKR 
has been observed in infected cells, and this protein-protein interaction may also play a role in 
inhibiting PKR activation (Cassady, Gross et al. 1998). The neurovirulence of the SUP mutant 
was tested by intracerebral injection of immuno-competent mice and rats and the virus 
showed that, like the ICP34.5 single mutant, it was severely attenuated (Mohr, Sternberg et al. 
2001; Simpson, Han et al. 2006).
Wild type HSV-1 infection causes down regulation of major histocompatibility complex 
(MHC) class I expression on the surface of infected cells (Jennings, Rice et al. 1985; Hill, 
Jugovic et al. 1995). The binding of ICP47 to the transporter associated with antigen 
presentation (TAP) blocks peptide transport in the endoplasmic reticulum and loading of 
MHC class I molecules (York, Roop et al. 1994; Fruh, Ahn et al. 1995; Hill, Jugovic et al. 
1995). Consequently human tumour cells infected with ICP47- mutants express high levels of 
MHC class I on a their surface compared to wild type HSV infected cells (Todo, Martuza et 
al. 2001; Liu, Robinson et al. 2003). This would be expected to improve any anti-tumour 
immune response following intra-tumoral injection of the virus due to the presentation of 
tumour antigens at much higher levels on the surface of both tumour cells and HSV infected 
antigen presenting cells. Deletion of ICP47 has been included in G207 (Mineta, Rabkin et al. 
1995) to give G47Delta. G47Delta has been demonstrated to give both enhanced antigen
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expression and enhanced anti tumour activity due to increased expression of U S ll (Taneja, 
MacGregor et al. 2001; Todo, Martuza et al. 2001).
In order to develop oncolytic HSV with greater tumour selective replicative ability, clinical 
isolates (BLl, JS-1) were tested for their ability to replicate in and kill human tumour cell 
lines as compared to the previously used laboratory strains (Liu, Robinson et al. 2003). Both 
clinical isolates showed greater tumour cell killing than serially passaged laboratory strains, 
suggesting that they provided a better starting point for the development of an oncolytic virus. 
ICP34.5 and ICP47 were then deleted from one of these clinical virus strains resulting in 
tumour selectivity, the expression of U S ll gene as an IE rather than a L gene to further 
increase tumour replication (Taneja, MacGregor et al. 2001), and increased antigen 
presentation (Hill, Jugovic et al. 1995; Todo, Martuza et al. 2001; Liu, Robinson et al. 2003). 
Both the use of the clinical isolate, and the increased expression of U S ll were shown to 
increase tumour shrinkage in mouse tumour models (Liu, Robinson et al. 2003). Finally, the 
gene encoding granulocyte macrophage colony-stimulating factor (GM-CSF) was inserted 
into this virus in place of ICP34.5, and this was demonstrated to increase the anti-tumuor 
immune response generated such that un-injected as well as injected tumours could be cured 
in mouse models. This virus was called OncoVEX®^’^ ^  ^ (Liu, Robinson et al. 2003). 
Expression of GM-CSF has previously been shown to induce myeloid precursor cells to 
proliferate and differentiate, is a recruiter and stimulator of dendritic cells and has shown 
promise in pre-clinical and clinical trials in cancer (Andreansky, He et al. 1998; Parker, 
Gillespie et al. 2000; Toda, Martuza et al. 2000; Bennett, Malhotra et al. 2001; Wong, Kim et 
al. 2 0 0 1 ).
A phase I clinical trial has been completed using OncoVEX^^'^^^ by intra-tumoral injection 
in patients with cutaneous or sub-cutaneous deposits of breast, head and neck and 
gastrointestinal cancer and malignant melanoma (Hu, Coffin et al. 2006). The virus was
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generally well tolerated with local inflammation, erythema and febrile responses being the 
main side effects seen, which were expected from previous studies with oncolytic viruses. 
Virus replication, and GM-CSF expression were observed, as was considerable tumour 
necrosis including in tumours adjacent to those which had been injected with the virus (Hu, 
Coffin et al. 2006). Some evidence of a more distant, potentially immune-mediated effect, 
was observed as in some cases distant tumours became inflamed. Following these promising 
results, OncoVEX^^'^^^ is currently in a number of Phase II studies in individual tumour 
types.
1.6.4 Herpes Simplex Virus against bladder cancer
Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex 
viruses G207 and Nvl020 was effective in an orthotopic syngeneic mice bladder tumour 
model. Both viruses were effective at infecting, replicating within, and achieving subsequent 
cell lysis for human bladder cancer cell lines and murine transitional cell carcinoma cells. 
Both viruses were found effective in the orthotopic mice tumour model, where single and 
even more multiple instillations were effective at reducing tumour burden. (Cozzi, Malhotra 
et al. 2001). A herpes simplex virus (HSV) type 1 mutant HFIO replicated well in both human 
and murine bladder cancer cells. Treatment with HFIO mutant significantly prolonged the 
survival periods and increased the survival rates through its oncolytic activity (Kohno, Luo et 
al. 2005).
1.6.5 OncoVex^^ '^"^^®
O n c o V w a s  derived from HSV-1 strain JS-1 and has two deletions, that of the genes 
encoding ICP34.5 and ICP47. Properties of the OncoVEX^^^^^^ virus due to these deletions 
were discussed above.
OncoVEX*^^^^^^ expresses the envelope of GALV minus the R - peptide under the CMV
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promoter and OncoVEX^^ expresses Fcy::Fur under the RSV promoter (Figure 1.5). 
OncoVex^'^^^^^ was developed and tested recently by Simpson et al. in 2006. 
OncoVex^^^^^^ combines GALV expression with prodrug conversion, which gave improved 
therapeutic effect compared with the use of either approach alone. Unlike when using, for 
example, adenovirus vectors to deliver the GALV gene (Diaz, Bateman et al. 2000), virus 
replication was not inhibited, which may be due to the faster replication time of HSV.
The combined expression of a highly potent prodrug activating gene (CD=cytosine deaminase 
fusion to uracil phosphoribosyltransferase) and the fusogenic glycoprotein from gibbon ape 
leukaemia virus (GALV) further increased the local tumour control on several cancer cell 
lines (other than bladder cancer cell lines) (eg. COLO 205, HCT 116, CAPAN-1, HT 1080, 
U87-MG, CALU-1) in vitro (Simpson, Han et al. 2006).
Simpson et al. have showed in vivo on a rat model that the effectiveness of the individual 
approaches gave 57% tumor cure for FcyxFur and 83% tumor cure for GALV expression, 
compared with only 16.6% with the backbone vector. Using OncoVex^^^^^^ with the double 
approach they reached a statistically significant improvement with 1 0 0 % tumor cure 
(Simpson, Han et al. 2006).
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Figure 1.5 Schematic representation of virus vectors used in this study. HSV-1 strain JS-1
was isolated, by taking a swab from a cold sore of an otherwise healthy volunteer (Liu et al,
2002). JS-1 34.5- 47- pA- has two deletions. The first involves removal of the coding region 
of the ICP34.5 gene (nucleotides 124948-125713 based on the sequence HSV-1 strain 17+). 
The second involves a 280bp deletion of ICP47 (nucleotides 145570-145290 based on the 
sequence HSV-1 strain 17+) (Liu et al, 2002). JS-1 34.5-GALV env R-47- pA- expresses the 
retroviral envelope of gibbon ape leukaemia virus -  the R- peptide (Genbank NC 001885, 
5552-7555bp) (Bateman et al, 2000, Galanis et al, 2001) under the control of the CMV 
promoter. JS-1 34.5- RSV Fcy:Fur 47- pA- expresses the enzyme prodrug activator yeast 
cytosine deaminase fusion to uracil phospho-ribosyltransferase (Invivogen) under the control 
of the RSV promoter. JS-1 34.5- GALV env R-/ Fey:Fur 47- pA- combines both fusogenic 
retroviral envelope and enzyme prodrug activator.
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1.7 Aims of the thesis
The aim of this thesis was to evaluate the effectiveness of the OncoVex^^^^^^ virus in the 
treatment of bladder cancer. We planned to study the antitumour effect of the 
OncoVex^"^^^^^ virus in vitro on different human bladder cancer cell lines. We aimed to test 
separately O n c o V v i r u s  for fusiogenic activity and for prodrug activation. We 
planned to set up a stable and useful rat orthotopic bladder tumour model to test in vivo the 
effectivity of OncoVex^^^^^^. Finally we aimed to evaluate whether O n c o V v i r u s  
has synergistic effect in combination with different chemotherapeutic drugs.
The multi-ftmctional cytoxicity of the OncoVex^^^^^^ virus through its own oncolytic 
activity, glycoprotein fusion and prodrug activation may lead to an enhanced local tumour 
control not just in vitro but in vivo as well within the bladder. As a multi-functional approach 
the O n c o V v i r u s  is much more likely to work than one single therapeutic approach 
alone. O n c o V v i r u s  may be useful for improving clinical outcomes in superficial 
(non-muscle invasive) bladder cancer. We aim to use the OncoVex^^^^^^ virus as an 
intravesival treatment for superficial bladder cancer, perhaps as an adjuvant to the currently 
used intravesical chemo (mitomycin C) therapies in the intermediate risk group and immuno 
therapy in the high risk group of superficial bladder cancers.
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Chapter 2
Materials and Methods
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2 Materials and Methods
2.1 Cell culture
Cell culture preparations were carried out under sterile conditions in a laminar flow safety 
cabinet class II. Tissue culture plasticware was obtained from Nunc, and media and 
supplements were supplied by Sigma.
2.1.1 Cell lines
Human bladder carcinoma cells (EJ, T24, RT112) and baby hamster normal kidney cells 
(BHK-21) were purchased from American Tissue Culture Collection (ATCC). Other human 
bladder carcinoma cells (VMVUB-I, TCCSUP-G, 5637, KU19-19) were kindly given by 
Professor Margaret Knowles (Cancer Research UK Clinical Centre, Leeds). The rat bladder 
carcinoma cell line (AY-27) was kindly given by Dr. Ronald B. Moore (University of 
Alberta).
Cell line Species
Source
Tissue Hystological
type
ECACC or 
ATCC No
Media
BHK-21 
(clone 13)
Baby Syrian 
Hamster
Kidney normal 85011433 DMEM
EJ Human Bladder carcinoma TCC 85061108 DMEM
T24 Human Bladder carcinoma TCC 85061107,
HTB-4
McCoy’
s
RT112 Human Bladder carcinoma TCC 85061106 MEME
VMCUB-I Human Bladder carcinoma TCC University
Leeds
DMEM
TCCSUP-G Human Bladder carcinoma TCC University 
Leeds HTB- 
5
DMEM
5637 Human Bladder carcinoma TCC University 
Leeds HTB- 
9
RPMI
KU19-19 Human Bladder carcinoma TCC University
Leeds
RPMI
AY-27 Rat Bladder carcinoma TCC University
Alberta
RPMI
Table 2.1 Mammalian Cell Lines used in following studies
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2.1.2 Cell Handling
BHK-21, EJ, VMCUB-I, TCCSUP-G cell lines were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM) and 5637, KU19-19 cell lines were grown in RPMI-1640 ( both Sigma). 
T24 cells were grown in McCoy’s 5A Medium and RT112 cells were grown in Minimum 
Essential Medium Eagle. All media was supplemented with 2mM GlutaMAX-1 supplement 
(Invitrogen), 100 units/ml penicillin, and 100 units/ml streptomycin (Sigma) and either 10% 
(v/v) foetal calf serum (PCS) for routine passage or 2% (v/v) PCS for experimental work. Cell 
culture work was carried out in a sterile environment provided by a laminar flow hood with 
double HEP A filter. Cell lines were regularly tested for mycoplasma infection. Passage of cell 
cultures was carried out when cells were approaching confluence: every 3-7 days depending 
on the cell line. Cells were washed with Hanks Balanced Salt Solution (HBSS) to remove any 
foetal calf serum and then 0.05% trypsin (Sigma-Aldrich) was added. Once the cells had been 
mobilised Jfresh medium containing foetal calf serum was added to stop the trypsinisation. The 
cell suspension was then centrifuged at 1500rpm for 3 minutes. The cell pellet was 
resuspended in the appropriate medium and plated out in the required dilution. Cells were 
incubated at 37°C and either 5% or 10% CO2 depending on the cell line.
2.1.3 Cell line storage
In order to maintain stocks of the various cell lines, cells were regularly frozen down. Cells in 
log phase of growth were pelleted and resuspended at lO^-lO^cells/ml in complete medium 
and an equal volume of 20% DMSG in foetal calf serum added. 1ml aliquots were transferred 
to labelled cryotubes which were then placed in a 1°C freezing container and stored overnight 
in a -80°C freezer. The isopropanol in these containers allows for slow freezing at 
approximately l°C/minute. Cells were then transferred to liquid nitrogen storage the 
following day.
Recovery of cells from liquid nitrogen storage was performed by rapid thawing in a 37°C
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water bath. Thawed cells were washed in 10ml of medium, harvested by centrifugation 
(ISOOrpm for 3 minutes) and were then transferred to 75cm^ flasks containing fresh culture 
medium.
2.1.4 OncoVex GFP and OncoVex GALV/CD stocks
OncoVex GFP (backbone virus) and OncoVex GALV/CD stocks were supplied by Bio Vex 
Inc. (34 Commerce way, Woburn, MA, 01801, USA). The OncoVex GFP and OncoVex 
GALV/CD stocks were stored at -80°C in lOOOpl aliquots.
OncoVEX was derived from HSV-1 strain JS-1 (Liu, Robinson et al. 2003) and has two 
deletions, that of the genes encoding ICP34.5 (nucleotides 124948-125713 based on the 
sequence of HSV-1 strain 17+) and ICP47 (nucleotides 145570-145290). OncoVEX®^^ 
expresses the envelope of GALV minus the R - peptide (Genbank accession no. NC 001885; 
5,552-7,555 bp) under the CMV promoter. OncoVEX^^ expresses FcyxFur under the RSV 
promoter. OncoVEX^^^^^^ expresses both the GALV and Fcy::Fur proteins (Simpson, Han 
et al. 2006) (Figure 1.5).
2.1.5 Viral titre assay (Plaque assay).
Virus stock titer and virus stability was measured by standard plaque assay. BHK cells were 
plated at 1.25 xlOf cells per well of a 24 well tray and incubated overnight (80% confluent). A 
1:10 serial dilution of virus suspension from 1x10'^ -  IxlO'^ml was prepared, 200pl of which 
was placed on the cells. The cells were then incubated for 1 hour at 3 7 ^C/5 %C0 2 . The media 
was then removed and replaced with Imls of 1:2 of 1.6% (v/v) carboxymethyl cellulose. The 
cells were then incubated for a further 48 hours at 3 7 ^C/5 %C0 2  and the wells were then 
assayed for the number of plaques in each well in order to determine titre of virus. Virus not 
expressing reporter gene were visualised by fixing and staining the plaques. (See section 
2.1.8). The cells were then digitally photographed (Figure 2.2) using an inverted microscope
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(Nikon Eclipse TE200) and Lucia Image (MV-1500 version 4.6). Virus expressing green 
fluorescent protein marker gene were visualised under an inverted fluorescent microscope 
{Nikon Eclipse TE200) at wavelength 520nm. The titre of virus was measured in plaque 
forming units per ml (pfu/ml).
Figure 2.1 Plaque visualized by Crystal Violet
2.1.6 Fusion assay (GALV dose response assay)
Test cells were plated at 1.25 x 10^  per well of a 24-well tray or at different amounts (1.5xlO\ 
2xlO\ 2.5x10 \  3x10"^ ) per well of a 96-well tray and incubated at 37°C/5% CO2 o/n. The
FGM was removed, and 200 pL of OncoVex*^^^^^^ or OncoVex^^’^ at MOIs of 0.0001, 
0.001, 0.01, and 0.1 in RPMI with 2% FCS were added. This was then incubated at 37°C/5% 
CO2 for 1 hour. The virus dilutions were removed and replaced with 1 mL FGM. This was 
then incubated at 37°C for 48 hours. From the 24 well trays the cells were washed and fixed in
G F P
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glutaldehyde, then stained with Crystal Violet for digital photographs. (See section 2.1.8). 
From the 96 well trays the cells were measured by the MTS assay.
2.1.7 Prodrug-activating assay
Test cells were plated at 1 x 10  ^per well of a 24-well tray and incubated at 37°C/5% CO2 
overnight. The cells were infected with OncoVEX^^^ and OncoVEX^^^^^^ at different MOIs 
(1, 0.1, 0.01) according to the fusion assay results (in 200 pL RPMI with 2%FCS) and no 
virus control. After 30 minutes at 37°C/5% CO2, the virus was removed, and 1 mL of FGM 
containing 5-FC (C4H4FN2O; Sigma) at different concentrations (600-800-1000-1200-1400 
pmol/L) was added and incubated for 48 hours at 37°C/5% CO2 . The cell supernatant was 
transferred into a fresh tube, and the cell debris was removed by spinning at 1,500 rpm (340 x 
g) for 5 minutes at 4°C. The supernatants were added to a fresh tube and then incubated at 
60°C for 10 minutes, to inactivate the virus. The resulting supernatants were allowed to cool 
to room temperature. Test cells were plated at 1 x 10"^  per well of a 24-well tray or 1 x 10  ^per 
well of a 96-well tray and were incubated at 37°C/5% CO2 overnight. The heat-treated 
supernatants were added to the fresh test cells and incubated at 37°C/5% CO2 for 72 hours. 
From the 24 well trays the cells were washed and fixed in glutaldehyde, then stained with 
Crystal Violet for digital photographs. (See section 2.1.8). From the 96 well trays the cells 
were measured by the MTS assay.
2.1.8 Fixing and staining protocol for cells or viral plaques
The cells were washed twice with PBS and then incubated with 2ml of 0.1% Glutaldehyde 
{Sigma) in PBS for 10 minutes at RT. After another two washes with PBS the cells were 
stained with 1ml of 0.1% w/v Crystal Violet solution (in 20% Ethanol) for 10 min in order to 
visualise the cells or plaques. Excess stain was removed with H2O, and the plates were 
allowed to dry. The cells were then digitally photographed.
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2.1.9 MTS Assay
Cell viability was quantified using a 3-(4,5-dimethyltliiazol-2-yl)-5-(3- 
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (Sigma-Aldrich). 
This assay is based on the reduction of the tétrazolium salt, MTS, to a coloured formazan 
compound by living cells in culture. This assay is similar to the MTT assay with the 
advantage that the formazan product of MTS reduction is soluble in cell culture medium, 
unlike MTT which has to be dissolved in DMSO. Metabolism in living cells produces 
“reducing equivalents” such as NADH or NADPH. These reducing compounds pass their 
electrons to an intermediate electron transfer reagent that can reduce MTS into the aqueous, 
formazan product. When the cell dies, it rapidly loses the ability to reduce tétrazolium 
products. Therefore the production of the coloured formazan compound is proportional to the 
number of viable cells in culture. The cell viability was quantified using the CellTiter 96 
AQueous One Solution Cell Proliferation Assay reagent 3-(4,5-dimethylthiazol-2-yl)-5-(3- 
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS; Promega) according to 
manufacturer’s instructions. Briefly, 20pl of MTS reagent in 180pl of fresh medium was 
added to each well. Following incubation at 37°C for 1-4 hours, absorbance was measured at 
495nm. Survival was calculated as a percentage compared to untreated cells using the 
formula:
(Treated Value -  background)
% Cell Survival = -----------------------------------  — x 100
(Untreated Value -  background)
2.2 Cell cloning techniques
2.2.1 Linearisation of DNA.
It was important to linearise the plasmid DNA to be transfected, as this increases the 
efficiency of integration. Ideally, the enzyme site chosen should be at least 200bp from either
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end of the promoter/poly A of the gene of interest since some bases can be removed from the 
plasmid during integration. lOpg of linearised DNA were prepared per cell type to be 
transfected.
The following digest was set up:
3pg DNA, lOpl restriction enzyme buffer (buffer E, buffer D), 5 pi appropriate enzyme 
(lOunits/pl) (SspI, Notl), ddH2 0  to lOOpl, Incubate for 4 hours at the appropriate temperature
The resulting DNA was then purified using the GFX PCR DNA and Gel Band Purification 
Kit {Amersham Biosciences) as per manufacturer’s instructions. The DNA was then eluted in 
a final volume of 50pl.
The Pc DNA3 HVEM plasmid and the pGAL CMV Luc Hygo plasmid were used in this 
study (Figure 2.3, Table 2.2)
T7 prom oter 
CMV prom oter |
amp
JVofl (4630)
Luc2 reporter gene
T7 prom oter^ 
CMV prom oter___
Sp6
BGH polyA
pGL4 CM V lue hygo
6494 bp j-  ^ S V 4 0  pA
P C D N A 3 -H V E M
6280 bp
Col El
synthetic pA
SV40 enhancer/prom oter
SspI (4390T ~ ~ - ^
Amplcllln
SV40 prom oter
NEOMYCIN
SV40polypA
\
C0IEIHygromyiin
Figure 2.2 Pc DNA3 HVEM and the pGAL CMV Luc Hygo plasmids
Plasmids Linearisation restriction enzyme
Pc DNA3 HVEM Ssp 1
pGAL CMV Luc Hygo Not I
Table 2.2 Pc DNA3 HVEM and the pGAL CV V Luc Hygo plasmids
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2.2.2 Antibiotic killing curves
The aim of the antibiotic killing curve was to determine the minimum concentration of 
antibiotic (G418 (Gibco), hygromycin (Sigma)) required to give complete cell death after 7 
days of treatment. Cells were plated at 5x10" -^1x10"  ^ cells per well of a 24 well tray and 
incubated overnight. The selection media was added to the wells at range of concentrations 
(e.g. for G418 which was used in this study at a concentration of ~300pg/ml we tried 0, 200, 
400, 600, 800, 1000, 1200, 1400, 1600, 1800 and 2000pg/ml). The plates were observed 
every day for 7 days, each time estimating the level of cell death. It was necessary to change 
the selecting media every 2 days. After 10 days the cells were fixed and stained as above.
2.2.3 Transfection of cells to produce luciferase/HVEM expressing cell 
lines
AY-27 cells were plate at 6x10^ cells per well of 6  well tray (using media without antibiotics) 
and incubate at 37^C o/n. Ipg of linearised plasmid (pcDNA3 HVEM, pGAL CMV Luc 
Hygo) was diluted in lOOpl of RPMI (without FCS) per transfection. The lipofectin 
(Invitrogen) was diluted in RPMI (without FCS). Both were let stand at room temperature for 
30-45 minutes. The diluted DNA and lipofectin were combined, gently mixed and incubated 
at room temperature for 15 minutes. The growth media from the AY-27 cells was removed 
and the cells were washed with 2ml of RPMI without FCS. 800pl of RPMI without FCS was 
added to DNA/ lipofectin mix and then added to the cells. The cells were incubated at 37^C 
for 7hrs. After this incubation the DNA/ lipofectin mix was removed, 2ml of FGM was added 
and incubated at 37®C o/n. After 48hrs the cells were split into 90mm culture dishes (x9) and 
incubated at 37®C o/n. After 24 hours FGM was removed and FGM containing the appropriate 
antibiotic was added.
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2.2.4 Selection and scale up of transfected clones
48 hours after transfection cells were split into 90mm culture dishes (x9) culture dishes and 
the appropriate selection media was added 24 hours later (Table 2.3). The concentrations of 
antibiotic used to treat the cells were pre-determined by carrying out an antibiotic killing 
curve (See section 2.2.2).
The cells were observed every day and the selection media was changed every 2-3 days 
(especially if there is a high level of cell death). Individual cell colonies were visualised 
between 5-20 days of selection (depending on the cell line and compound). Once the colonies 
were clearly observable, they could be transferred to individually wells of a 96-well tray 
containing lOOpl of selection media. This was achieved by picking the colonies, with a p20 
gilson, directly from the plate whilst observing it under an inverted microscope {Nikon 
Eclipse TE200). The cells were then transferred to one well of a 96-well tray and pipetted up 
and down a few times to break up the cells. The individual cell lines took between 2-14 days 
to produce a confluent monolayer in a well of a 96-well tray. Once confluent, the cell lines 
were transferred to one well of a 24-well dish containing 500pl selection media/well, using 
50|li1 trypsin versene to remove the cells from the 96-well dish. The cell lines were grown 
from 24 well stage to a 6  well stage and finally up to a 25cm^ flask. At all times the cell lines 
were exposed to selection media. Once confluent, the flask of cells was frozen down into 3 
ampoules, one of which was kept as a master stock. Once a suitable cell line was identified, it 
was scaled up and frozen stocks were produced.
Antibiotics AY-27 cells
G418 (Gibco) dissolve in H2O 300pg/ml
Hygromycin (Sigma) dissolve in H2 O lOOpg/ml
Table 2.3 Concentration of selection agents used in this study
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2.2.5 Sub-cloning cell lines
This protocol was carried out after a suitable cell line had been identified fiom a relevant 
screening process in order to ensure that the cell line was derived from an individual 
transfected cell. 1x10^ cells per well in 200pl fresh FGM with appropriate concentrations of 
selection antibiotics were added to every well in row A of 96-well tray. lOOpl selection media 
was added to rows B-H of the dish. Then a 1:2 serial dilution of cells suspension was carried 
out from row A to row H. The trays were incubated until the wells containing 1 cell become 
confluent. The new sub-clones were grown up and re-screened to identify positives.
2.2.6 Infection screening assay for AY-27 HVEM
To identified clones of AY-27-HVEM that support replication of HSV-1 test cells were plated 
at IxlO^cells per well of a 24 well tray and incubated at 37°C/5% CO2 o/n. The media was 
then removed and the cells infected with OncoVex^^^ virus at MCI 0.1 (in a volume of 200pl 
RPMI) and incubated at 37°C/5% CO2 for IHr. The virus was removed and 1ml of fresh FGM 
media was added. The infection was incubated at 37°C/5% CO2 for 72 hrs. Infection of 
OncoVex^^^ virus expressing green fluorescent protein marker gene were visualised under an 
inverted fluorescent microscope {Nikon Eclipse TE200) at wavelength 520nm.
2.2.7 Luciferase activation screening assay.
AY-27 HE cells were plated at 5x10^ cells per well of 6  well tray and incubated at 37^C o/n. 
After this incubation the FGM was removed and the cells were washed (3x) with 1.5ml ice 
cold PBS. The PBS was removed and 120pl of cell Ix culture lysis reagent (Sigma 5x cell 
culture lysis Reagent, C 4707) was added. The lysate was incubated at room temperature for 
15 minutes after which the cells were scrape off and spun at 12,000g at 4^C for 1 minute. The 
supernatant was removed and store on ice. The lyophilized luciferase assay substrate (sigma L 
0407) was resuspended in 10ml of luciferase assay buffer (Sigma L 0532). The luciferase
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substrate and the tested cell lysate were allowed to equilibrate to room temperature before use. 
20pl of the cell lysate was added to lOOpl of the luciferase substrate assay buffer. Light 
emission was read after 10 seconds incubation at room temperature using Beckman 
colterDTX 880. _(Luciferase assay kit MB-260)
2.3 Quantitative Reverse Transcrpition Polymerase Chain 
Reaction (QRT-PCR)
2.3.1 RNA extraction
Urine and bladder tissue samples were screened using QRT-PCR to detect expression of 
HVEM gene as a marker for the presence of tumour.
RNA extraction was performed using Qiagen RNeasy Plus Micro Kit (cat no 74034). Prior to 
starting, lOpl of 6 -mercaptoethanol was added for every 1ml of buffer RLT Plus used. Rat 
urine was spun at 16K for 10 minutes at 4 C° tp produce a cell pellet. These cell pellets from 
the urine were lysated with 350pl buffer RLT, then the lysate was vortexed for 1 minute. 
Bladder tissue was homogenized with a tissue ruptor and cells were lysated with 3 5Oui RTL, 
then vortexed for 1 minute. The lysate was homogenized by passing at least 5 times through a 
21 gauge needle. The urine or bladder tissue lysate was transferred to gDNA Eliminator spin 
column placed in a 2ml collection tube and centrifuged for 30 seconds at 8,000rpm. The 
column was discarded and 350pl of 70% ethanol added to the flow through and mixed. 700pl 
of the sample was then transferred to an RNeasy MinElute spin colunm placed in a 2ml 
collection tube and centrifuged for 15 seconds at 8,000rpm. The flow through was discarded 
and 700pl of buffer RWl added to the RNeasy MinElute spin column and centrifuged at 
8,000rpm for 15 seconds. The flow through was discarded and 500pl of buffer RPE added to 
the spin column and centrifuged for a further 15 seconds. The flow through was discarded and 
500pl of 80% ethanol added to the spin column and centrifuged for 2 minutes at 10,000rpm. 
The RNeasy MinElute spin column was placed in a new 2ml collection tube and centrifuged
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at 10,000rpm for 5 minutes. The spin colunm was then placed in a 1.5ml collection tube and 
14pl of RNase-free water added directly to the colunm membrane. This was then centrifuged 
for 2 minutes at 10,000rpm to elute the RNA. The RNA was quantified using Nano-drop 
spectrophotometer and stored at -80°C.
2.3.2 cDNA formation and QRT-PCR
RNA was reverse-transcribed as described below. 0.5qg of the target RNA was first 
denatured by heating to 65°C for 5 min then place on ice. The resulting RNA was incubated 
in a volume of 20pL at 50°C for 1 h with final concentrations of O.IM of DTT, 10 mM of 
deoxynucleotide triphosphate mix (dNTP) , as well as 100 pg/pL of poly-T primers, 5x 
cDNA synthesis buffer, 15 units of reverse transcriptase (Invitrogen), and 40 units of 
RNaseOUT (Invitrogen). The cDNA synthesis reaction was terminated by placing tubes at 
85°C for 5 min. 180pl of water was added to each cDNA sample and 5pi of cDNA was added 
for a Q-PCR.
Quantitative reverse transcription-PCR was done using the Stratagene MX4000 real-time 
PCR machine. The Stratagene MX4000Note: measures PCR product accumulation during the 
exponential phase of the reaction, prior to the amplification becoming vulnerable to limited 
reagents and cycling variability. Fluorescence increases in accordance with increasing levels 
of PCR product. 5pi of cDNA was added to Ipl of primer mix, 6.25pi of water, 0.25pl 
reference dye and 12.5pl of SYBR green and run in the PCR machine.
2.4 Synergy testing
2.4.1 Assessment of Synergy
The effect of combination of agents on cell proliferation was assessed by calculating 
combination index (Cl) values using CalcuSyn software (Biosoft). Derived from the median-
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effect principal of Chou and Talalay, the Cl provides a quantitative measure of the degree of 
interaction between two agents.
Analysis using the CalcuSyn programme performs optimally when data is collected from a 
constant ratio combination design experiment. Typically the combination agents are chosen at 
their equipotent ratio (eg at the ratio of their ICsos) and mixtures of the agents at 4x, 2x, Ix, 
0.5x and 0.25x IC50 are prepared and tested, (Table 2.5.).
Agent 1
0 0.25x
(ED5o) i
0.5x
(ED5o) i
Ix
(EDsoIi
2x
(ED5o)i
4x
(ED5o) i
0
Control
(fa)o (fa)i (fa)i (fa)i (6)1 (f^)i
0.25x
(ED5o)2 (fa)2 (fa)i.2
Agent
0.5x
(ED5o)2 (fa)2 (fa)i.2
2 Ix
(ED5o)2 (&)2 (fa)i,2
2x
(EDso)2 (&)2 (fa)i.2
4x
(ED5o)2 (fa)2 (fa)i.2
Table 2.4 Synergy testing protocol
Because the ratio is constant, each mixture can be treated as a single agent to obtain the Dm 
(median effect dose or concentration -  ED50, IC50 or LD50 or TD50 if appropriate), m 
parameter (exponent signifying the sigmoidicity i.e. shape of the dose-effect curve), construct 
an automated Fa-CI (fraction affected-combination index) table and plot classic and 
conservative isobolograms.
In situations where the ratios are random or arbitrary or one concentration changes and the 
other is fixed, CalcuSyn can still be used to calculate combination index (Cl) values for each 
data point provided the m and Dm parameters for each single agent are available. Fa-CI plot 
simulations are not available, although the combination data plots can be placed on the Fa-CI 
plot
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Broadly speaking, a Cl value of 1 is additive, < 1 is synergistic and > 1 is antagonistic. This is
rather over simplified and the CalcuSyn authors suggest
Range of Cl______________ Symbol _________ Description________
<0.1 + + + + + very strong synergism
0.1-0.3 + + + + strong synergism
0.3-0.7 + + + synergism
0.7-0.85 + + moderate synergism
0.85-0.90 + slight synergism
0.90-1.10 +/- nearly additive
1.10-1.20 - slight antagonism
1.20-1.45 - -  moderate antagonism
1.45-3.3 ----  antagonism
3.3-10 ------  strong antagonism
> 1 0  ........... very strong antagonism
2.4.2 In vitro synergy assay
The effect of the combination of OncoVex GALV/CD and chemotherapy (cisplatin, 
gemcitabine) on bladder tumour cell (EJ, TCCSUP-G, T24) proliferation was assessed by 
calculating combination-index (Cl) values using CalcuSyn software (Biosoft, Ferguson, MO). 
Derived fiom the median-effect principle of Chou and Talalay (Chou and Talalay 1984) the
Cl provides a quantitative measure of the degree of interaction between two or more agents. A
Cl of 1 denotes an additive interaction, >1 antagonism and <1 synergy.
Cisplatin stock was at 1 mg/ml (=lg/l), Mwt = 290.1g/mol 
lg/14- 290.1g/mol—> 0.003447M = 3.447mM = 3447|xM 
Gemcitabine stock was at 40mg/ml (=40g/l), Mwt = 299.66g/mol 
40g/l 4 - 299.66g/mol-4 0.133484M = 133.48mM
Test cells were plated at 1 X 10"^  per well of a 96-well tray in appropriate FGM. Doubling 
dilution series were prepared from Oncovex GALVCD and chemotherapy (cisplatin or 
gemcitabine) in 2% FCS medium. Equipotent ED ratio of each agent was mixed for 
combination. lOOpL of appropriate dilution was added to each well as shown in Table 2.6 and 
incubate 48hr. After 2 days the cells were measured by the MTS assay.
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Cells only Cisplatin lxED$o
Oncovex 0.25xED5o M Cisplatin 2xED$o
Oncovex 0.5 xEDso E Cisplatin 4 xED5o
Oncovex IxEDso D Oncovex 0.25xED5o Cisplatin 0.25xEDso
Oncovex 2xEDso I Oncovex 0.5 xEDso Cisplatin 0.5 xEDso
Oncovex 4 xED5o U
M
Oncovex IxEDso Cisplatin IxEDso
Cisplatin 0.25xED5o Oncovex 2xEDso Cisplatin 2xEDso
Cisplatin 0.5 xEDso Oncovex 4 xED5o Cisplatin 4xEDso
Table 2.5 Prepared 96 well tray for synergy testing
2.5 Orthotopic rat bladder tumour model
All procedures were approved by United Kingdom Home Office and institutional boards. All 
animal experiments were repeated at least three times. Fischer F344 female rats were 
purchased from B&K Universal Ltd and from HARLAN.
2.5.1 Anaesthesia and analgesia of the rats
Female Fischer F344 rats were anesthetised either with intraperitioneal injections of Domitor 
and Ketaset or with balanced inhalation of Isoflurane. The used doses of Domitor and Ketaset 
is shown in Table 2.4. After the procedure the same amount Antisedant as Domitor was given 
to each animal to terminate the anaesthesia.
Anaesthetic Concentration 
of the stock
Diluted stock 
5x dilution in 
PBS *
Used dose Dilute drug 
volume per lOOg
Domitor
(Medotomi
dine)
1 mg/ml 0 .2 0 mg/ml 0.25mg/kg
ip
0.125ml/100g
Ketaset
Ketamine
lOOmg/ml 2 0 mg/ml 35mg/kg
ip
0.175ml/100g
Table 2.6 Anaesthetic drug doses used in this study
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At the induction part of balanced Isoflurane anaesthesia the average dose of Isoflurane was 
20.25 ml/hour and after 2 minutes the average dose was turned to 6.75 ml/hour of Isoflurane 
(Figure 2.4)
Figure 2.3 Inhalation anaesthesia with Isoflurane and the shared inhalation tube
There was no need to use painkillers (Vetergesic) during and after the procedures in this
study.
2.5.2 Bladder tumour implantation
Rats were placed in a supine position (on a homeothermic blanket). A 18-gauge plastic 
intravenous cannula (BD Venflon ™ Pro 393207) was used as a catheter. The catheter was 
inserted into the bladder via the urethra. To facilitate the tumour seeding the bladder mucosa 
was damaged by instillation of 0.4 ml 0.1 N hydrochloric acid for 15 seconds followed by a 
15-second rinse with 0.4ml of 0.1 N sodium hydroxide for neutralization. The bladder was 
then drained and washed five times with 0.6ml PBS (pH 7.4). A suspension of freshly 
harvested AY-27 cells (1.5-2.5x10^ cells in 0.4ml of medium) was then instilled and
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maintained in the bladder for 1 hour on homeothermic blanket to maintain. The rats were 
turned 90° laterally every 15 minutes to ensure exposure of the entire bladder wall to the 
tumour cells. After 1 hour the catheters were removed, and the rats were allowed to void 
spontaneously.
2.5.3 Assessment of tumour growth
2.5.3.1 Quantitative reverse transcription polymerase chain reaction
The frequent catheterisation to collect urine samples for the various assays may cause more 
damage and pain for the animals. We collected urine samples by holding the rats in a 
metabolization cage (Figure 2.5) for 1 hour (on day 0,4,7,11,14 after tumour implantation). 
Quantitative reverse transcription polymerase chain reaction (QRT-PCR) was performed on 
the collected urine samples to evaluate whether tumour growth is detectable by QRT-PCR.
Figure 2.4 Metabolization cage
2.5.3.2 Bioluminescent imaging using IVIS camera
Fischer F344 rats were anaesthetised and 1x10^ AY-27 HL-S cells in lOOul RPMI (without 
FCS) were injected subcutaneously. Luc expression was quantitated by real-time
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bioluminescent imaging using the IVIS System 200 series (Xenogen Biosciences) o-Luciferin 
Firefly Potassium salt (15 mg/mL; Xenogen Biosciences) was administered at 150 mg/kg and 
imaging was performed after 5 min. 30s exposures were obtained at high sensitivity using the 
machine default settings (Estop, 1; emission filter, open; field of view d, 12 cm; and subject 
height, 1.5 cm). The Xenogen software provides visual images of bioluminescence detection 
using a coloured overlay on a photographic image taken immediately before luminescence 
measurements. The areas shown in colour represent the regions of bioluminescence detected. 
Results were analyzed using Living Image 2.60.1 software (Xenogen Biosciences). Areas of 
Luc expression were defined using the autocontouring tool and the photon flux and average 
radiance (photons/cm^/s) were estimated over the defined area.
2.5.4 In vivo treatment of orthotopic rat bladder tumour model
Female Fischer F344 rats were anesthetised and place in a supine position on a homeothermic 
blanket. A catheter was inserted into the bladder via the urethra with the use of an 18-gauge 
plastic intravenous cannula (BD Venflon ™ Pro 393207). The rats were randomly assigned to 
3 treatment groups. Group A was treated with Oncovex GALV/CD + Prodrug, Group B was 
treated with Oncovex GALV/CD + PBS, Group C was treated with PBS + Prodrug. On day 
7,14 and 21 rats in Group A and B were treated with Oncovex GALV/CD, in Group C with 
PBS. On day 7-8, 15-16 and 22-23 rats in Group A and C were treated with prodrug, in Group 
B with PBS. (Figure 2.6)
All kind of treatments were instilled transurethrally through the catheter and were maintained 
in the bladder for 40 minutes. The rats were turned 90° laterally every 10 minutes to ensure 
exposure of the entire bladder wall. 9x10.7 pfti Oncovex GALV/CD virus was administered in 
600pl PBS (Virus stock: 1.8xl0.5pfu/pl). bOOpl of 5-Fluorocytosine (5-FC) in RPMI was 
then instilled (Concentration of stock: 15.0mg/ml). As control 600pl PBS (pH 7.4) was
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added. After 1 hour the catheters were removed, and the rats were allowed to void 
spontaneously.
O n c G A L V / C D
9e7 pfu 
Day 7
O n c G A L V / C D
9e7 pfu 
Day 14
O n c G A L V / C D
9e7 pfu 
Day 21
Kill
Day 28
ft +t w
IMPLANTATION 5-FC 12mg 5-FC 12mg 5-FC 12mg
Day 0 Day 8-9 Day 15-16 Day 22-23
Figure 2.5 Protocol for in vivo studies
After the treatment the animals were monitored daily for general health status and for signs 
symptoms of advanced bladder cancer (weight loss, abdominal mass, haematuria). The rats 
were sacrificed after a 28 days. There bladders were removed and assessed for tumour 
abundance. The harvested bladders were weighed, then opened up and the bladder surface 
which macroscopically contained tumour was measured with a caliper. Other organs within 
peritoneal cavity (liver, kidneys, spleen) were also checked during the autopsy for signs of 
macroscopic metastasis. The removed bladders were stored either in RNA later (for q-PCR) 
or either fixed in 10% phosphatebuffered formalin (for histological evaluation).
2.6 Statistics
The values of the experiments were presented as the mean ± standard deviation and analyis of 
variance was measured with using unpaired Student's t-test. Statistical significance was 
determined at P value less than 0.05. The survival curves were generated using the Kaplan- 
Meier method and compared using log-rank test.
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Chapter 3
The expression of fusogenic glycoprotein within an 
oncolytic Herpes Simplex Virus to enhance 
cytotoxicity killing of bladder tumour cells in vitro
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3 The expression of fusogenic glycoprotein within an 
oncolytic Herpes Simplex Virus to enhance 
cytotoxcity killing of bladder tumour control in 
vitro
3.1 Introduction
One of the approaches for cancer gene therapy is the transduction of tumour cells with viral 
fusogenic membrane glycoproteins (FMG) (Bateman, Bullough et al. 2000). A number of 
different viruses kill their target cells by causing fusion between infected and non-infected 
cells, via the interaction between the viral envelope with its receptor. This fusion of 
uninfected cells with infected cells represents a type of bystander effect. The fusogenic 
portions of membrane glycoproteins have been identified for the VSV, measles virus and 
HIV-1 (Sodroski, Goh et al. 1986; Duus, Hatfield et al. 1995; Laurent-Crawford, Coccia et al. 
1995; Cathomen, Naim et al. 1998). Transduction of these viral glycoproteins alone into 
human tumour cells has been shown to induce cell to cell fusion and formation of lethal multi­
nucleated syncytia (Sodroski, Goh et al. 1986; Cathomen, Naim et al. 1998). The cytotoxic 
activity of three envelope genes from different groups of viruses was originally evaluated 
(Bateman, Bullough et al. 2000), these include the rhabodoviral VSV-G envelope gene, the 
combination of F and H genes from measles virus and a mutated version of the retroviral 
Gibbon Ape Leukaemia Virus (GALV env R-) (Bateman, Bullough et al. 2000). In this early 
in vitro study all three membranes showed a high level of cell killing, with GALV enw R- 
showing the highest killing. Truncation of the GALV protein by removing 16 amino acids in 
the transmembrane R-peptide, which normally serves to restrict fusion of the envelope until it 
is cleaved during viral infection renders it constitutively highly fusogenic and therefore 
cytotoxic to human tumour cells (Diaz, Bateman et al. 2000).
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Transfection with GALV env R- or measles proteins F and H induces the formation of multi­
nucleated syncytia, bound by a single cellular membrane encompassing nuclei that 
individually still retain clearly defined nuclear membranes (Bateman, Bullough et al. 2000). 
Typically, these syncytia remain metabolically active and alive for anywhere from 12-120 
hours post-transfection. However, by 120 hours post-transfection, >90% of cells in culture are 
dead (Bateman, Bullough et al. 2000). Recruitment of bystander cells into the syncytium 
occurs by a process that appears to involve the organization of incoming nuclei along actin 
and microtubule bundles, such that large numbers of nuclei are localized close together. Later, 
adjacent nuclei can fuse together, but classic features of apoptosis, such as nuclear 
condensation or fragmentation and caspase activity are not detected (Higuchi, Bronk et al. 
2000; Bateman, Harrington et al. 2002).
Early studies in vitro showed that transfected FMG were able to cause cell fusion in a wide 
range of human cell lines including: 293, Mel624 (human melanoma), HT1080 (human 
fibrosarcomas), Hela (cervical carcinoma) and Tel.CeBb (human rhabdomyosarcoma) 
(Bateman, Bullough et al. 2000). Before FMG were successfully encoded into viral vectors, 
they were in vivo tested by transfecting plasmids in tumour cell lines, followed by injection of 
transfected cells into the flanks of nude mice. Transfected control plasmids showed no tumour 
regression of Mel624 and HT1080 cells in contrast cells transfected with FMG (in this case 
GALV env R-) under the CMV promoter showed up to 100% tumour regression in vivo nude 
mice models (Bateman, Bullough et al. 2000).
Early attempts to produce adenovirus virus vectors encoding GALV env R- failed because 
rapid cell fusion inhibited adenovirus replication (Diaz, Bateman et al. 2000). Therefore 
retroviral and lenti-viral delivery was investigated both of which encountered problems in 
generating high titre virus stocks. Such vectors were tested against human tumour xenografts.
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growing in nude mice, and resulted in considerable reduction in size of tumours compared to 
control vectors (Diaz, Bateman et al. 2000).
The authors detected, in GALV em  R- treated tumours, several immune stimulatory 
molecules associated with a stress response, such as heat shock proteins (Melcher, Todryk et 
al. 1998) the NK cell receptor (Groh, Steinle et al. 1998) and murine IFN-y. This suggests that 
the immune system may partly contribute to the mode of action of GALV env R- even in 
immuno-compromised animals such as nude mice.
The problems of expression were solved by encoding GALV env R- in HSV, initially inserted 
into strain G207 (Fu, Tao et al. 2003) and later a second generation virus OncoVEX^'^^ 
(Simpson, Han et al. 2006). These showed no impairment of viral replication such that virus 
stocks could easily be produced (Simpson, Han et al. 2006). The expression of GALV env R- 
caused syncytia formation in tumour cells of a variety of origins including from colon, brain, 
pancreas, lung, liver, prostate and connective tissue cancers (Fu, Tao et al. 2003; Simpson, 
Han et al. 2006). This fusogenic property also translated into a significantly increased tumour 
cell killing as compared to previous versions of oncolytic HSV vectors (Fu, Tao et al. 2003; 
Simpson, Han et al. 2006). In rodent tumour models, improved tumour shrinkage was seen 
with an approximately 5-10 fold reduction in the virus dose required to give equivalent 
tumour shrinkage or cure (Fu, Tao et al. 2003; Simpson, Han et al. 2006).
3.2 Study objectives
The prime aim of the study was to test the efficacy of Oncovex^^LV/CD on several 
transitional cell human bladder tumour cell lines (EJ, RT112, T24, VMCUB-I, TCCSUP-G,
5637, KU19-19) compared to the backbone virus (Oncovex^J^P) Xo establish this efficacy 
we need to first test for HSV infection alone in these cells and then elucidate whether
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expression of fusogenic glycoprotein from this virus increases cytotoxic cell killing within 
these cells.
3.3 Results
A panel of human bladder cancer cell lines was infected with OncoVex^^^ and 
OncoVEX^^^^^^ to compare plaque morphology, which may change with expression of the 
fusogenic glycoprotein from Gibbon Ape Leukaemia Virus. All the bladder cells infected with 
OncoVex^^^ showed a classic HSV-1 cytopathic effect. In contrast, four out of the seven cell 
lines infected with OncoVEX^'^^^^^ showed fusion in the form of large multinucleated 
syncytia which were then surrounded with cells showing the more classic HSV-1-mediated 
effect, (EJ cells, T24 cells, VMCUB-1 cells, and 5637 cells). To study whether the formation 
of multinucleated syncytia increases cytopathic effect of this virus (OncoVEX^"^^^^^) when 
compared to backbone vector (OncoVex^^^) in vitro MTS assays were carried out. Bladder 
tumour cells were infected with both viruses at a range of MOl (10,1, 0.1, 0.01, 0.001, 0), 
incubated for 48 hrs and the resulting infected cells were then tested for MTS activity, which 
measures the activity of mitochondrial enzymes needed for cell proliferation/cell survival, 
HSV replication should inhibit cell proliferation and therefore MTS activity (Promega). 
Lower levels of MTS activity was seen with OncoVEX^^^^^^ than OncoVex^^^ on infected 
EJ (42-54% decrease in cell survival), T24 (35-45%) VMCUB-1 (36-37%), 5637 (35%) cells. 
This suggests that the presence of GALV env R- results in a higher cytotoxicity and therefore 
increased tumour cell killing (Figure 3.1-4). In contrast RT112, TCCSUP-G, and KU19-19 
human bladder tumour cells did not show a fusogenic plaque morphology when infected with 
OncoVEX^^^^^^, or an increase in tumour cell killing in the presence of fusogenic 
glycoprotein from Gibbon Ape Leukaemia Virus (Figure 3.5).
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In summary all bladder tumours cells tested showed oncolysis in the presence of HSV. The 
presence of fusogenic glycoprotein enhanced the tumour cell killing by up to 54% in four out 
of seven bladder tumour cell lines (Table 3.1).
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AB
EJ cells
A # .  ■ sv -
Control
OncoVex^ '^ '^
MO! 10 MO! 1 MO! 0.1
15 100
I
□  O n e  G F P  
■  O N C G A L V  CD
10 1 0,1 MOI
P values: MOI 10:<0.001 MOI 1:<0.001 MOI 0.1: 0.056
Figure 3.1 2x10^ EJ cells were infected with OncoVex^^^ or OncoVex G A L V / C D at MOIs of 10,
1, 0.1 and incubated at 37°C/5% CO2 for 48 hours. Then assayed by Crystal Violet staining 
(A) or MTS assay (Promega). Average cell survival was calculated as a percentage compared 
to untreated cells (B). Experiments were repeated at least three times. The figure shows a 
representative experiment, where the error bars are standard deviations.
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T24
Control
OncoVex'G FP
OncoVexG A LV/C D
MOI 0.1 MOI 0.01 MOI 0.001
B
100
90
80
70
60
50
40
30
20
10
0 m
□  O ne GFP 
■  ONC GALV CD
0,1 0,01 0,001 MOI
P values: MOI 0.1 :<0.001 MOI 0.01:0.040 MOI 0.001: 0.611
Figure 3.2 2x10"^  T24 cells were infected with OncoVex^^^ or OncoVex^"^^^^  ^at MOIs of 
0.1, 0.01, 0.001 and incubated at 37°C/5% CO2 for 48 hours. Then assayed by Crystal Violet 
staining (A) or MTS assay (Promega). Average cell survival was calculated as a percentage 
compared to untreated cells (B). Experiments were repeated at least three times. The figure 
shows a representative experiment, where the error bars are standard deviations.
VMCUB-I cells
Control
OncoVexG FP
OncoVex G A LV /C D
MOI 1 MOI 0.1 MOI 0.01
B
90
80
7 0
SP 6 0
=  4 0
□  O n e  G F P  
■  O N C  GA LV  CD
0.1 0.01 MOI
Rvalues: MOI 1:< 0.059 MOI 0.1 :< 0.001 MOI 0.01: :< 0.001
Figure 3.3 2x10^ VMCUB-I cells were infected with OncoVex^^^ or OncoVex 
MOIs of 1, 0.1, 0.01 and incubated at 37°C/5% CO2 for 48 hours. Then assayed by Crystal 
Violet staining (A) or MTS assay (Promega). Average cell survival was calculated as a 
percentage compared to untreated cells (B). Experiments were repeated at least three times. 
The figure shows a representative experiment, where the error bars are standard deviations.
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89
A5637 cells
Control
mu
OncoVexGFP
t  V # OncoVexGALV/CD
MOI 0.1 MOI 0.01 MOI 0.001
B
100
« 80
<u
0,1 0,01
■  One GFP 
□  ONC GALV CD
0,001 MOI
Rvalues: MOI 0.1 :< 0.001 MOI 0.01: 0.002 MOI 0.001:0.359
Figure 3.4 2x10^ 5637 cells were infected with OncoVex^^^ or OncoVex^"^^^^^ at MOIs of 
0.1, 0.01, 0.001 and incubated at 37°C/5% CO2 for 48 hours. Then assayed by Crystal Violet 
staining (A) or MTS assay (Promega). Average cell survival was calculated as a percentage 
compared to untreated cells ( B ) .  Experiments were repeated at least three times. The figure 
shows a representative experiment, where the error bars are standard deviations.
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Figure 3.5 2x10^ RT112, TCCSUP-G and KU19-19 cells were infected with OncoVex^^^ or 
OncoVex^^^^^^ at MOIs of 10, 1, 0.1, 0.01, 0.001 and incubated at 37°C/5% CO2 for 48 
hours. MTS assay (Promega) did not show increase in cell killing with OncoVEX*^^^^^^ 
compared OncoVex^^^ backbone alone (P was > 0.05). Experiments were repeated at least 
three times. The figure shows a representative experiment, where the error bars are standard 
deviations.
Human bladder 
tumour cell lines
Histological
type
HSV-1
CPE
Increase efficacy due 
to GALV env R-
EJ ICC 4- 42-54%
T24 ICC + 35-45%
RT112 ICC -t- 0%
VMCUB-I TCC + 36-37%
TCCSUP-G ICC + 0-6%
5637 TCC 4- 35%
KU19-19 TCC + 0%
Table 3.1 Summary of fusion assay results on human cell lines
3.4 Discussion
Our in vitro studies using different bladder tumour cell lines showed that OncoVEX^^^'^^^ 
increases tumour killing in over half of the bladder cancer cell lines compared to backbone 
virus alone. We can therefore conclude from this study that expression of the truncated 
retroviral envelope GALV env R- greatly improves the dose response of the OncoVex^^^ 
backbone in bladder tumour cell lines. It is important to remember that the aim of this study is 
to improve the efficacy of the oncolytic HSV backbone virus. To allow expression of the 
truncated retroviral glycoprotein the backbone needs to enter the target cells and viral 
transcription needs to take place. The MTS assay data showed that all bladder cells tested 
demonstrated some efficacy to HSV alone (Figure 3.1-5), with T24, VMCUB-I, 5637 cells 
requiring lower levels of virus to see viral infection (MOI 0.1 and 0.01) whereas other cell 
lines, such as EJ cells, needed higher levels (MOI 10 and 1). RT112, TCCSUP-G and KU19- 
19 cells did not show increase in cell survival at any MOIs (MOI 10, 1, 0.1, 0.01, 0.001).
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An important point to note is that infection by HSV is needed for fusion but it is not the only 
control factor needed. Cellular factors are likely to play a role in fusion. Pit-1 is the GALV 
receptor, mandatory for fusion and entry for wild type Gibbon Ape Leukaemia Virus into 
their target cells.
In 1990 O’Hara and coworkers cloned, sequenced, and characterized the human cDNA 
encoding the receptor for GALV (O'Hara, Johann et al. 1990). The normal function of this 
multiple membrane-spanning receptor, designated Pit-1 (Kavanaugh, Miller et al. 1994; Olah, 
Lehel et al. 1994), is that of a type 111 sodium-dependent phosphate transporter. Pitl is 
ubiquitously expressed in mammalian normal tissues (Johann, Gibbons et al. 1992; 
Kavanaugh, Miller et al. 1994) and it plays a fundamental housekeeping role in Pi transport, 
(such as absorbing inorganic phosphate from interstitial fluid for normal cellular functions 
(cellular metabolism, signal transduction, and nucleic acid and lipid synthesis).
Limited studies have been carried out on the expression of Pit-1 on tumour tissue. What is 
known is that in human osteosarcoma, melanoma and renal carcinoma cells expression of Pit- 
1, at the level mRNA, occurs to different degrees (Palmer, Bonjour et al. 1997; Grabarczyk, 
Gryska et al. 2001). No direct relationship was found between the Pit-1 mRNA level and 
transduction efficiency on melanoma and renal carcinoma cells (Grabarczyk, Gryska et al. 
2001). Stimulation of retroviral receptor expression (Pit-1 and Pit-2) by phosphate depletion 
induced a limited increase of receptor mRNA levels, but did not improve the gene transfer 
efficiency (Grabarczyk, Wysocki et al. 2002). We can conclude that mRNA levels of Pit-1 
seem to show little correlation with viral fusion.
The presence of Pit-1 receptor has not been described yet in the literature in bladder cancer 
cell lines. Although all cell lines tested by our group were transitional cell type of bladder 
cancer it is very likely that there is a difference between them in the presence of Pit-1 receptor 
and this may account for which bladder tumour cell types fuse and which do not fuse.
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We found effective fusogenic activity by the OncoVEX^'^^^^^ at different MOI levels when 
testing the bladder cancer cell lines. The cause of the different effective MOI levels might be 
the different expression level of Pit-1 receptor in each bladder cancer cell line. In the future it 
would be an interesting question to evaluate the protein levels for Pit-1 receptor in bladder 
tumour cell lines as well.
We have detected fusogenic activity by both MTS and fixing/staining of infected cells. Each 
has shown a clear difference between backbone and Onc^^^^^^ on EJ, T24, VMCUB-1 and 
5637 cells. Athough we have seen some differences between the results of the MTS assay and 
fixing and staining method. The MTS results showed effective fusogenic activity at slightly 
higher MOI levels compared to the fixing and staining method in each cell line. This is related 
to the technique of fixing and staining method where we wash the cells at least four times 
with PBS which leads to a slightly lower concentration of cells on the slides.
3.5 Conclusion
In conclusion the results presented in this study indicate that the transduction of bladder 
tumour cells with viral fusogenic membrane glycoprotein (GALV) is new and effective 
approach for bladder cancer gene therapy in vitro using the OncoVEX^^^^^^ virus.
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Chapter 4
Expression of Fcy::Fur with (5-FC administration) 
to improve the cell killing of bladder tumours m vitro 
in conjunction with HSV oncolysis
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4 Expression of Fey: :Fur (with 5-FC 
administration) to improve the cell killing of 
bladder tumours in vitro in conjunction with HSV 
oncolysis
4.1 Introduction
4.1.1 Prodrug activation therapy for cancer
Prodrug activation therapy strives to deliver genes to cancer cells, which convert non-toxic 
prodrugs into active chemotherapeutic agents (Figure 4.1). The net gain is that a systemically 
administered prodrug can be converted into high local concentrations of an active anticancer 
drug in the tumour. To be clinically successful, both enzymes and prodrugs should meet 
certain requirements for this strategy (Niculescu-Duvaz, Spooner et al. 1998; Xu and McLeod 
2001; Yazawa, Fisher et al. 2002). The prodrug activating genes should be either of non­
human origin or a human protein that is absent or expressed only at low concentrations in 
normal tissues (Rigg and Sikora 1997; Weedon, Green et al. 2000). To provide catalytic 
activity the prodrug activating genes need to be sufficiently highly expressed in tumour cells. 
The prodrug should be a good substrate for the activating enzyme in tumours, but not be 
activated by cellular enzymes in non-tumour cells. An ideal prodrug system will have a 
bystander effect; that is the ability to kill non-expressing neighbouring tumour cells by the 
export of toxic metabolites. In addition, the half-life of active drug should be long enough to 
induce a bystander effect, but short enough to avoid leakage of the drug into the systemic 
circulation.
Different types of prodrug activation therapies were discussed above (see section 1.4.2.2) in 
this thesis.
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Prodrug Viral or non-viral transduction
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Cell death
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Death of neighbouring tumour cells
Figure 4.1 The three stages of activity of a prodrug activating system. In the first stage, a 
prodrug activating gene is transduced into and expressed in tumour cells. In the second stage a 
non-toxic prodrug is administered to the cells. The prodrug works as a substrate for the 
activating enzyme resulting in the production of toxic metabolites. These metabolites inhibit 
DNA or RNA replication resulting in cell death. The final stage is the export of these 
metabolites to kill the surrounding tumour tissue (bystander effect).
4.1.2 Prodrug activation therapies using Herpes Simplex Virus
4.1.2.1 Cytosine deaminase (CD)/uracil phosphoribosyltransferase (UPRT) and 
the prodrug (5-FC).
A commonly utilised enzyme prodrug combination is the E-coli /yeast enzyme cytosine 
deaminase (CD) and 5-fluorocytosine (5-FC). CD, a pyrimidine salvage enzyme, is the only 
known route by which cytosine is metabolised through hydrolytic deamination to uracil and
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ammonia. CD also deaminates the anti-fungal compound 5-fluorocytosine (5-FC) into 5- 
fluorouracil (5-FU), a highly toxic compound, widely used as a cancer chemotherapeutic 
agent (Moolten 1994). This enzyme has been found in prokaryotes and lower eukaryotes, but 
appears to be absent in higher eukaryotes (Kilstrup, Meng et al. 1989; Austin and Huber 
1993). Consequently, mammalian cells are resistant to 5-FC but not 5-FU (Mullen, Kilstrup et 
al. 1992; Pirollo, Rait et al. 2008). The cytotoxicity of 5-FU is determined by its conversion 
into 5-fluoro deoxyuridine monophosphate (5-FdUMP) and 5-fluorouridine triphosphate (5- 
FUTP) (Figure 4.2). 5-FdUMP is an irreversible inhibitor of thymidylate synthase, and 
depletes replicating cells of the thymidine nucleotide precursor, deoxythymidine triphosphate 
(dTTP), during DNA synthesis, while 5-FUTP inhibits RNA maturation and processing. The 
rate limiting step is the formation of an intermediary metabolite, 5-fluorouridine 
monophosphate (5-FUMP) (Niculescu-Duvaz, Spooner et al. 1998). It has been reported that 
the E. coli uracil phosphoribosyltransferase (UPRT) can markedly potentiate the anti-tumour 
effects of 5-FU by converting it directly into its intermediary 5-FUMP, thereby leading to 
more efficient generation of its active metabolites 5-FdUMP and 5-FUTP (Tiraby, Cazaux et 
al. 1998). A construct containing a fusion between the yeast Fey 1 and Fur 1 genes encoding 
cytosine deaminase and uracil phosphoribosyltransferase, respectively, is commercially 
available (Invivogen) and an identical chimera (FcyiFur). has been described by (Erbs, 
Régulier et al. 2000). FcyiFur exhibited similar UPRTase activity to the natural yeast gene, 
but CDase activity was 100 fold elevated compared to the yeast CD gene alone.
The mechanism of 5-FU cytotoxicity is unclear, because it is converted to several metabolites 
which each have different biochemical actions (Nakamura, Mullen et al. 2001). However, 
much interest has been placed in a metabolite 5 -fluorodeoxyuridylate that inhibits thymidylate 
synthase, which has been suggested to inhibit cellular DNA synthesis more than viral DNA 
synthesis (Nakamura, Mullen et al. 2001).
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The CD/5-FC prodrug activating system has been studied as a potential gene therapy strategy 
in a number of solid tumours. Investigators have demonstrated the efficacy of the CD gene/5- 
FC prodrug activating system when treating colon carcinoma (Austin and Huber 1993), 
pancreatic cancer (Evoy, Hirschowitz et al. 1997), breast cancer (Li, Shanmugam et al. 1997; 
Anderson, Krotz et al. 2000), and peritoneal carcinomatosis (Bentires-Alj, Hellin et al. 2000). 
Adenovirus-mediated (Ohwada, Hirschowitz et al. 1996; Topf, Worgall et al. 1998; Block, 
Freund et al. 2000) transfer of the CD gene showed enchanced local tumour control in colon 
carcinoma in the presence of prodrug 5-FC.
A murine leukaemia virus-based replication-competent retrovirus containing yeast cytosine 
deaminase gene plus 5-fluorocytosine dramatically inhibited the tumour growth in an 
orthotopic bladder animal model (Kikuchi, Menendez et al. 2007). An adenovirus-mediated 
CD gene therapy driven by human telomerase reverse transcriptase promoter was tested and 
found effective in combination with low-dose etoposide in bladder cancer cells (Shieh, Shiau 
et al. 2006). A double suicide gene therapy using adenovirus mediated cytosine deaminase- 
thymidine kinase fusion gene with ganciclovir or 5-fluorocytosine in a murine subcutaneous 
bladder carcinoma model was effective by significantly inhibiting tumour growth. The 
treatment efficacy of combining ganciclovir and 5-fluorocytosine was superior to only 
ganciclovir or 5-fluorocytosine groups (Tan, Xie et al. 2006).
Expression of yeast CD from a replication competent HSV-1 oncolytic virus mediates intra- 
tumoral conversion of 5-FC to 5-FU, which results in enhanced tumour cell killing compared 
with the backbone virus alone (Nakamura, Mullen et al. 2001; Simpson, Han et al. 2006). In 
vitro studies have shown increased killing in cell lines derived from lung cancer (A549, 
H460), pancreatic cancer (CAPAN-1, MIA PACA-2, BXPC-3) and colon cancer (HCT 116, 
HT-29, SW620) without inhibiting virus replication (Nakamura, Mullen et al. 2001; Simpson, 
Han et al. 2006).
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OncoVEX'GALV/CD described above, express both a highly potent version of CD (Fcy::Fur)
and the fusogenic glycoprotein from gibbon ape leukaemia virus (GALV). In the presence of 
5-fluorocytosine (5-FC), OncoVEX^^^^^^ showed greatly improved tumour contol in vitro 
and in vivo (Simpson, Han et al. 2006).
5-fluorocytosine (5-FC)
CD
UPRT
5-FUTP RNAsynthesis
•I UDP^ ^ UDK
5-fluorouracil -► 5-F-undme -► 5-FU M P  ■►5-FdUMP
(5-FU) .\
2’d-5F-uridlne
DPD
5-Fp-alanine
(renaily excreted metabolite of 5-FU)
UDF UDK
U r a c i l ^ ^  U r i d i n e ^ ^  UMP dUMP dlM P
(Thymidine precursor 
in DNA synthesis)
Figure 4.2 The metabolism of 5-fluoro-cytosine (5-FC) by cytosine deaminase (CD), and 
uracil phosphoribosyltransferase (UPRT) during DNA synthesis. CD converts 5-FC into 5- 
fluoro-uracil (5-FU). UPRT then converts 5-FU directly to 5-FUMP, which is then converted 
to its active metabolites 5-FdUMP and 5-FUTP. This bypasses the rate limiting mammalian 
cellular enzymes such as UDP (uridine phosphorylase), UDK (uridine kinase) and TK
100
(thymidine kinase). This also reduces the degradation of 5-FU by the competitive enzyme, 
DPD (dihydropyrimidine dehydrogenase). UMP (uridine monophosphate), dUMP (deoxy 
uridine monophosphate), dTMP (deoxy thymidine monophosphate), 2M-5F- uridine, (2’ 
deoxy 5-fluoro uridine), TS (thymidylate synthase)
4.2 Study objectives
We aimed to test in vitro the efficacy of Oncovex^-^LV/CD the presence of 5- 
fiuorocytosine on several human bladder tumour cell lines (EJ, RT112, T24, VMCUB-I, 
TCCSUP-G, 5637, KU19-19) compared to the backbone virus (Oncovex^FP),
4.3 Results
FcyxFur is a fusion of two genes CD and UPRT, which metabolizes 5-FC more efficiently 
than either gene alone. To study the cell killing effects of HSV-expressing Fcyr.Fur gQViQ in 
the presence of 5-FC human bladder tumour cells were infected with OncoVEX^^^^^ or 
OncoVEX^^^ in the presence or absence of 5-FC. The cell supernatants were then heat 
inactivated to neutralize the virus, allowing the effects of any 5-FU produced to be determined 
on fresh tumor cells (Figure 4.3).
In the presence of supernatants from cells infected with OncoVEX^^^ no cell death was seen 
with or without 5-FC (Figure 4.4A). However, in the presence of the supernatant from 
OncoVEX^^^^^ infected cells displayed effective cell killing in the presence of 5-FC (Figure 
4.4A). Results were similar in a range of human bladder tumor cell lines, including EJ cells, 
RT112 cells, TCCSUP-G cells, 5637 cells, KU19-19 cells (Figure 4.4-8). In contrast no 
observed tumour cell killing was seen with T24 or VMCUB-I human bladder tumour cells 
suggesting that either the cells are not sensitive to 5-FU metabolites or that the cells did not 
allow the active metabolism of 5-FC into 5-FU (Figure 4.9). MTS assays have allowed us to 
quantitate the effects of prodrug activation therapy on bladder tumour cells. EJ cells are the 
most susceptible for the prodrug activation therapy. A 55% decrease in tumour cell survival 
was detected on EJ cells at the concentration of 100pm 5-FC, which decreased further to 78%
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at 600|am 5-FC. RTl 12 and KU19-19 cells belong to the mid group in terms of sensitivity for
OneoVEX G A L V / C D prodrug aetivation therapy. At between 600-1000pm 5-FC these cell lines
showed around 70% deerease in tumour cell survival. Finally TCCSUP-G and 5637 eells 
showed the lowest sensitivity for this prodrug aetivation therapy. They showed around 53% 
decrease in tumour cell survival at 1000pm 5-FC.
OncovexGALV/CD
\
Human bladder cancer cells
48Hrs
Human bladder cancer cells
Cell Death
Remove supernatant 
and heat at 60®C for 
lOmins. Let cool to 
room temp
5-FC
Human bladder cancer cells
Cell Death
Figure 4.3 Outline of the protoeol for studying the effects of Fcy:Fur, expressed in HSV-1 
backbone veetor, in presence of 5-FC.
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Figure 4.4 1 x 10  ^EJ cells were infeeted with OncoVex^^^ and O n e o V a t  MOI of 1 
aceording to the fusion assay results and no virus control. After 30 minutes at 37°C/5% CO2 , 
the virus was removed, and 1 mL of PGM containing 5-FC (C4H4FN2 O; Sigma) at different 
coneentrations (0-100-300-600 pmol/L) was added and ineubated for 48 hours at 37°C/5% 
CO2 . The cell supernatants were then heat inaetivated and added to 1 x 10"^  fresh EJ cells and 
incubated at 37°C/5% CO2 for 72 hours. Assayed by Crystal Violet staining (A) or MTS assay 
(Promega)(B) was performed. Average eell survival was calculated as a percentage compared 
to untreated cells. All results showed enchanced tumour killing in the presence of 
OneoVEX*^ ^^ "^ *^^  ^ and 5-FC. Quantification of the prodrug studies showing that in all cases 
the differences were signifieant {P <0.05). (P values: GALV/CD+Opm Vs GFP+Opm =0.03, 
GALV/CD+lOOpm Vs GALV/CD+Opm =<0.000, GALV/CD+300pm Vs GALV/CD+Opm 
=<0.000, GALV/CD+600pm Vs GALV/CD+Opm =<0.000) Experiments were repeated at 
least three times. The figure shows a representative experiment, where the error bars are 
standard deviations.
103
RT112 cells
re
>
160
140
120
100
S 80
a>o 60
40
20
0
T
□ No virus 
■ ONC GFP
□ ONC GALV CD
OuM 800um lOOOum 5-FC
P values: 5FC 0pm: 0.531, 800 pm: <0.001, 1000 pm: <0.001
Figure 4.5 1x10^ RTl 12 cells were infected with OneoVex^^^ and OneoVex^^^^^^ at MOI 
of 0.1 and no virus control. After 30 minutes at 37°C/5% 00%, the virus was removed, and 1 
mL of FGM containing 5-FC (C4H4FN2O; Sigma) at different coneentrations (0-800-1000 
pmol/L) was added and incubated for 48 hours at 37°C/5% CO2 . The eell supernatants were 
then heat inaetivated and added to 1 x lO"^  fresh RTl 12 eells and incubated at 37°C/5% CO2 
for 72 hours and assayed by MTS assay (Promega). Average eell survival was calculated as a 
percentage compared to untreated cells. All results showed enchanced tumour killing in the 
presence of OneoVEX^^^^^^ and 5-FC. Quantification of the prodrug studies showing that in 
all eases the differences were signifieant (P <0.05). (P values: GALV/CD+Opm Vs GFP+Opm 
=0.531, GALV/CD+800pm Vs GALV/CD+Opm =<0.000, GALV/CD+lOOOpm Vs 
GALV/CD+Opm =<0.000) Experiments were repeated at least three times. The figure shows 
a representative experiment, where the error bars are standard deviations.
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Figure 4.6 1 x 10^  TCCSUP-G cells were infected with OncoVex®^^ and OncoVex^^^^^^ at 
MOI of 0.1 and no vims control. After 30 minutes at 37°C/5% CO2 , the vims was removed, 
and 1 mL of FGM containing 5-FC (C4H4FN2O; Sigma) at different concentrations (0-1000- 
1200-1400 pmol/L) was added and incubated for 48 hours at 37°C/5% CO2 . The cell 
supernatants were then heat inactivated and added to 1 x 10"^  fresh TCCSUP-G cells and 
incubated at 37°C/5% CO2 for 72 hours and assayed by MTS assay (Promega). Average cell 
survival was calculated as a percentage compared to untreated cells. All results showed
enchanced tumour killing in the presence of OneoVEX G A L V / C D and 5-FC. Quantification of
the prodmg studies showing that in all cases the differences were significant {P <0.05). (P 
values: GALV/CD+Opm Vs GFP+Opm =0.212, GALV/CD+1000pm Vs GALV/CD+Opm 
=<0.000, GALV/CD+1200pm Vs GALV/CD+Opm =<0.000, GALV/CD+1400pm Vs 
GALV/CD+Opm =<0.000) Experiments were repeated at least three times. The figure shows 
a representative experiment, where the error bars are standard deviations.
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Figure 4.7 1x10^ 5637 cells were infected with OncoVex^^^ and OncoVex^^^^^° at MOI of 
0.1 according to the fusion assay results and no virus control. After 30 minutes at 37°C/5% 
CO2 , the virus was removed, and 1 mL of FGM containing 5-FC (C4H4FN2O; Sigma) at 
different concentrations (0-600-800-1000 pmol/L) was added and incubated for 48 hours at 
37°C/5% CO2 . The cell supernatants were then heat inactivated and added to 1 x 10"^  fresh 
5637 cells and incubated at 37°C/5% CO2 for 72 hours and assayed by MTS assay (Promega). 
Average cell survival was calculated as a percentage compared to untreated cells. All results 
showed enchanced tumour killing in the presence of OncoVEX*^^^^^^ and 5-FC. 
Quantification of the prodrug studies showing that in all cases the differences were significant 
(P <0.05). (P values: GALV/CD+Opm Vs GFP+Opm =0.856, GALV/CD+600pm Vs 
GALV/CD+Opm =<0.000, GALV/CD+800pm Vs GALV/CD+Opm =<0.000, 
GALV/CD+1000pm Vs GALV/CD+Opm =<0.000) Experiments were repeated at least three 
times. The figure shows a representative experiment, where the error bars are standard 
deviations.
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Figure 4.8 1x10^  KU19-19 cells were infected with OncoVex*^^  ^ and Onco Vex 
MOI of 0.1 and no virus eontrol. After 30 minutes at 37°C/5% CO2 , the virus was removed, 
and 1 mL of FGM containing 5-FC (C4H4FN2O; Sigma) at different concentrations (0-600- 
800-1000 pmol/L) was added and incubated for 48 hours at 37°C/5% CO2 . The cell 
supernatants were then heat inactivated and added to 1 x 10"^  fresh KU19-19 cells and 
incubated at 37°C/5% CO2 for 72 hours and assayed by MTS assay (Promega). Average cell 
survival was calculated as a percentage compared to untreated cells. All results showed 
enchanced tumour killing in the presence of OncoVEX^^^^^^ and 5-FC. Quantifieation of 
the prodrug studies showing that in all cases the differences were signifieant {P <0.05). (P 
values: GALV/CD+Opm Vs GFP+Opm =0.769, GALV/CD+600pm Vs GALV/CD+Opm 
=<0.000, GALV/CD+800pm Vs GALV/CD+Opm =<0.000, GALV/CD+1000pm Vs 
GALV/CD+Opm =<0.000) Experiments were repeated at least three times. The figure shows 
a representative experiment, where the error bars are standard deviations.
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Figure 4.9 1 x 10^  T24 and VMCUB-I cells were infected with OneoVex*^^  ^ and 
OncoVex^"^^^^^ at MOI of 0.1 and no virus control. After 30 minutes at 37°C/5% CO2 , the 
virus was removed, and 1 mL of FGM containing 5-FC (C4H4FN2O; Sigma) at different 
concentrations (0-100-300-600-800-1000-1200-1400 pmol/L) was added and incubated for 48 
hours at 37°C/5% CO2 . The cell supernatants were then heat inactivated and added to 1 x 10"^  
fresh T24 and VMCUB-I cells and ineubated at 37°C/5% CO2 for 72 hours. MTS assay 
(Promega) did not show enchanced tumour killing in the presence of OncoVEX^^^^^^^ and 5- 
FC (P was > 0.05). Experiments were repeated at least three times. The figure shows a 
representative experiment, where the error bars are standard deviations.
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In summary five out of seven bladder tumour cell line showed increased tumour cell killing in 
vitro when infected with OncoVEX^^^^^^ virus in the presence of 5-FC (Table 4.1). We 
have tried to calculate IC50’s of each cell line, but we do not have enough data yet to 
accurately calculate an IC50. We would need to repeat our experiments with a bigger spread 
of 5-FC concentration.
Cell type
Effective dose 
of 5-FC.
% Decrease 
cell survival
EJ 600uM 78%
T24 600uM -0%
RTl 12 SOOuM 68%
VMCUB-I 1400uM 0%
TCCSUP-G lOOOuM 54%
5637 lOOOuM 53%
KU19-19 600uM 67%
Table 4.1 Summary of prodrug assay results on human bladder tumour cell lines.
4.4 Discussion
Prodrug activation therapy strives to deliver genes to cancer cells, whieh convert non-toxic 
prodrugs into active chemotherapeutic agents. Using this method a systemically administered 
prodrug can be converted into high local concentrations of an active anticancer drug in the 
tumour. We evaluated the prodrug activating effect of the OncoVEX^^^^^^ virus in vitro on 
seven bladder tumour cell lines.
We can conclude from these in vitro experiments that expression of the Fcy:Fur gene within 
the HSV-1 backbone vector promotes active metabolism of 5-FC into 5-FU and further into 
its metabolites, resulting in tumour cell killing in five out of seven bladder tumour cell lines 
(EJ, RTl 12, TCCSUP-G, 5637, KU19-19). The percentage cell survival is based on the 
uninfected cells as control (100%). Most of the virus controls appear to be over 100% (120- 
130%). We feel that this may be due to the fact that virus infected cells will not use up as
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many nutrients in the media compared to uninfected cells. Therefore after heat activation the 
viral media offers a greater growth potential then the uninfected control. Two out of seven 
tested bladder tumour cell lines (T24, VMCUB-I) failed to improve tumour cell killing when 
infected with OncoVEX^"^^^^° in the presence of 5-FC. This failure to improve tumour cell 
killing by prodrug activation, may be due to a number of factors, that include either the cells 
are not sensitive to 5-FU metabolites or that the cells did not allow the active metabolism of 
5-FC into 5-FU metabolites.
A recent proteomic study on colorectal adenocarcinoma cells transfected ^vith cytosine 
deaminase in the presence of 5-FC, has shown an upregulation of a wide range of proteins 
involved in resistance to anticancer drugs and resistance to apoptosis (Negroni, Samson et al. 
2007). Examples of some of the genes that are upregulated include the antioxidative gene 
thioredoxin-like 2 protein, aldehyde dehydrogenase, dihydropyrimidine-related protein 2 and 
Ezrin. The antioxidative gene thioredoxin-like 2 protein controls redox balance, cell growth 
and apoptosis, and has also been shown to increase tumour cell growth and chemotherapy 
resistance (Powis, Mustacich et al. 2000). Aldehyde dehydrogenase is a mitochondrial 
enzyme, genetic variability in this gene has been linked to resistance to the anti agent 
cyclophosphamide (Di Paolo, Danesi et al. 2004). The dihydropyrimidine-related protein 2 is 
involved in the pyrimidine metabolism and in the catabolism of 5-FU (Nyhan 2005). Patients 
with a partial dihydropyrimidine deficiency proved to be at risk of developing severe toxicity 
after 5-FU administration (van Kuilenburg, Meinsma et al. 2004). Ezrin is a cytoskeletal 
protein which has a major role in cell polarization through actin binding and the role of ezrin 
in metastasis behaviour has been well documented (Fais 2004). Also ezrin is connected to P- 
glycoprotein, which regulates the efflux pumps that are responsible for some of the multidrug 
resistance mechanisms of tumours (Luciani, Molinari et al. 2002). From this study we can 
hypothesize that some of the drug resistance genes up-regulated in colorectal adenocarcinoma
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cells expressing CD/5-FC, may be also up-regulated in bladder TCC carcinoma cell lines, 
although the expression of UPRT will alter the down stream effects dramatically. Further to 
this, genetic variation in such drug resistance genes within each TCC cell line may well be a 
controlling factor in the different level of susceptibility to prodrug seen in these cells. In the 
future a proteomic study on different TCC cell lines infected with our virus in the presence of 
prodrug could answer some of these questions.
4.5 Conclusion
In conclusion the results presented in this study indicate that the transduction (by an oncolytic 
HSV) of bladder tumour cells with prodrug activating (CD) gene in the presence of 5-FC led 
to enhanced tumour control in vitro.
Cell type
Hystologic
type
HSV-1 CPE
Fusion Prodrug
EJ TCC + + +
T24 TCC + + -
RT112 TCC + - +
VMCUB-I TCC + + -
TCCSUP-G TCC + - +
5637 TCC + + +
KU19-19 TCC + - +
Table 4.2 Summary of fusion and prodrug assay results on human bladder tumour cell lines.
We can also conclude from the summary of results (Table 4.2) that all human bladder tumour 
cell lines tested are susceptible to HSV oncolysis and showed enhanced tumour cell killing in 
at least one type (fusion or prodrug) of the assays when infected with OncoVEX^^^^^^ virus. 
The combination of oncolytic transduction of bladder tumour cells with viral fusogenic 
membrane glycoprotein (GALV) and a prodrug activating system (CD) can further increase
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tumour control in vitro. Therefore OncoVEX^"^^^^^ would need to be tested as a potential 
new approach against bladder cancer in vivo.
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Chapter 5
Efficacy of OncovexGALV/CD in combination with
chemotherapeutic drugs
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5 Efficacy of OncovexGALV/CD in combination 
with chemotherapeutic drugs
5.1 Introduction
Surgery and chemotherapy still remain the principal treatments for bladder cancer and the 
combination of two has become the gold standard treatment for bladder cancers. In selected 
cases radiotherapy also remains an alternative therapeutic option. While the combination of 
surgery and chemotherapy has undoubtedly led to improvements in survival there is still a 
significant need for new treatment modalities. It is well accepted that one single therapy is 
unlikely to cure a particular cancer since evidence from conventional therapies suggests that a 
combination of therapies is much more likely to work in the clinic.
The field of molecular cancer therapy using viral vectors embraces a range of technologies 
including direct attack on tumour cells using oncolytic viruses or prodrug activating systems, 
and enhancement of the immune response to tumour antigens. The combination of these new 
treatment modalities (such as the gene therapy with viral vectors) with the conventional 
therapies (chemotherapy, radiotherapy) might be a promising alternative therapeutic option. 
Ionizing radiation and chemotherapy approaches to cancer therapy destroy dividing cells 
because tumour cells divide more rapidly than normal cells. These therapies have to be 
balanced between causing maximum damage to the cancer cells, while keeping toxicity in 
normal host cells within acceptable levels. The combination of conventional therapies and the 
gene therapy may further improve the efficacy. (Advani, Chmura et al. 1997; Advani, Chung 
et al. 1999; Chahlavi, Todo et al. 1999; Toyoizumi, Mick et al. 1999; Stanziale, Petrowsky et 
al. 2002).
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It was previously shown that a replication-selective herpes simplex virus type 1 ICP34.5 
mutant (HSV-1716) was effective both in vitro and in vivo against human non-small cell lung 
cancer (NSCLC) cell lines but complete eradication of tumor has not been accomplished with 
a single viral treatment in a murine xenograft model (Toyoizumi, Mick et al. 1999). 
Mitomycin-C is a natural anti-tumor antibiotic, used clinically as a chemotherapy agent. The 
bioreductive activation of MMC allows for alkalization of guanine residues leading to DNA 
inter and intra-strand cross-linking (Paz, Das et al. 1999). Toyoizumi et al evaluated the 
oncolytic activity of HSV-1716 in NCI-H460 cells in combination with mitomycin C (MMC). 
The oncolytic effect of HSV-1716 in combination with MMC was synergistic in two of five 
NSCLC cell lines. In the other three cell lines, the combined effect appeared additive and no 
antagonism was observed. The in vivo effect of this combination was then examined in a 
murine xenograft model. NCI-H460 flank tumors were directly injected with HSV-1716 
followed by intravenous MMC administration 24 hours later. After 3 weeks, the mean tumor 
weight in the combined treatment group was significantly less than either individual treatment 
in an additive manner. The synergistic dose of MMC neither augmented nor inhibited viral 
replication in vitro and HSV-1716 infection did not upregulate DT-diaphorase, which is the 
primary enzyme responsible for MMC activation (Toyoizumi, Mick et al. 1999).
Mullerad et al tested the strain of HSV called NV1066 in combination with MMC in KU19- 
19 and SKUB cell lines and they found significantly improved cell kill for the combination 
treatment (P<0.001) (Mullerad, Bochner et al. 2005). Based on the nine different combination 
ratios tested, it was determined that a ratio of 1:10 NV1066 to mitomycin-C conveyed the 
strongest synergistic effect, as the combination index achieved for this ratio was the lowest. 
The combination of the oncolytic replication competent herpes simplex virus type-1 (HSV) 
and mitomycin C as a chemotherapeutic agent demonstrated synergistic effect with about 
90% estimated cell killing in an orthotopic murine model (Mullerad, Bochner et al. 2005).
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Other types of vector, in addition to herpes simplex viral gene therapies, were tested in combination 
with conventional therapies. In vitro treatment with an adeno-associated virus-2 vector encoding 
p53 gene treatment in combination with cisplatin showed a synergistic killing effect on the 
5637 bladder cell line (Ruifa, Liwei et al. 2006). The systemic administration of recombinant 
IL-2 in combination with ADV/RSV-HSV-tk gene therapy with acyclovir was tested in a 
murine bladder tumor model and exhibited an enhanced antitumor effect (Terao, Shirakawa et 
al. 2005). The combination of adenoviral vector containing wild-type human p53 gene 
(Ad5CMV-p53) and cisplatin revealed synergy which is a potential method for overcoming 
resistance (Pagliaro, Keyhani et al. 2003).
Gene therapy combined with radiation represents another new approach for cancer treatment. 
An adenovirally directed, cytosine deaminase plus 5-fluorocytosine gene therapy was tested 
in combination with radiotherapy. This combination resulted in enhanced tumour cell killing 
of human bladder-cancer cells in vitro and enhanced tumour-growth inhibition in the KK47 
subcutaneous tumour model (Zhang, Shirakawa et al. 2003).
As discussed above complete eradication of bladder tumours has not been accomplished with 
a single viral treatment in a murine model, therefore we investigated the combined effect of 
oncolytic HSV and chemotherapy agents.
5.2 Study objectives
We aimed to test in vitro the efficacy of O n c o v e x ^ ^ L V / C D  combination with 
conventional chemotherapies such as mitomycin, cisplatin, gemcitabine on human bladder 
tumour cell lines (EJ, T24, TCCSUP-G, KU19-19). We planned to assess these agents in 
combination with cytotoxicity assays and using the CalcuSyn programme to evaluate the 
effect of combination by calculating the combination index (Cl) values.
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5.3 Results
The effect of the combination of OncoVex^'^^^^^ and chemotherapy (mitomycin, cisplatin, 
gemcitabine) on bladder tumour cell (EJ, TCCSUP-G, T24, KU19-19) proliferation was 
assessed by calculating combination-index (Cl) values using CalcuSyn software (Biosoft, 
Ferguson, MO). Derived from the median-effect principle of Chou and Talalay (Chou and 
Talalay 1984), the Cl provides a quantitative measure of the degree of interaction between 
two or more agents. A Cl of 1 denotes an additive interaction, >1 antagonism and <1 synergy. 
Analysis using the CalcuSyn programme performs optimally when data is collected from a 
constant ratio combination design experiment. Typically the combination agents are chosen at 
their equipotent ratio (eg at the ratio of their ICsqs). The human bladder cancer cell lines were 
infected with OncoVEX^^^^^^ or treated with one of the chemotherapeutical agents 
(mitomycin, cisplatin, gemcitabine) or both in combination where the equipotent ED ratio of 
each agent was mixed for combination. The cells were measured by the MTS assay after 2 
days. Our results showed synergistic effect when OncoVEX^^^^^^ was combined with 
mitomycin in EJ, T24 and KU19-19 cells (Figure 5.1, 5.2, 5.3). Whereas the combination 
effect of OncoVEX^^^^^^ with cisplatin or gemcitabine was antagonistic in EJ, T24 and 
TCCSUP-G cells (Figure 5.4, 5.5, 5.6, 5.7, 5.8, 5.9) (Table 5.1). In order to evaluate whether 
this antagonistic effect is related to the Herpes Simplex Virus instead of to the implanted 
GALV and CD genes we have tested the backbone OncoVEX^^^ in combination with 
cisplatin or gemcitabine in EJ cells. Results showed antagonistic effect both with cisplatin or 
gemcitabine (Table 5.1).
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Figure 5.1 EJ cells were plated at 1 x 10 per well of a 96-well tray in appropriate FGM.
Doubling dilution series were prepared from Oncovex G A L V C D and mitomyein in 2% PCS
medium. Equipotent ED ratio of each agent was mixed for combination. lOOpL of appropriate 
dilution was added to each well and incubate 48hr. After 2 days the cells were measured by 
the MTS assay (A). The isobologram curves (B) and the combination indexes were prepared 
by using CalcuSyn programme (Biosoft, Ferguson, MO). Experiments were repeated at least 
three times. The figure shows a representative experiment, where the error bars are standard 
deviations.
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Figure 5.2 T24 cells were plated at 1 x 10"^  per well of a 96-well tray in appropriate FGM. 
Doubling dilution series were prepared from Oncovex^^^^^^ and mitomycin in 2% PCS 
medium. Equipotent ED ratio of each agent was mixed for combination. 1 OOpL of appropriate 
dilution was added to each well and incubate 48hr. After 2 days the cells were measured by 
the MTS assay (A). The isobologram curves (B) and the combination indexes were prepared 
by using CalcuSyn programme (Biosoft, Ferguson, MO). Experiments were repeated at least 
three times. The figure shows a representative experiment, where the error bars are standard 
deviations.
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Figure 5.3 KU19-19 cells were plated at 1 x 10 per well of a 96-well tray in appropriate 
FGM. Doubling dilution series were prepared from Oncovex^^^^^ and mitomycin in 2% 
PCS medium. Equipotent ED ratio of each agent was mixed for combination. lOOpL of 
appropriate dilution was added to each well and incubate 48hr. After 2 days the cells were 
measured by the MTS assay (A). The isobologram curves (B) and the combination indexes 
were prepared by using CalcuSyn programme (Biosoft, Ferguson, MO). Experiments were 
repeated at least three times. The figure shows a representative experiment, where the error 
bars are standard deviations.
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Figure 5.4 EJ cells were plated at 1 x lO'^  per well of a 96-well tray in appropriate FGM. 
Doubling dilution series were prepared from Oncovex^"^^^^^ and cisplatin in 2% PCS 
medium. Equipotent ED ratio of each agent was mixed for combination. 1 OOpL of appropriate 
dilution was added to each well and incubate 48hr. After 2 days the cells were measured by 
the MTS assay (A). The isobologram curves (B) and the combination indexes were prepared 
by using CalcuSyn programme (Biosoft, Ferguson, MO). Experiments were repeated at least 
three times. The figure shows a representative experiment, where the error bars are standard 
deviations.
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Figure 5.5 T24 cells were plated at 1 x 10"^  per well of a 96-well tray in appropriate FGM.
Doubling dilution series were prepared from OncovexG A L V C D and cisplatin in 2% PCS
medium. Equipotent ED ratio of each agent was mixed for combination. 1 OOpL of appropriate 
dilution was added to each well and incubate 48hr. After 2 days the cells were measured by 
the MTS assay (A). The isobologram curves (B) and the combination indexes were prepared 
by using CalcuSyn programme (Biosoft, Ferguson, MO). Experiments were repeated at least 
three times. The figure shows a representative experiment, where the error bars are standard 
deviations.
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Figure 5.6 TCCSUP-G cells were plated at 1 x 10"^  per well of a 96-well tray in appropriate
FGM. Doubling dilution series were prepared from Oncovex G A L V C D and cisplatin in 2% PCS
medium. Equipotent ED ratio of each agent was mixed for combination. 1 OOpL of appropriate 
dilution was added to each well and incubate 48hr. After 2 days the cells were measured by 
the MTS assay (A). The isobologram curves (B) and the combination indexes were prepared 
by using CalcuSyn programme (Biosoft, Ferguson, MO). Experiments were repeated at least 
three times. The figure shows a representative experiment, where the error bars are standard 
deviations.
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Figure 5.7 EJ cells were plated at 1 x 10 per well of a 96-well tray in appropriate FGM.
Doubling dilution series were prepared from Oncovex G A L V C D and gemcitabine in 2% PCS
medium. Equipotent ED ratio of each agent was mixed for combination. 1 OOpL of appropriate 
dilution was added to each well and incubate 48hr. After 2 days the cells were measured by 
the MTS assay (A). The isobologram curves (B) and the combination indexes were prepared 
by using CalcuSyn programme (Biosoft, Ferguson, MO). Experiments were repeated at least 
three times. The figure shows a representative experiment, where the error bars are standard 
deviations.
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Figure 5.8 T24 cells were plated at 1 x 10"^  per well of a 96-well tray in appropriate FGM.
Doubling dilution series were prepared from Oncovex G A L V C D and gemcitabine in 2% FCS
medium. Equipotent ED ratio of each agent was mixed for combination. lOOpL of appropriate 
dilution was added to each well and incubate 48hr. After 2 days the cells were measured by 
the MTS assay (A). The isobolgram curves (B) and the combination indexes were prepared by 
using CalcuSyn programme (Biosoft, Ferguson, MO). Experiments were repeated at least 
three times. The figure shows a representative experiment, where the error bars are standard 
deviations.
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Figure 5.9 TCCSUP-G cells were plated at 1 x 10  ^per well of a 96-well tray in appropriate
FGM. Doubling dilution series were prepared from Oncovex G A L V C D and gemcitabine in 2%
FCS medium. Equipotent ED ratio of each agent was mixed for combination. lOOpL of 
appropriate dilution was added to each well and incubate 48hr. After 2 days the cells were 
measured by the MTS assay (A). The isobologram curves (B) and the combination indexes 
were prepared by using CalcuSyn programme (Biosoft, Ferguson, MO). Experiments were 
repeated at least three times. The figure shows a representative experiment, where the error 
bars are standard deviations.
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OncovexGALVCD
Origin Cell type ^ Mitomycin Cisplatin Gemcitabine
Human EJ Synergistic Antagonistic Antagonistic
T24 Synergistic Antagonistic Antagonistic
TCCSUP-G NAD Antagonistic Antagonistic
KU19-19 Synergistic NAD NAD
OncovexGFP
Origin Cell type Mitomycin Cisplatin Gemcitabine
Human EJ NAD Antagonistic Antagonistic
Table 5.1 The coadministration of Oncovex^^^^^ and mitomycin was synergistic whereas 
the coadministration of both Oncovex^"^^^^ or Oncovex^^^ and cisplatin or gemcitabine was 
antagonistic. (NAD: no available data)
5.4 Discussion
The use of combined drug treatments is becoming commonplace in the treatment of cancer. 
We have tested the efficacy of Oncovex^^LV/CD jn combination with conventional 
chemotherapies such as mitomycin, cisplatin, gemcitabine on human bladder tumour cell 
lines.
Why is oncolytic HSV synergistic with mitomycin C but not cisplatin/gemcitabine on bladder 
transitional cell carcinoma? During the past decade gemcitabine gained widespread use for 
the treatment of bladder cancer (Moore, Tannock et al. 1997; Fechner, Perabo et al. 2003; 
Muramaki, Miyake et al. 2004). Gemcitabine, a cytotoxic pyrimidine deoxynucleoside 
analogue, is transported into the cell mostly by human nucleoside transporters (hENT and 
hCNT, respectively. As with other analogues of pyrimidines, the triphosphate analogue of
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gemcitabine replaces one of the nuclosides to be incorporated into growing DNA strands and 
therefore acts as a chain terminator to stop DNA polymerase (Blackstock, Lightfoot et al. 
2001). The process arrests tumour growth, resulting in apoptosis (Blackstock, Lightfoot et al. 
2001). The majority of drugs used in the clinical treatment of HSV-1 related diseases target 
the viral DNA polymerase activity by also acting as a nucleoside analog inhibitor 
(Ganciclovir, Acyclovir and l-(2’-deoxy-2’-fluoro-y^-D-arabinofuranosyl)-5-iodouracyl). The 
virus thymidine kinase gene catalyses the phosphorylation of the purine nucleosides 
analogues converting them to their corresponding nucleoside monophosphates, which are 
catalysed to nucleoside diphosphates by mammalian nucleoside monophosphate kinases and 
are subsequently converted to the tri phosphate form by nucleoside diphosphate kinase (Miller 
and Miller 1980). The triphosphate form is able to stall DNA synthesis by inhibiting DNA 
polymerase and by incorporation into DNA causing chain termination (Elion 1980; Davidson, 
Kaufman et al. 1981; Mar, Chiou et al. 1985), thus killing infected cells (Elion 1980). It is 
possible that gemcitabine causes chain termination of both viral and host DNA which results 
in the failure of replication of the virus and synergy between this chemo agent and oncolytic 
HSV-1.
Cisplatin is commonly used in combination regimes for the treatment of bladder cancer. Its 
cytotoxicity is mediated through platinum-DNA adducts, resulting in apoptosis and cell cycle 
arrest (Boulikas and Vougiouka 2003). However, this apoptosis is responsible for the 
characteristic nephrotoxicity, ototoxicity, and neurotoxicity (Boulikas and Vougiouka 2003). 
Adusumilli et al (Adusumilli, Chan et al. 2006) showed that low-dose cisplatin was used to 
induce the cellular stress response, with minimal activation of apoptotic pathways against 
malignant pleural mesothelioma. High-dose cisplatin caused not only toxicity but also a high 
apoptotic cell fraction, which hindered HSV-1 oncolysis by limiting viral replication 
(Stanziale, Petrowsky et al. 2004). Other investigators have shown that cisplatin did not
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inhibit the efficacy of replication-competent HSV in the treatment of head and neck squamous 
cell carcinoma and in non-small cell lung cancer (Chahlavi, Todo et al. 1999; Toyoizumi, 
Mick et al. 1999).
Mitomycin C is an antibiotic that is a potent cross-linker of DNA and has widely been used in 
cancer chemotherapy (Tomasz 1995). A single crosslink per genome has shown to be 
effective in killing bacteria (Szybalski and Iyer 1964). A general mechanism of action for 
MMC has emerged that is activated regardless of the source of reducing equivalents, 
comprising three competing pathways that give rise to unique reactive intermediates and 
different DNA adducts. Partitioning into the pathways is dictated by chemical considerations 
such as pH and drug concentration. DT-diaphorase stands out in this mechanism, since it is 
much less effective at metabolizing MMC at neutral pH. At least five different enzymes can 
catalyse MMC bioreduction in vitro, and as many activities may be present in solid tumours, 
including a series of novel mitochondrial reductases such as a cytochrome P450 reductase. 
Competition between reductases for MMC appears to be based solely on protein levels rather 
than enzyme kinetics. Consequently, DT-diaphorase can occupy a central role in MMC 
metabolic activation since it is often highly overexpressed in cancer cells (Cummings, 
Spanswick et al. 1998). It would be interesting to study the expression of DT-diaphorase 
within infected cells. Oncolytic HSV-1 viruses (NV1066, G207) has previous been shown to 
be synergistic with mitomycin C on one bladder transitional cell carcinoma cell line (Rul9- 
19)(Mullerad, Bochner et al. 2005) and a number of gastric cancer cell lines (Bennett, 
Adusumilli et al. 2004). Mitomycin C cross-links in a specific DNA sequence manner, its 
target being CpG sites. CpG sites are regions of DNA where a cytosine nucleotide occurs next 
to a guanine nucleotide in the linear sequence of bases along its length. Why does oncolytic 
HSV act synergistically with mitomycin C? A hypothesis could be that the HSV genome 
lacks the target CpG and therefore does not inhibit the cross-linker effects of mitomycin C. It
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has been shown that the genome of HSV resembles bacterial DNA in having a high content of 
“CpG motifs” (Krieg, Yi et al. 1995; Klinman, Yi et al. 1996) suggesting it would be a better 
target for cross-linking than the host genome. Mitomycin C is one of a range of DNA- 
damaging agents which induces the expression of GADD34 (growth arrest and DNA damage 
-inducible protein) (Chou and Roizman 1994; Hollander, Zhan et al. 1997). There is great 
homology between the carboxyl terminus of the mammalian GADD34 gene and the 
corresponding carboxyl domain of the viral ICP34.5 (Chou and Roizman 1994). ICP34.5 
functions as a virulence factor by preventing the shutoff of protein synthesis in virus-infected 
cells (Chou and Roizman 1992), deletion of which allows tumour selective viral replication 
(Rampling, Cruickshank et al. 2000). Bennett et al (2004) (Bennett, Adusumilli et al. 2004) 
shows that mitomycin C and HSV were synergistic on gastric cancer cell lines. Their 
Northern blot analysis confirmed that expression of GADD34 mRNA was increased by 
mitomycin C treatment. RNAi targeting GADD34 decreased mitomycin C -associated 
enhancement of HSV replication and resulted in decreased viral synergy with the 
chemotherapy on gastric cancer cell lines (Bennett, Adusumilli et al. 2004). This would 
suggest in bladder tumour cells, that synergy seen between oncolytic HSV and mitomycin C 
maybe due to the up regulation of GADD34, which aids viral tumour replication. On this 
basis we would expect cisplatin to show synergy with HSV in bladder transitional cell 
carcinoma because cisplatin has been shown to up-regulate GADD34 in malignant 
mesothelioma and head / neck squamous carcinoma cell lines (Adusumilli, Chan et al. 2006; 
Fishel 2006). Our results do not show synergy between cisplatin and oncolytic HSV on 
bladder transitional cell carcinoma cells. Therefore, it suggests that the cellular components 
needed for up regulation of GADD34 by cisplatin are present in malignant mesothelioma and 
head/neck squamous carcinoma cell lines but may not be present in bladder TCC cells.
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These mechanisms describe viral exploitation of the host cellular stress response following 
exposure to chemotherapeutic agents or ionizing radiation. Eisenberg et al (Eisenberg, 
Adusumilli et al. 2005) demonstrated that the production of viral progeny is significantly 
enhanced in the presence of either 5-FU or gemcitabine. Their data also suggest that this 
potentiation of viral replication is responsible for the synergism observed. The differential 
improvement in cell killing in the combination therapy part of the experiments did not appear 
to be an initial cytotoxic effect. Rather, it became evident five to six days following treatment 
after several viral life cycles had been completed and after the differential increase in viral 
progeny production was evident by plaque assay. This amplification is limited only to the 
extent that viable cancer cells are present to support viral replication.
Our results showed synergistic effect when OncoVEX^^^^^^ was combined with mitomycin 
C in EJ, T24 and KU19-19 cells. The synergistic interaction between OncoVEX^"^^^^^ and 
MMC may provide an opportunity to eradicate bladder cancer microscopic deposits that each 
agent alone at acceptable dosage cannot reach. The combined effect of OncoVEX^^^^^^ with 
cisplatin or gemcitabine was antagonistic in EJ, T24 and TCCSUP-G cells. This antagonistic 
effect was not related to the implanted GALV and CD genes as the backbone OncoVEX^^^ 
virus showed antagonistic effect in combination with cisplatin or gemcitabine.
In order to evaluate the mechanism of interaction between OncoVEX^^^^^^ and cisplatin or 
gemcitabine further experiments are needed. According to previous studies we plan to 
examine simultaneous and subsequent adiminstration of these agents, where primary 
administration of chemotherapeutical drug followed by a subsequent administration of the 
OncoVEX^"^^^^^ virus may lead to promising results.
5.5 Conclusion
The effect of OncoVex^^^^^^ treatment in combination with chemotherapies (mitomycin, 
cisplatin, gemcitabine) on cell proliferation was assessed by calculating combination index
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values using CalcuSyn software. In conclusion the results presented in this study indicate that 
the coadministration of OncoVex^^^^^^ and mitomycin showed synergistic, whereas the 
coadministration with cisplatin or gemcitabine showed antagonistic effect in vitro. This data 
provide a basis for the clinical investigation of combined use of mitomycin-C with oncolytic 
HSV therapy in the treatment of superficial bladder cancer. Both agents can be instilled 
intravesically following transurethral resection of bladder tumor, to achieve synergistic 
efficacy while minimizing dosage and toxicity. To evaluate the mechanism of interaction 
between OncoVEX^^^^^^ and cisplatin or gemcitabine further experiments are needed.
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Chapter 6
Development of an orthotopic rat bladder tumour
model
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6 Development of an orthotopic rat bladder tumour 
model
6.1 Introduction
6.1.1 Orthotopic rat bladder tumour model
An animal tumour model that resembles human disease both histologically and in behaviour is 
essential for preclinical evaluation of new treatment modalities. The ideal animal bladder 
tumour model should include the following characteristics:
• The tumour should grow intravesically (orthotopically), such that the tumour can be 
directly exposed to antitumour drugs in its natural environment.
• The tumour should be of pure TCC origin, with different stages of disease progression 
(CIS, papillary and invasive diseases) and, as for the human disease, the majority of 
the tumours should be superficial, but not progressive.
• The animal host should be immunocompetent and reasonably large, so it can be 
treated by various antitumour modalities.
• The tumour should be technically easy to develop within a reasonable time period, and 
highly reproducible with respect to its natural history.
Soloway (Soloway 1977) showed that bladder tumour cells (MBT-2) could be implanted on 
the murine bladder mucosa by intravesical tumour inoculation, if the bladder mucosa was 
pretreated with A-methyl-A-nitrosourea (MNU). He reported about 60% tumour takes. 
Ibrahiem and colleagues (Ibrahiem, Nigam et al. 1983) injected rat tumour cells into rat 
bladder muscularis to develop an invasive bladder tumour model, because of tumour cell 
growth failure when inoculated on the bladder mucosa using Soloway’s procedure. Their 
model did not closely mimic the human counterpart because the tumour was actually invasive 
and covered with normal bladder mucosa (Ibrahiem, Nigam et al. 1983; linuma, Bachor et al. 
1995). Chin et al (Chin, Kadhim et al. 1991) established an orthotopic mouse bladder tumour
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model by implanting MBT-2 tumour cells on bladder mucosa, which was pretreated with mild 
HCl/KOH. Compared with Soloway’s procedure, the one used by Chin et al was more 
convenient. Carcinogen could be avoided and higher tumour takes (75-80%) were achieved 
(Chin, Kadhim et al. 1991). The advantages and limitations of previous animal bladder 
tumour models were reviewed by Oyasu (Oyasu 1995). In mice, most of the deeply invasive 
bladder tumours were squamous cell carcinomas, as opposed to TCC. The carcinomas 
observed in mice tended to invade into the perivesical organs by direct extension, and seldom 
showed metastasis to regional lymphnodes or lung as observed in humans.
However, the rat model, because of its size, is easier to work with for intravesical therapies 
and, furthermore, it may parallel the human disease processes better than a mouse model 
(Ohtani, Kakizoe et al. 1986; Oyasu 1995).
In our experiments we used a technique to develop a rat ortothopic bladder tumour model that 
was described by Xiao at al in 1999 (Xiao, McCallum et al. 1999). Using the AY-27 cell line 
they have developed and characterized a highly reproducible, transplantable, purely TCC rat 
orthotopic bladder tumour model. The procedures are not technically complicated, are well 
tolerated by the animals and result in minimal morbidity associated with occasional mild 
haematuria subsequent to tumour cell instillation. The fact that tumour cells used for 
intravesical instillation originated from cell cultures rather than directly from solid tumour 
fragments, might contribute to the high tumour establishment observed. Tumour cells 
prepared from tumour fragments may also contain stromal cells, lymphocytes, etc., and their 
viability might be compromised due to mechanical or enzymatic treatment.
To facilitate tumour seeding, the bladder mucosa was conditioned with an acid rinse. The 
conditioning consisted of intravescal administration of hydrochloric acid and neutralized with 
potassium hydroxide. Histologically, HCl/KOH instillation elicited focal urothelial 
denudation with slight submucosal blood vessel dilatation. Immediately after bladder
135
conditioning, the AY-27 cells were instilled and left indwelling for at least 1 hour. If single­
cell suspensions of AY-27 cells were instilled in normal (unconditioned) bladder it did not 
elicit tumour establishment.
According to Xiao’s results prior to 13 days post-inoculation, all tumours detected were 
superficial (Tl, CIS). In a group of animals sacrificed on days 16-17 post-inoculation, the 
tumour establishment was 97%, with 65% being superficial (Tl, CIS), 29% superficially 
invasive (T2), and 6% deeply invasive (T3) disease. With time, there was progression of the 
disease process with invasive tumours detected in 66% of the animals followed 21-50 days 
post-tumour inoculation.
To determine the starting point of treatment in an orthotopic rat bladder model is an important 
question. Ideally all rats should have formed tumours before the treatment starts.
Xiao et al. described three stages of tumour growth, i.e. early tumour establishment (1-13 
days), mid-stage intravesical progression (14-21 days), and advanced intravesical progression 
and extravesical spread (22-50 days) (Xiao, McCallum et al. 1999). Thus 14-16 days post­
inoculation seems to be the most suitable time for intravesical therapies.
Hendricksen at al. showed tumour cell growth and extension along the basement membrane 
only at 3 and 4 days and it appeared as a patchy or Pagetoid subtype of CIS. From 6 days on, 
40% of rats had early progression to muscle-invasive disease. The fast progression toward 
muscle-invasive growth leaves a narrow window for the start of experimental intravesical 
treatment against NMIBC, preferably at 5 days after tumour cell inoculation (Hendricksen, 
Molkenboer-Kuenen et al. 2008).
6.1.2 Assesment of tumour growth
6.1.2.1 Cystoscopy
In human the gold standard for the detection of bladder cancer is cystoscopy, which is an 
invasive and relatively expensive method. Evaluation of an orthotopic rat bladder urothelial
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cell carcinoma model by cytoscopy was recently described by Hendricksen et al. 
(Hendricksen, Molkenboer-Kuenen et al. 2008). The authors performed pneumocystoscopy 
using a fibre-optic needle arthroscope of 1.0 mm diameter with a miniature straight 0° 
telescope, which resulted in excellent bladder visualization. With serial cystoscopy to 17 days 
they were able to compare in vivo macroscopy with the
histology of rats. Overall, tumour establishment was >80%, with predominantly carcinoma in 
situ preceding or concomitant with invasive tumour growth. All tumours were formed at 3-5 
days, and remained non-muscle-invasive up to 5 days. From 6 days, tumours progressed to 
muscle-invasive disease in 40% of the rats. The tumours were apparent in >90% of rats from 
5 days on, with a specificity and sensitivity of >90%. But cystoscopy could not differentiate 
NMIBC from muscle-invasive bladder cancer in that bladder model.
6.1.2.2 Urine cytology
In human voided urine cytology is a highly specific, noninvasive adjunct to cystoscopy. Urine 
cytology is the interpretation of a pathologist concerning the nature of cells disaggregated 
from their environment in the urothelium. Urinary specimens do not always contain a 
representative sample of the bladder and may not contain tumour cells even when a tumour is 
present. Therefore the diagnostic yield of urine cytology is increased if at least 3 samples are 
obtained. The accuracy of cytology depends upon the reviewer’s expertise. The endpoint of 
urine cytology is to identify the tumor cells themselves, therefor the predictive value of a 
positive result is very high. It has good sensitivity and specificity for detecting high grade 
bladder tumors, but has poor sensitivity to detect low grade disease.
Cytology was used in a rat orthotopic superficial bladder cancer model to assess tumour 
growth in an experiment where the authors evaluated the effect of whole-bladder 
photodynamic therapy (PDT) against bladder cancer. Cytology of the urine sediment failed to
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detect half the tumours in the treatment groups resulting in poor correlation with actual 
bladder cancer formation (Gronlund-Pakkanen, Wahlfors et al. 2003).
6.1.2.3 Tumor markers
There are several types of bladder cancer markers and tests that are available in humans. 
These tumour markers can be divided into 2 groups, soluble urine markers (BTA-Stat, BTA- 
TRAK, NMP-22, BLCA-4, BLCA-1, Survivin, Cytokeratins, HA-HAase Test) and cell- 
associated markers (Microsatellite Analysis, Telomerase, DD23, Quanticyt Nuclear 
Karyometry, Multi-target Multi-color FISH Assay (UroVysion Test)), depending upon 
whether urine specimens or exfoliated cells in urine are used in the assay. All of these tumour 
markers are used in human and have no major role in animal bladder cancer models.
6.1.2.4 Ultrasound
Ultrasound scan is an important tool in human, which can detect bladder tumours with at least 
5 mm size. The accuracy of ultrasound depends upon the examiner’s expertise. Rooks et al. 
(Rooks, Beecken et al. 2001) evaluated the use of ultrasound in an orthotopic bladder tumour 
model in mice treated with TNP-470 (an angiogenic inhibitor). They found intraabdominal 
tumours as small as 1.5 mm with ultrasonography. Ultrasound can provide accurate 
intermediate end points for monitoring experimental intraabdominal tumor growth and 
response to therapy in the mouse model.
6.1.2.5 Magnetic resonance imaging (MRI) scan
Magnetic resonance imaging has an important role not in the diagnosis but in the staging of 
bladder cancer in human. Mazurchuk et al. showed that MRI as an imaging technique is 
feasible to construct tumour growth curves (Mazurchuk, Glaves et al. 1997), but the technique 
is difficult for small early lesions, and is relatively complicated (Chin, Kadhim et al. 1991).
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Xiao et al. reported little benefit from MRI, due to the tumour detection limit of >2 mm, and 
the high reproducibility of their model (Xiao, McCallum et al. 1999).
6.1.2.6 Quantitative reverse transcription polymerase chain reaction
Quantitative reverse transcription polymerase chain reaction (QRT-PCR) is a modification of 
the polymerase chain reaction used to rapidly measure the quantity of DNA, complementary 
DNA or ribonucleic acid present in a sample. Like other forms of polymerase chain reaction, 
the process is used to amplify DNA samples, via the temperature-mediated enzyme DNA 
polymerase. PCR was usefull to examine transduction and vectors spread of different 
therapeutical viral vectors in an orthotopic mice bladder tumour model (Kikuchi, Menendez et 
al. 2007).
6.1.2.7 Bioluminescence imaging
Bioluminescence imaging has become a very popular tool for noninvasive monitoring of 
fundamental biological and molecular processes in small living subjects. The non-invasive 
IVIS camera detects the luciferase activity of the tumour. Luciferase is a light-emitting 
enzyme that can generate light (known as bioluminescence) after reacting with specific 
substrates (eg. tumour cells). These enzymes are isolated from various organisms, 
conveniently modified for expression in mammalian cells, and are extensively used in 
molecular biology and cell culture experiments (Ray 2007). The emitted light is used as a 
detection system for luciferase activity. At selected time intervals tumour implantation an 
intravenous injection of luciferin should be given and the animal should be placed within a 
light-tight chamber for imaging. The light-tight chamber has a vertically-mounted 
highsensitivity cooled CCD camera. This operates in single photon-counting mode, since the 
luminescence signal is extremely weak. The animal is placed within the cabinet, attached to 
an anaesthetic machine, and image collection takes place over a period of 5 minutes.
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Bioluminescence imaging in vivo is a powerful new optical tool for monitoring the response 
of tissue (in this case malignant tumour) to treatments (Wilson 2003).
6.2 Study objectives
We aimed to set up a stable and usefull rat orthotopic bladder tumour model that is suitable to 
evaluate the effectivity of different therapeutical options (eg. O n c o v e x ^ A L V / C D  treatment). 
We planed to test whether A Y - 2 7  rat bladder tumour cells are susceptible for HSV entry. Due 
to the lack of HSV receptor on the surface of A Y - 2 7  cells we aimed to stably transfect A Y - 2 7  
cells with the herpesvirus entry receptor (HYEM) and select a clone of these cells that support 
infection with Herpes Simplex Virus. We planed to test the in vitro efficacy of
O n c o v e x ^ - ^ L V / C D  on the new AY-27 H V E M  cell line with the fusion assay and also to test 
the in vitro efficacy of O n c o v e x ^ A L V / C D  the presence of 5-fluorocytosine with the 
prodrug assay. We aimed to assess the the rate of tumour growth on a flank tumour model and 
compare the new AY-27 H V E M  cell line to the original AY-27 cells. We aimed to set up a 
stable rat orthotopic bladder tumour model with the AY-27 H V E M  cell line and to assess the 
effectiveness of Q R T - P C R  in detecting tumour growth using urine and tissue samples. Finally 
we planed to stably transfect AY-27 H V E M  cell clone with a plasmid encoding the luciferase 
enzyme and select a clone of these cells that show luciferase activity for bioluminescence 
imaging. We aimed to evaluate the effectivity of this bioluminescence imaging on the rat 
orthotopic bladder tumour model.
6.3 Results
6.3.1 Infection screening of wild type AY-27 rat bladder tumour cells
To set up a rat orthotopic bladder tumour model first we planned to test AY-27 rat bladder 
tumour cells for their susceptibility for HSV entry. Oncolytic HSV viruses have been shown 
to infect a wide range of human and animal tumour cell types including all human bladder
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cancer cell lines so far tested (See more details in part 1.6.1). To assess whether rat AY-27 
cells were suitable targets for HSV vectors we infected the cells with OncoVEX^^^ at various 
MOIs and incubated for 48hrs (Figure 6.1).
AY-27
Figure 6.1 Infection of AY-27 and BHK control cells with OncoVex^^^. AY-27 and BHK 
cells were plated at IxlO^cells per well of a 24 well tray and incubated at 37°C/5% CO2 o/n. 
The media was then removed and the cells were infected with OncoVex^^^ virus at MOI 10 
and incubated at 37°C/5% CO2 for 24/48Hr. Infection of OncoVex^^^ virus expressing green 
fluorescent protein marker gene were visualised under an inverted fluorescent microscope 
{Nikon Eclipse TE200) at wavelength 520nm.
From the results we can conclude that AY-27 cells are a rare exception in failing to support 
HSV entry and/or replication. To overcome this problem AY-27 cells had to be stably 
transfected with the herpesvirus entry receptor. Although HSV does not appear to infect the 
particular rat cell line we used (AY-27), this is not a potential problem for human cells.
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because all human bladder cells we have tested are able to be infected by HSV. Therefore this 
problem should not affect the effectiveness of OncoVEX^"^^^^^ in the treatment of bladder 
cancer in human.
6.3.2 Transfection of AY-27 cells with the herpesvirus entry receptor 
(HVEM) and infection screening
Wild type AY-27 cells were transfected using a linearised plasmid of pcDNA3 CMV HVEM 
with lipofectin (Introvitrogen). The cells were selected under G418 media for 5-20 days. 72 
individual clones were isolated and grow up under G418 selection. The 72 clones were tested 
for infection by HSV where the cells were infected with OncoVEX^^^ at MOI 10 and 
incubated for 48hrs. From these results the 3 most suitable new cell clones (E6, E5, B9) were 
chosen which support HSV entry on the largest scale (Figure 6.2).
Normal
UV
B9 clone E5 clone E6 clone AY-27 normal BHK
Figure 6.2 Infection of wt AY-27, AY27 HVEM clones and BHK control cells with 
OncoVex^^^ AY-27 HVEM clones and control cells were plated at 1x10^ cells per well of a 
24 well tray and incubated at 37°C/5% CO2 o/n. The cells infected with OncoVex*^^  ^virus at 
MOI 10 and incubated at 37°C/5% CO2 for 48Hr.. Infection of OncoVex^^^ virus expressing 
green fluorescent protein marker gene were visualised under an inverted fluorescent 
microscope {Nikon Eclipse TE200) at wavelength 520nm.
We have chosen AY-27 HVEM E6 clones for our further experiments as this cell clone 
showed the strongest infectibility by HSV. AY-27 HVEM E6 clone was scaled up and frozen 
stocks were produced.
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6.3.3 Testing the efficacy of Oncovex^ALV/CD on AY-27 HVEM cell clone 
with Fusion and Prodrug assay
To test for improved tumour cell killing effects of GALV expression in vitro, AY-27 HVEM 
cells were infected with OncoVex^^^^^^ or OncoVex^^^ under previously described 
conditions. These fusion assay results were confirmed by a reduction in metabolic enzyme 
activity of up to 30% (MTS assay) in AY-27 HVEM cells infected with OncoVex^^^^^^ 
compared to the OncoVex^^^ control (Figure 6.3).
AY-27 HVEM cells were further tested in our prodrug assay, which showed that 
OncoVex^"^^^^° can metabolize 5-FC within these cells, resulting in a decrease in metabolic 
enzyme activity of up to 81% (MTS assay) when compared to controls (Figure 6.4).
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Figure 6.3. 2x10"^  AY-27 HVEM E6 cells were infected with OncoVex^^^ or 
OncoVex^^^^^^at MOIs of 0.1, 0.01, 0.001 and incubated at 37°C/5% CO2 for 48 hours and 
then assayed by Crystal Violet staining (A) or MTS assay (Promega). Average cell survival 
was calculated as a percentage compared to untreated cells (B). Experiments were repeated at 
least three times. The figure shows a representative experiment, where the error bars are 
standard deviations.
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Figure 6.4 1 x 10  ^ AY-27 HVEM E6  cells were infected with OncoVex G F P and
OncoVex G A L V / C D at MOI of 0.1 according to the fusion assay results and no virus control. 
After 30 minutes at 37°C/5% CO2 , the virus was removed, and 1 mL of FGM containing 5-FC 
(C4H4FN2O; Sigma) at different concentrations (0-100-300-600 pmol/L) was added and 
incubated for 48 hours at 37°C/5% CO2 . The cell supernatants were then heat inactivated and 
added to 1 x lO"^  fresh EJ cells and incubated at 37°C/5% CO2 for 72 hours and then assayed 
by MTS assay (Promega). Average cell survival was calculated as a percentage compared to 
untreated cells. All results showed enchanced tumour killing in the presence of 
OncoVEX^^'^^*^^ and 5-FC. Quantification of the prodrug studies showing that in all cases 
the differences were significant {P <0.05). (P values: GALV/CD+Opm Vs GFP+Opm =0.645, 
GALV/CD+lOOpm Vs GALV/CD+Opm =<0.000, GALV/CD+300pm Vs GALV/CD+Opm 
=<0.000, GALV/CD+600pm Vs GALV/CD+Opm =<0.000) Experiments were repeated at 
least three times. The figure shows a representative experiment, where the error bars are 
standard deviations.
6.3.4 AY-27 and AY-27 HVEM flank tumour model
In order to assess whether AY-27 HVEM cells can grow in rats we set up a flank tumour 
model with the rat bladder tumour cells. It was shown that both AY-27 and AY-27 HVEM E6  
rat bladder tumour cells were able to grow in rats. The rate of tumour growth on a flank 
tumour model showed slightly slower tumour development when using the new AY-27 
HVEM E6  cell line compared to the original AY-27 cell line (Figure 6.5). Therefore slower
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rate of tumour growth is expected in our orthotopic bladder model as well compared to the 
data from the literature. The difference in xenograft growth curves might be related to 
differing passage numbers between the parental cell line and the derived luciferase-expressing 
clone (AY-27 HVEM E6).
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Figure 6.5 In vivo growth AY-27 HVEM cells. Eight rats randomly assigned into two groups.
1x10^ AY-27 HVEM or WT AY-27 cells in 10Oui RPMI (without PCS) were injected 
subcutaneously into the flank of the rats (both side). The tumours were measured every 2-3 
days. Experiments were repeated three times with two animals in each group. The figure 
shows a representative experiment, where the error bars are standard deviations.
6.3.5 Rat orthotopic bladder tumour model
The anaesthesia of the female Fischer F344 rats was carried out with two different protocols. 
In our early experiments rats were anesthetised with intraperitoneal injections of Domitor 
(Pfizer Animal Health) and Ketaset (Pfizer Animal Health). The doses of Domitor and 
Ketaset used is shown earlier in chapter 2 (2.5.1). After the procedure the same amount of 
antidote as Domitor (Pfizer Animal Health) was given to each animal to terminate the 
anaesthesia. In our later experiments we used balanced inhalation of Isoflurane (Novartis
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Animal Health UK Ltd) for anaesthesia. Comparing the two methods we found that the 
balanced inhalation of Isoflurane anaesthesia seemed much safer, reproducible and showed 
less side effects. Using this inhalation anaesthesia also showed the recovery period was much 
quicker and this method caused less harm to the rats. The percentage of anaesthetic related 
deaths was about 19.2% when using intraperitioneal injections of Domitor and Ketaset and 
this was elevated up to 30% when we repeated the anaesthesia weekly 3 times during the 
treating phase of our studies. The percentage of anaesthetic related deaths were about 6.6% 
when using balanced Isoflurane inhalation anaesthesia.
The tumour cell implantation was performed via a transurethral catheter. To facilitate the 
tumour seeding the bladder mucosa was damaged by instillation of hydrochloric acid followed 
by a rinse with sodium hydroxide for neutralization. A suspension of freshly harvested AY-27 
cells was then instilled and maintained in the bladder for 1 hour (Figure 6.6).
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Figure 6.6 Fischer F344 rats were anesthetised and placed in a supine position (on a 
homeothermic blanket). An 18-gauge plastic (Braun) intravenous cannula was used as a 
catheter. The catheter was inserted into the bladder via the urethra. To facilitate the tumour 
seeding the bladder mucosa was damaged by instillation of 0.4 ml 0.1 N hydrochloric acid for 
15 seconds followed by a 15 seconds rinse with 0.4ml of 0.1 N sodium hydroxide for
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neutralization. The bladder was then drained and washed five times with 0.6ml PBS (pH 7.4). 
A suspension of freshly harvested AY-27 cells (1.5-2.5x10^ cells in 0.4ml of medium) was 
then instilled and maintained in the bladder for 1 hour on homeothermic blanket. The rats 
were turned 90° laterally every 15 minutes to ensure exposure of the entire bladder wall to the 
tumour cells. After 1 hour the catheters were removed, and the rats were allowed to void 
spontaneously.
After the tumour implantation the rats were monitored daily for general health status and for 
signs and symptoms of advanced bladder cancer. The animals were sacrificed in different 
time periods (10,14,18 days). The extent of tumour burden at necropsy was evaluated by 
macroscopic examination of the bladder. Our necropsy results showed 1-2 mm average 
tumour diameter at day 10 and 14 and 2-5mm average tumour diameter at day 18. All rats 
developed tumour in their bladder, resulting in a 100% success rate of tumour imlpantation. 
After 35-50 days all rats showed 1.5-2 cm average diameter tumour masses in their bladder 
(Figure 6.7).
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After 14 days
After 18 days
(Rat 4 did not get tumour cells)
After 34 days
Figure 6.7 After the tumour implantation (6.3.5) the animals were sacrificed in different time 
periods, at 10 (n:4),14 (n:5),18(n:4) and 34 (n:8) days of implantation. The bladders were 
removed and the size of the tumours were measured, (n: number of rats)
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6.3.6 Detection of HVEM RNA by QRT-PCR as a marker for tumour cells
In rat tissue and urine samples we aimed to demonstrate the presence of the HVEM receptor 
on AY-27 HVEM rat bladder tumour cells by QRT-PCR as a marker of tumour load. We 
collected urine samples by holding the rats in a metabolization cage for 1 hour on day 0, 4, 7, 
11 and 14 after tumour implantation. Quantitative reverse transcription polymerase chain 
reaction was carried using primers to HVEM (and control primers to rat p-actin) and cDNA 
were produced by reverse transcription (Invitrogen) (Figure 6.8). QRT-PCR measures how 
much target cDNA was present compared to control rat p-actin (xlOOO). After necropsy QRT- 
PCR was performed on the removed bladder tissue and showed significant signals in the 
tumour bearing animals compared to the control animals (Figure 6.9).
200
o
03 180
CD.
O 160•*->
TD
Q) 140
CD
Q . 120
E
o 100Ü
c
o 80
'(/)
60
E
Q .
X 40
CD
20
LU
> 0
X
-r
-L
A
r U g  1
□  Rat1
■  Rat2
□  Rats
□  Rat4
■  Rats
□  Rate
■  Rate
□  Rats
■  control
Figure 6.8 QRT-PCR for HVEM on rat urine. 14 days after tumour implantation quantitative 
reverse transcription polymerase chain reaction was performed on the collected urine samples. 
The method of QRT-PCR was discussed in more detail earlier in chapter 2.3. The figure 
shows a representative experiment, where the error bars are standard deviations.
In collected urine samples no significant difference in the tumour bearing animals was
observed compared to the controls, therefore tumour growth was not detectable by QRT-PCR
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on the collected urine samples (Figure 6.8). In contrast after necropsy QRT-PCR was 
performed on the removed bladder tissue and showed significant signals in the tumour bearing 
animals compared to the control animals (Figure 6.9). Our results show that we can detect 
HVEM in rat bladder tumour tissue but not in urine from the same animals. Therefore we can 
conclude that measuring HVEM in urine by QRT-PCR is not an effective method for 
quantitating tumour load in this model.
1
0,8
I 
s
c  I 0,6 
.2 ”
«  «  0 ,4 — Ba.
s
I
0,2
0
□ R at1
D Rat 2
□ R a ts
□ Rat 5
O Rat 5
■ contro l ra t
After 14 days
r  
I "
Ta 4
S 
> 0 ■
□  Rat1 
■  Rat 2
□  Rat 3
□  Rat 4 control
After 18 days
Figure 6.9 QRT-PCR for HVEM on rat tumour bladder tissue. 14-18 days after tumour 
implantation the rats were sacrificed and QRT-PCR was performed on the removed bladder 
tissues. The method of QRT-PCR was discussed in more detail earlier in chapter 2.3. The 
figure shows a representative experiment, where the error bars are standard deviations.
6.3.7 Transfection of AY-27 HVEM cells with a luciferase encoding 
plasmid for bioluminescence imaging
AY-27 HVEM cells were transfected using linearised plasmid of pGAL CMV Luc Hygro 
(Promega) with lipofectin (Invitrogen). The cells were then selected under G418 + 
Hygromycin. We could observe approximately 35 individual cell colonies which were
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isolated and grown up under G418/Hygromycin selection. The resulting 35 clones were tested 
for luciferase activation (Sigma). From these results the most suitable new cell clone (HL-S) 
was chosen that showed the highest luciferase activity (Figure 6.10). Therefore, AY-27 HL S 
clone was chosen for further investigation in vivo bioluminescence imaging experiments.
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Figure 6.10 Luciferase assay (Sigma). AY-27 HVEM+Luciferase cells were plated at 5x10 
cells and incubated at 37^C o/n. The cells were washed (3x) with ice cold PBS. Ix cell 
culture lysis reagent was added and the lysate was incubated at RT for 15 minutes after which 
the cells were scraped off and spun at 12,000g at 4^C for 1 minute. The supernatant was 
removed and stored on ice. The luciferase substrate and the tested cell lysate were allowed to 
equilibrate to room temperature before use. 20pl of the cell lysate was added to lOOpl of the 
luciferase substrate assay buffer. Light emission was read after 10 seconds incubation at room 
temperature using Beckman counter DTX 880.
6.3.8 Bioluminescence imaging rat flank tumour model
(This work was carried out in Dr Kevin Harrington Laboratory at Institute of Cancer Research 
London)
In order to assess whether AY-27 HVEM+Luciferase cells were able to grow in rats we set up 
a flank tumour model. It was shown that until day 7 after tumour implantation tumours grew 
in the flank of the rats and they were detectable by the non-invasive IVIS bioluminescence
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imaging camera. After 11 days the tumours disappeared from the flank and activity was not 
detectable by IVIS camera (Figure 6.11).
Day 11
Figure 6.11 Fischer F344 rats were anaesthetised and 1x10^ AY-27 HL-S cells in lOOuI 
RPMI (without FCS) were injected subcutaneously. Luc expression was quantitated by real­
time bioluminescent imaging using the IVIS System 200 series (Xenogen Biosciences) d -  
Luciferin Firefly Potassium salt (15 mg/mL; Xenogen Biosciences) was administered at 150 
mg/kg and imaging was performed after 5 min. 30s exposures were obtained at high 
sensitivity using the machine default settings (f/stop, 1; emission filter, open; field of view d, 
12 cm; and subject height, 1.5 cm). The Xenogen software provides visual images of 
bioluminescence detection using a coloured overlay on a photographic image taken 
immediately before luminescence measurements. The areas shown in colour represent the 
regions of bioluminescence detected. Results were analyzed using Living Image 2.60.1 
software (Xenogen Biosciences). Areas of Luc expression were defined using the 
autocontouring tool and the photon flux and average radiance (photons/cm^/s) were estimated 
over the defined area.
These results suggest that the tumours may be destroyed by an immune response which may 
relate to the expression of luciferase protein within the tumours. We have not found any data 
in the literature about using similar bioluminescence imaging in immuno-competent rats. We 
can conclude that the non-invasive IVIS bioluminescence imaging camera is not suitable to 
detect tumour growth in our rat orthotopic bladder tumour model.
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6.4 Discussion
An animal tumour model is essential for preclinical evaluation of new treatment modalities. 
We have set up a useful rat orthothopic bladder tumour model to test the effectiveness of the 
Oncovex^^^LV/CD virus. Entry of herpes simplex virus type 1 (HSV-1) into cells requires 
the envelope glycoprotein D (gD), gB, gH, and gL. After virion adsorption to cell surface 
proteoglycans, gD binds to one of its receptors, herpesvirus entry mediator (HVEM), nectin-1 
(HveC), or 3-0-sulfated heparan sulfate (3-0-S HS) (Montgomery, Warner et al. 1996; 
Geraghty, Krummenacher et al. 1998; Shukla, Liu et al. 1999). Receptor binding results in a 
conformational change in gD, which is believed to activate either or both gB and gH as 
mediators of fusion between the viral envelope and the plasma membrane or an endosomal 
membrane. Fusion leads to nucleocapsid release into the cytoplasm for subsequent viral 
genome delivery to the nucleus. Since productive HSV-1 infection is set in motion by the gD- 
receptor interaction, cellular susceptibility to HSV-1 is initially determined by the presence of 
one or more functional gD receptors on the cell surface.
In addition to supporting HSV-1 entry, gD receptors also support HSV-1 cell-to-cell spread 
(Roller and Rauch 1998; Cocchi, Menotti et al. 2000). However, it is not clear whether they 
act by the same mechanism in entry and spread. Two additional glycoproteins, gE and gl, are 
important for HSV-1 spread but are dispensable for entry (Johnson and Huber 2002). The 
individual contributions of HVEM and nectin-1 to infection in vitro and in vivo are difficult to 
assess since cells often express both receptors (Krummenacher, Baribaud et al. 2004).
Oncolytic HSV viruses have been shown to infect a wide range of human and animal tumour 
cells. The following studies have shown that oncolytic HSV infects and replicates in vitro and 
in vivo in a wide range of human tumour cell types: glioma (Chambers, Gillespie et al. 1995; 
Andreansky, He et al. 1996; Andreansky, Soroceanu et al. 1997; Samoto, Ehtesham et al. 
2002; Detta, Harland et al. 2003), colon carcinoma (Carroll, Chiocca et al. 1996),
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retinoblastoma (Nicolo and Chiocca 1998), epithelial ovarian cancer (Coukos, Makrigiannakis 
et al. 1999), colorectal cancer (Kooby, Carew et al. 1999; Reinblatt, Pin et al. 2004), prostate 
cancer (Walker, McGeagh et al. 1999; Cozzi, Burke et al. 2002), non-small cell lung cancer 
(Toyoizumi, Mick et al. 1999), gallbladder carcinoma (Nakano, Todo et al. 2001), head and 
neck squamous cell carcinoma (Wong, Kim et al. 2001), esophageal adenocarcinoma (Stiles, 
Bhargava et al. 2003), breast cancer (Pin, Reinblatt et al. 2004; Teshigahara, Goshima et al. 
2004; Liu and Rabkin 2005), thyroid cancers (Yu, Eisenberg et al. 2004), hepatocellular 
carcinoma (Pin, Reinblatt et al. 2004) and rhabdomyosracoma (Currier, Adams et al. 2005). 
Although HSV viruses have been shown to infect a wide range of human and animal tumour 
cells, but AY-27 rat bladder tumour cells are rare exceptions in failing to support HSV entry 
and/or replication. To overcome this problem AY-27 cells were stably transfected with the 
herpesvirus entry receptor (HVEM).
After the transfection our in vitro fusion assay results showed increased tumour cell killing 
with OncoVex^^^^^^ compared to the OncoVex^^^ control on AY-27 HVEM E6 cells. 
OncoVex^^^ gave a classic HSV-1 cytopathic effect, in contrast, cells infected with 
OncoVEX^^^^^^ showed fusion in the form of large multinucleated syncytia, which were 
then surrounded with cells showing the more classic HSV-1-mediated effect.
AY-27 HVEM E6 cells were further tested in our prodrug assay. We can conclude from these 
in vitro experiments that expression of the FcyiFur gene within the OncoVex^^^^^^ 
promotes active metabolism of 5-FC into 5-FU and further into its metabolites, resulting in 
tumour cell killing in AY-27HVEM E6 cells.
In our in vivo experiments we used a technique to develop a rat ortothopic bladder tumour 
model that was described by Xiao et al in 1999. To facilitate tumour seeding, the bladder 
mucosa was conditioned with an acid rinse followed by neutralization with alkali. After 
tumour implantation all rats developed tumour in their bladder, resulting in a high success rate
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of tumour imlpantation. The tumour implantation procedure was well tolerated by the animals 
and resulted in minimal morbidity associated with occasional mild haematuria subsequent to 
tumour cell instillation.
We planed to use QRT-PCR to demonstrate the presence of the HVEM receptor of the AY-27 
rat bladder tumour cells as a marker for tumour load. However while we obtained positive 
signals on bladder tissue QRT-PCR, signals using urine samples were insignificant, therefore 
tumour growth was detectable by QRT-PCR only on bladder tissue samples.
As another option we planed to use a bioluminescence imaging technique that has become a 
very popular tool for noninvasive monitoring of fundamental biological and molecular 
processes in small living subjects. The non-invasive IVIS camera can detect the luciferase 
activity of the implanted tumours. We have cloned a new AY-27 bladder tumour cell line that 
contains both HVEM receptor and luciferase activating gene. Unfortunately our experiments 
showed that the implanted AY-27 tumours expressing luciferase regress after a period growth. 
We think this tumour regress may be due to immune responses to the luciferase (insect) 
proteins. This view is support by the fact that the majority of IVIS bioluminescence imaging 
studies are carried out on nude mice which have a deletion of thymus function resulting 
greatly reduced number of T cells. Therefore nude mice are unable to mount most types of 
immune responses, which results them fail to reject xenograft tissue. Fischer F344 rats 
(inbred) on the other hand have a fully competent immune system, which do not reject wild 
type AY-27 cells due to the fact that the tumour cells are derived from the same strained of 
mice. But Fischer F344 rats may make specific immune responses to the insect luciferase 
protein leading to the regress of the tumours. Therefore the non-invasive IVIS 
bioluminescence imaging camera is not suitable to detect tumour growth in this rat orthotopic 
bladder tumour model. In the future we plan to use a non-invasive MRI scanner to detect the 
tumour development and the effect of the different treatment options.
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With an immune-competent rat orthotopic bladder model it was necessary to use a non-human 
cell line, which required transfection of a viral receptor-encoding construct, and raises 
questions regarding immune response against luciferase transgene expression. The use of an 
immune-deficient model would lose the component of treatment response which may be 
attributable to immune recognition of tumour antigens following induced death of tumour 
cells, but would avoid all the above problems.
The reasons for choosing an immune-competent rat orthotopic bladder model are complex 
and are as follows. Advantages of a rat versus a mouse model include its size and evidence 
that the rat model may represent the human disease processes better than the mouse 
equivalent (Oyasu 1995). It was also important for us to match our in vivo model with the anti 
cancer agent used. We are testing Onco^^^^^^ which expresses the gibbon ape leukaemia 
virus envelope, which needs the pitl receptor for fusion. The effects of this could be shown in 
both rat immune-competent model and a xenograft mouse (immune-deficient model). But any 
side effects of GALV control fusion would not be evident on normal mouse tissue because a 
pitl receptor homolog is not present mouse cells (Sommerfelt and Weiss 1990). This could be 
overcome by using a costly immune-deficient rat model. Oncolytic viruses work by 
replicating in and therefore destroying tumours, but can also show efficacy by stimulating an 
immune response to viral and tumour antigen’s by cross priming (Pesonen, Kangasniemi et al. 
2011). Onco^^^^^^ has a deletion in ICP47 which increases the antitumor immune response 
in the presence of HSV and this efficacy would not be see in an immune- deficient model 
(Liu, Robinson et al. 2003). Therefore we felt to see full efficacy and possible side effects of 
Onco^^^^^^ our model needed to based on an immune-competent rat.
6.5 Conclusion
We have set up a stable rat orthotopic bladder tumour model with the transfected AY-27 
HVEM cell line that contains the herpesvirus entry receptor. This rat orthotopic bladder
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tumour model will be suitable for further in vivo testing of the OncoVex^"^^^^^ virus. QRT- 
PCR on the removed bladder tissue samples (after necropsy) showed effective detection of 
tumour growth, but failed to detect a signal in urine from the same animals. Non-invasive 
IVIS bioluminescence imaging camera was also not suitable to detect tumour growth in this 
rat orthotopic bladder tumour model, due to host immune response to the luciferase 
expression. At this stage in the study our record of implantation using the orthotopic tumour 
model is strong (almost 100% after necropsy) and therefore the next stage is a blind test, to 
implant and treat tumours.
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Chapter 7
Efficacy of OncovexGALV/CD on a rat orthotopic
bladder tumour model
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7 Efficacy of OncovexGALV/CD on a rat orthotopic 
bladder tumour model
7.1 Introduction
In vivo studies are essential for preclinical evaluation of new treatment modalities. In the 
literature different herpes simplex viral therapies were published against bladder cancer. 
Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex 
viruses G207 and Nvl020 were studied in an orthotopic syngeneic mice bladder tumour 
model (Cozzi, Malhotra et al. 2001). Animals treated with a single instillation of G207 
showed a significant reduction in tumor weight compared to the control group. No bladder 
tumor was found in G207 treated animal group examined macroscopically and 
microscopically at necropsy, whereas control animals exhibited signs of excessive tumor 
burden, including weight loss, hematuria, and a palpable mass (Cozzi, Malhotra et al. 2001). 
Animals tolerated the treatment well with no adverse events and no deaths. Both G207 and 
NV1020 were highly effective when administered weekly for 3 weeks. Treatment was well 
tolerated with no adverse events and no treatment-related deaths. Tumor weight was also 
significantly reduced between groups treated with virus when compared with control (Cozzi, 
Malhotra et al. 2001). There was no statistically significant difference between viruses and 
similarly, there was no difference when comparing NV1020 and BCG or G207 and BCG 
(Cozzi, Malhotra et al. 2001). In conclusion both viruses were effective at infecting, 
replicating within, and achieving subsequent cell lysis for human bladder cancer cell lines and 
murine transitional cell carcinoma cells. Both viruses were found effective in the orthotopic 
mice tumour model, where single and even more multiple instillations were effective at 
reducing tumour burden. (Cozzi, Malhotra et al. 2001).
A herpes simplex virus (HSV) type 1 mutant HFIO was studied in both human and murine 
bladder cancer cells. HFIO replicated well in both T24 and MBT-2 cells, and it induced
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extensive cell lysis. Treatment with HFIO mutant significantly prolonged the survival periods 
and increased the survival rates through its oncolytic activity in an immunocompetent 
orthotopic mouse bladder model (Kohno, Luo et al. 2005).
As previously described O n c o V w a s  derived from HSV-1 strain JS-1. 
OncoVEX^^^^^^ expresses both the envelope of GALV and Fcy::Fur (CD). OncoVex^^^^^^ 
was developed and tested by Simpson et al. in 2006. O n c o V c o m b i n e s  GALV 
expression with prodrug conversion, which gave improved therapeutic effect on top of the 
oncolysis provided by the virus. Simpson et al examined whether the combined expression of 
GALV, FcyxFur and oncolysis enhances tumour killing m vivo on a Fischer F344 rat flank 
model. 9L LacZ gliosarcoma cells were implanted s.c. in the flank. The animals were in five 
treatment groups, OncoVEX, OncoVEX®'^'', OneoVEX™, OncoVEX®'^'''^, or media 
alone. All rats were also administered with 5-FC by the i.p. route. In this tumour model the 
OncoVEX-treated group showed similar tumour growth to the untreated group. In contrast, 
treatment with OncoVEX^^^ or OncoVEX^^ gave both a considerable reduction in the 
average tumour diameters and a considerable increase in the number of tumours cured. 
OncoVEX^^^ had cured 57.0% of the tumors, OncoVEX^^ had cured 83% of the tumours, 
and OncoVEX^^^^^^ had cured 100% of the tumours. In conclusion Simpson et al. have 
showed in vivo the effectiveness of OncoVex^^^^^^ double approach with a significant 
improvement in a gliosarcoma rat flank model (Simpson, Han et al. 2006).
7.2 Study objectives
We aimed to evaluate in vivo the efficacy of Oncovex^^LV/CD on our previously developed 
rat orthotopic bladder tumour model.
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7.3 Results
Here we carried out a previously described method to implant bladder tumours within the 
bladders of catheterized Fischer F344 rats, which involves chemical abrasion of bladder 
mucosa followed by installing of freshly harvested AY-27 HVEM cells (Day 0). The tumour 
bearing animals were assigned into three treated groups either OncoVex^^^^^^+5 -FC (n=10), 
OncoVex^^^^^^ +PBS (n=10) or PBS+5-FC (control group) (n=8). Intravesical treatment of 
implanted tumours was carried out with virus ( O n c o V 9 e 7  pfu) or Control PBS on 
Days 7, 14 and 21. Prodrug 5-FC (12mg) or PBS was installed in the same manner on Days 8, 
9,15, 16, 22 and 24 (Figure 7.1).
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Figure 7.1 Treatment of a rat orthotopic bladder tumour model. Female Fischer F344 rats 
were anesthetised and a catheter was inserted into the bladder via the urethra with the use of 
an 18-gauge plastic intravenous cannula. 3 treatment groups. Group A Oncovex GALV/CD + 
Prodrug, Group B Oncovex GALV/CD + PBS, Group C PBS + Prodrug. On day 7,14 and 21 
rats in Group A and B were treated with Oncovex GALV/CD, in Group C with PBS. On day 
8-9, 15-16 and 22-23 rats in Group A and C were treated with prodrug, in Group B with PBS. 
All kind of treatments were instilled transurethrally through the catheter and were maintained 
in the bladder for 1 hour. The rats were turned 90° laterally every 15 minutes to ensure 
exposure of the entire bladder wall. 9x10^ pfu Oncovex GALV/CD virus was administered in 
600pl PBS (Stock: 1.8xl0^pfu/pl). bOOpl of 5-Fluorocytosine (5-FC) in RPMI was then 
instilled (Concentration of stock: 15.0mg/ml). As control 600pl PBS (pH 7.4) was added. 
After 1 hour the catheters were removed, and the rats were allowed to void spontaneously.
163
After the treatment the animals were observed for signs and symptoms of advanced bladder 
cancer. There was no detectable abdominal mass during the 28 days period. The weight of the 
animals was measured in every 3 days (Figure 7.2). The data showed a trend that the animals 
treated with OncoVex^^^^^^ + 5-FC are ll!5g heavier than controls, suggesting that they are 
in a healthier condition compared to controls. Statistical analysis of the data shows no 
significant difference detected between the three treated groups. Mild haematuria subsequent 
to treatment days was detected in some of the rats, but this was not related to each treatment 
group.
The animals were sacrificed on day 28 and their bladders were removed and assessed for 
tumour abundance. The harvested bladders were weighed, then opened up and the bladder 
surface which macroscopically contained tumour was measured with a caliper. From these 
tumour measurements we could calculate tiimour volume. Results showed enhanced local 
tumour control in the presence of both OncoVex^"^^^^^ and prodrug when compared to 
control (No virus +prodrug, P=0.001) or virus alone (P=0.034) (Figure 7.3, 7.4). A smaller 
amount of tumour shrinkage seen with virus alone was not statistically significant when 
compared to control animals (No virus +prodrug, P=0.13). The results strongly suggest that a 
combination of oncolysis, prodrug activation and fusogenic glycoprotein therapy offers an 
opportunity for improved tumour control within the bladder.
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Figure 7.2 Animals body weight after treatment with Oncovex GALV/CD. The weight of the 
animals was measured in every 3 days. Body weights of all animals at various time points in 
the study (A): where we show that independently from treatment group there wasn’t any 
significant difference between animals and there also wasn’t any major weight loss during the 
experiment. Average body weights comparing each treatment group (B) did not show 
significant difference. (OncoVex°^'"'=°+5-FC (n=10), OncoVex°^‘-'"“ +PBS (n=10), 
PBS+5-FC (control group) (n=8)) Experiments were repeated at least three times. The figure 
shows a representative experiment, where the error bars are standard deviations.
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Figure 7.3 Bladders removed after autopsy from treatment groups Oncovex^^^^^^ +5-FC 
and PBS + 5-FC.
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Average bladder and tumour weights (in group 10)
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Figure 7.4 Average tumour volume and average bladder weight of treatment groups Oncovex 
GALV/CD +5-FC, Oncovex GALV/CD + PBS and PBS + 5-FC. The rats were sacrificed 
after 28 days. There bladders were removed and assessed for tumour abundance. The 
harvested bladders were weighed, then opened up and the bladder surface which 
macroscopically contained tumour was measured with a caliper. Average Tumour volume 
was calculate by measure length x width x width. This experiment was repeated and similar 
results were obtained. (OncoVex^^'"™-t5-FC (n=10), OncoVex°^‘'* ‘^ ‘’-FPBS (n=10), 
PBS+5-FC (control group) (n=8)) Experiments were repeated at least three times. The figure 
shows a representative experiment, where the error bars are standard deviations.
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7.4 Discussion
OncoVex^'^^^^^ has been found to be effective in treating various experimental cancers while 
maintaining an excellent safety profile. Bladder cancer is an ideal target for novel therapies 
because the ease of intravesical delivery allows the tumor to be exposed to large titres of 
vector. In addition, replication-competent oncolytic viruses, which selectively infect and 
replicate within rapidly dividing cells, are potentially very useful for bladder cancer because 
the umbrella cell layer (i.e., the luminal surface of the urothelium) of the bladder is not rapidly 
dividing and should therefore be resistant to infection and lysis. HSV is inactivated at low pH, 
and the relative acidity of the urine is of concern with this route of administration. These 
experiments demonstrate that these viruses maintain their infectivity and efficacy in this 
animal model when administered by intravesical instillation in PBS. It is likely that these 
agents will exert their therapeutic effect prior to inactivation by a low pH when administered 
with PBS as a buffer.
Data from our current experiments in a well-accepted, orthotopic rat bladder model confirm 
safety, efficacy, and ease of delivery of oncolytic viral therapy for experimental treatment of 
bladder cancer. O n c o V v i r u s ,  when administered with prodrug weekly for 3 weeks 
by intravesical instillation, was clearly more effective than control or virus alone at reducing 
tumor burden. In these experiments, treated animals continued to groom themselves and 
behave normally, no adverse events were noted, and there were no treatment-related deaths. 
However, these oncolytic viruses will likely be more efficacious in vivo in humans because 
HSV are human viruses and human tumors are significantly more susceptible to their effects 
than murine tumors (Cozzi, Malhotra et al. 2001). Although OncoVex^^^^^^ is highly 
attenuated, therapeutic use of replicating viruses still raises concerns about viral proliferation 
and dissemination. Unlike many other viruses, effective antiviral agents currently available 
for the treatment of HSV infection. Antiviral agents such as acyclovir can be used effectively
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for therapy if dissemination of virus and severe systemic toxicities are encountered. It is also 
worth noting that a version of this virus expressing GM-CSF has shovm promising results in 
Phase I and II (Hu, Coffin et al. 2006; Senzer, Kaufman et al. 2009) with limited toxicity to 
patients and is currently in III clinical trials. Our results suggested that OncoVex^"^^^^^ 
intravesical therapy in the presence of 5-FC prodrug is suitable for further human phase I 
studies.
7.5 Conclusion
We have evaluated in vivo the efficacy of O n c o v e x ^ 7 \ . L V / C D  our previously developed rat 
orthotopic bladder tumour model. OncoVex^^^^^^ intravesical therapy Avith the combined 
transduction of viral fusogenic membrane glycoprotein ( G A L V )  and a prodrug activating 
system ( C D )  in the presence of 5 - F C  prodrug led to enchanced local tumour control within the 
bladder. Therefore OncoVex^^^^^^ intravesical therapy is a promising alternative therapeutic 
option in the future.
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8 Final discussion
In the UK approximately 12,000 new cases of bladder cancer are diagnosed every year 
making it the fifth commonest cancer in men and the eleventh commonest cancer in women. 
Approximately 80% of these cases are non muscle invasive bladder cancer (NMIBC) defined 
as stage Ta-Tl, grade 1-3 and carcinoma in situ. Current guidelines suggest that all patients 
with non muscle invasive bladder cancer should receive one immediate post operative 
instillation of chemotherapy Avithin 6 hours after TURBT. Further treatment depends on the 
patients' risk of recurrence and progression to muscle invasive disease (Sylvester, van der 
Meijden et al. 2006). For low risk group patients no further treatment is recommended prior to 
a subsequent recurrence (Hall, Parmar et al. 1994; EAU April 2008). For the high risk group 
patients a further transurethral resection (re-TURBT) and 1-3 years of maintenance BCG 
(bacillus Calmette-Guérin) intravesical immunotherapy is recommended (EAU April 2008). 
Patients with intermediate risk NMIBC form a heterogeneous group with varying risks of 
recurrence and progression. All patients in this group would benefit ftom one immediate 
instillation of intravesical chemotherapy after TURBT, but require further intravesical therapy 
to minimize the risk of recurrence and progression. There is no clear consensus as to the 
optimal type, schedule and duration of such therapy. At present, efforts are focused on 
defining the optimum period for intravesical chemotherapy maintenance and reducing the 
side-effects of BCG (Horvath and Mostafid 2009). Despite current operative and 
postoperative treatment options there is recurrence rate of 15-61% and significant risk of 
progression (1-17%).
Gene therapy strategies have been developed as a therapeutic approach for a number of 
malignances. Cancer gene therapy is the introduction of DNA or RNA which cause cellular 
changes that inhibit the uncontrolled groAvth of tumour cells. To achieve the delivery of the 
transgene to the tumour cells several viral and nonviral vectors have been developed. Gene
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transfer by viral vectors takes the advantage of the natural ability of viruses to enter cells and 
express transgenes by the infected cells. The bladder represents an ideal target for intravesical 
gene therapy in the management of bladder cancer. The vectors are in direct local tumour 
contact, eliminating the difficulties associated with systemic administration and ensuring a 
low risk of gene transfer to other organs.
We have tested the OncoVex^^^^^° virus which is a modified oncolytic herpes simplex virus. 
The most important factor in defining oncolytic vectors is whether they can replicate in and 
destroy human tumour cells. Receptors for viral entry must be expressed on the target tumour 
cells. Ideally the wild-type virus should cause no disease or a mild, well characterised human 
or animal disease. The availability of drug treatment is also an advantage. OncoVex^"^^^^^ is 
deleted for ICP34,5 region to provide tumour selective replication and also deleted for the 
ICP47 region to increase antigen presentation and the antitumor immune response. The 
OncoVex^^^^^^ virus carries a highly potent prodrug activating gene for suicide gene 
therapy (Fcyifur gene = cytosine deaminase enzyme gene, the enzyme which converts 5- 
fluorocytosine (5-FC) to active 5-fiuorouracil (5-FU)) and a fusogenic glycoprotein gene 
(GALV). OncoVEX®'^^^^^ expresses the envelope of GALV minus the R - peptide under the 
CMV promoter and CD expresses FcyxFur under the RSV promoter. OncoVex®"^^^^^ has 
shown enhanced local tumour control by combining its oncolytic activity with the expression 
of a highly potent pro-drug activating gene and a fusogenic glycoprotein firom gibbon ape 
leukemia virus. Effective use (enhanced cell killing and tumour shrinkage) of 
OncoVex^^^^^^ vector has been previously described in vitro and in vivo ) (Simpson, Han et 
al. 2006) at other tumour sites (eg. COLO 205, HCT 116, CAP AN-1, HT 1080, U87-MG, 
CALU-1) but not the bladder. A version of this virus expressing GM-CSF has shown 
promising results in Phase I (Hu, Coffin et al. 2006) and II clinical trials.
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The present thesis aimed to test in vitro and in vivo the OncoVex^'^^^^^ as an intravesical 
therapy for NMIBC and to test the efficacy of the virus in combination Avith current 
chemotherapies.
One of the approaches for cancer gene therapy is the transduction of tumour cells Avith viral 
fusogenic membrane glycoproteins (FMG) (Bateman, Bullough et al. 2000). A number of 
different viruses kill their target cells by causing fusion betAveen infected and non-infected 
cells, via the interaction betAveen the viral envelope with its receptor. Transduction of viral 
membrane glycoproteins into human tumour cells has been shoAvn to induce cell to cell fusion 
and formation of lethal multi-nucleated syncytia (Sodroski, Goh et al. 1986; Cathomen, Naim 
et al. 1998). The cytotoxic activity of three envelope genes from different groups of viruses 
was originally evaluated (Bateman, Bullough et al. 2000), these include the rhabodoviral 
VZV-G envelope gene, the combination of F and H genes from measles virus and a mutated 
version of the retroviral Gibbon Ape Leukaemia Virus (GALV env R-) (Bateman, Bullough et 
al. 2000). In this early in vitro study all three membrane proteins showed a high level of cell 
killing, with GALV enw R- shoAving the highest killing. Recruitment of bystander cells into 
the syncytium occurs by a process that appears to involve the organization of incoming nuclei 
along actin and microtubule bundles, such that large numbers of nuclei are localized close 
together. Later, adjacent nuclei can fuse together, but classic features of apoptosis, such as 
nuclear condensation or fragmentation and caspase activity are not detected (Higuchi, Bronk 
et al. 2000; Bateman, Harrington et al. 2002). In GALV env R- treated tumours several 
immune stimulatory molecules were detected associated Avith a stress response, such as heat 
shock proteins (Melcher, Todryk et al. 1998) the NK cell receptor (Groh, Steinle et al. 1998) 
and murine IFN-y. This suggests that the immune system may partly contribute to the mode of 
action of GALV env R- even in immuno-compromised animals such as nude mice. The 
problems of expression were solved by eneoding GALV env R- in HSV, initially inserted into
173
strain G207 (Fu, Tao et al. 2003) and later a second generation virus OncoVEX^^^ 
(Simpson, Han et al. 2006). The expression of GALV env R- caused syncytia formation in 
tumour cells of a variety of origins including from colon, brain, pancreas, lung, liver, prostate 
and connective tissue cancers (Fu, Tao et al. 2003; Simpson, Han et al. 2006). This fusogenic 
property also translated into a significantly increased tumour cell killing as compared to 
previous versions of oncolytic HSV vectors (Fu, Tao et al. 2003; Simpson, Han et al. 2006). 
Our in vitro studies using different bladder tumour cell lines showed that OncoVEX^^^^^^ 
increases tumour killing in over half of the bladder cancer cell lines compared to backbone 
virus alone. We have detected fusogenic activity by both MTS and fixing/staining of infected 
cells. We can therefore conclude from this study that expression of the truncated retroviral 
envelope GALV env R- greatly improves the dose response of the OncoVex^^^ backbone in 
bladder tumour cell lines. The presence of Pit-1 receptor as a GALV receptor has not been 
described yet in the literature in bladder cancer cell lines. Although all cell lines tested by our 
group were transitional cell type of bladder cancer it is very likely that there is a difference 
between them in the presence of Pit-1 which may have an important role. In conclusion the 
results indicate that the transduction of bladder tumour cells with viral fusogenic membrane 
glycoprotein (GALV) is new and effective approach for bladder cancer gene therapy in vitro 
using the OncoVEX^^^^^^ virus.
Anoher approach for cancer gene therapy is prodrug activation, where the delivered gene 
converts non-toxic prodrugs into active chemotherapeutic agents. A systemically administered 
prodrug can be converted into high local concentrations of an active anticancer drug in the 
tumour. An ideal prodrug system will have a bystander effect; that is the ability to kill non­
expressing neighbouring tumour cells by the export of toxic metabolites. A commonly utilised 
enzyme prodrug combination is the E-coli /yeast enzyme cytosine deaminase (CD) and 5- 
fluorocytosine (5-FC). CD deaminates the anti-fungal compound 5-fluorocytosine (5-FC) into
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5-fluorouracil (5-FU), a highly toxic compound, widely used as a cancer chemotherapeutic 
agent (Moolten 1994). This enzyme has been found in prokaryotes and lower eukaryotes, but 
appears to be absent in higher eukaryotes (Kilstrup, Meng et al. 1989; Austin and Huber 
1993). It has been reported that the E. coli uracil phosphoribosyltransferase (UPRT) can 
markedly potentiate the anti-tumour effects of 5-FU by converting it directly into its 
intermediary 5-FUMP, thereby leading to more efficient generation of its active metabolites 
5-FdUMP and 5-FUTP (Tiraby, Cazaux et al. 1998). A construct containing a fusion between 
the yeast Fey 1 and Fur 1 genes encoding cytosine deaminase and uracil 
phosphoribosyltransferase, respectively, is commercially available {Invivogen) and an 
identical chimera (FcyrFur) has been described (Erbs, Régulier et al. 2000). OncoVEX^^^^^^ 
expressing both a highly potent version of CD (FcyxFur) and the fusogenic glycoprotein from 
gibbon ape leukaemia virus (GALV). In the presence of 5-fluorocytosine (5-FC), 
OncoVEX^^^^^^ showed greatly improved tumour contol in vitro and in vivo (Simpson, Han 
et al. 2006).
Our in vitro studies showed that the expression of the FcyiFur gene within the HSV-1 
backbone vector promotes active metabolism of 5-FC into 5-FU and further into its 
metabolites, resulting in tumour cell killing in five out of seven bladder tumour cell lines. A 
recent proteomic study on colorectal adenocarcinoma cells transfected Avith cytosine 
deaminase in the presence of 5-FC, has shoAvn an upregulation of a Avide range of proteins 
involved in resistance to anticancer drugs and resistance to apoptosis (Negroni, Samson et al. 
2007). Examples of some of the genes that are upregulated include the antioxidative gene 
thioredoxin-like 2 protein (Powis, Mustacieh et al. 2000), aldehyde dehydrogenase (Di Paolo, 
Danesi et al. 2004), dihydropyrimidine-related protein 2 (Nyhan 2005) and Ezrin (Fais 2004). 
From this study we can hypothesize that some of the drug resistance genes up-regulated in 
colorectal adenocarcinoma cells expressing CD/5-FC, may be also up-regulated in bladder
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TCC carcinoma cell lines. In conclusion the results indicate that the transduction (by an 
oncolytic HSV) of bladder tumour cells with prodrug activating (CD) gene in the presence of
5-FC led to enhanced tumour control in vitro. We can also concltide from the summary of 
results that all human bladder tumour cell lines tested are susceptible to HSV oncolysis and 
showed enhanced tumour cell killing in at least one type (fusion or prodrug) of the assays 
when infected Avith OncoVEX*^^^^^^ virus. The combination of oncolytic transduction of 
bladder tumour cells with viral fusogenic membrane glycoprotein (GALV) and a prodrug 
activating system (CD) can further increase tumour control, and therefore it is a new and 
effective approach against bladder cancer.
It is well accepted that one single therapy is unlikely to cure a particular cancer since evidence 
from conventional therapies suggests that a combination of therapies is much more likely to 
work in the clinic. The combination of new treatment modalities, such as the gene therapy 
with the conventional therapies (chemotherapy, radiotherapy) might be a promising 
alternative therapeutic option. Mullerad et al tested the strain of HSV called NV1066 in 
combination Avith MMC in KU19-19 and SKUB cell lines and they found significantly 
improved cell kill for the combination treatment (Mullerad, Bochner et al. 2005). We have 
tested the efficacy of Oncovex^T^LV/CD in combination with conventional chemotherapies 
such as mitomycin, cisplatin, gemcitabine on human bladder tumour cell lines. The effect of 
OncoVex^^^^^^ treatment in combination Avith chemotherapies on cell proliferation was 
assessed by calculating combination index values using CalcuSyn software. Our results 
showed synergistic effect when OncoVEX^^^^^^ was combined with mitomycin whereas the 
combination effect of Onco VEX^^^^^^ with cisplatin or gemcitabine was antagonistic. 
Gemcitabine is a cytotoxic pyrimidine deoxynucleoside analogue and its triphosphate 
analogue replaces one of the nuclosides to be incorporated into growing DNA strands and 
therefore acts as a chain terminator to stop DNA polymerase (Blackstock, Lightfoot et al.
176
2001). The process arrests tumour growth, resulting in apoptosis (Blaekstock, Lightfoot et al. 
2001). The majority of drugs used in the clinical treatment of HSV-1 related diseases target 
the viral DNA polymerase activity by also acting as a nucleoside analogue inhibitor. It is 
possible that gemcitabine causes chain termination of both viral and host DNA which results 
in the failure of replication of the virus and synergy between this chemo agent and oncolytic 
HSV-1. Cytotoxicity of cisplatin is mediated through platinum-DNA adducts, resulting in 
apoptosis and cell cycle arrest (Boulikas and Vougiouka 2003). Adusumilli et al (Adusumilli, 
Chan et al. 2006) showed that high-dose cisplatin caused not only toxicity but also a high 
apoptotic cell fraction, which hindered HSV-1 oncolysis by limiting viral replication 
(Stanziale, Petrowsky et al. 2004). Other investigators have shown that cisplatin did not 
inhibit the efficacy of replication-competent HSV in the treatment of head and neck squamous 
cell carcinoma and in non-small cell lung cancer (Chahlavi, Todo et al. 1999; Toyoizumi, 
Miek et al. 1999). Mitomycin C is an antibiotic that is a potent cross-linker of DNA and has 
widely been used in cancer chemotherapy (Tomasz 1995). DT-diaphorase can occupy a 
central role in MMC metabolic activation since it is often highly overexpressed in cancer cells 
(Cummings, Spanswick et al. 1998). Mitomycin C cross-links in a specific DNA sequence 
manner, its target being CpG sites. A hypothesis could be that the HSV genome lacks the 
target CpG and therefore does not inhibit the cross-linker effects of mitomycin C. Mitomycin 
C induces the expression of GADD34 (growth arrest and DNA damage -inducible protein) 
(Chou and Roizman 1994; Hollander, Zhan et al. 1997). There is great homology between the 
carboxyl terminus of the mammalian GADD34 gene and the viral ICP34.5 (Chou and 
Roizman 1994). The synergy between oncolytic HSV and mitomycin C maybe due to the up 
regulation of GADD34, which aids viral tumour replication.
Our results showed synergistic effect when OncoVEX^^^^^î^ was combined with mitomycin 
C. The synergistic interaction between OncoVEX^^^^^^ and MMC may provide an
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opportunity to eradicate bladder cancer microscopic deposits that each agent alone at 
acceptable dosage cannot reach. The combined effect of OncoVEX^^^^^^ with cisplatin or 
gemcitabine was but it was not related to the implanted GALV and CD genes as the backbone 
OncoVEX^^^ virus showed antagonistic effect as well. In order to evaluate the mechanism of 
interaction between OncoVEX^^^^^^ and cisplatin or gemcitabine further experiments are 
needed.
An animal tumour model that resembles human disease both histologically and in behaviour is 
essential for preclinical evaluation of new treatment modalities. A rat model, because of its 
size, is easier to work with for intravesical therapies and, furthermore, it may parallel the 
human disease processes better than a mouse model (Ohtani, Kakizoe et al. 1986; Oyasu 
1995). In our experiments we used a technique to develop a rat ortothopic bladder tumour 
model that was described by Xiao at al in 1999 (Xiao, McCallum et al. 1999). Using the AY- 
27 cell line they have developed and characterized a highly reproducible, transplantable, 
purely TCC rat orthotopic bladder tumour model. The fact that tumour cells used for 
intravesical instillation originated from cell cultures rather than directly from solid tumour 
fragments, might contribute to the high tumour establishment observed. To facilitate tumour 
seeding, the bladder mucosa was conditioned with an acid rinse and neutralized Avith 
potassium hydroxide. The assesment of tumour groAvth is very important in an animal model. 
Cytoscopy (Hendricksen, Molkenboer-Kuenen et al. 2008), urine cytology (Gronlund- 
Pakkanen, Wahlfors et al. 2003), tumour markers, ultrasound (Rooks, Beecken et al. 2001), 
MRI (Mazurchuk, Glaves et al. 1997); Q-PCR (Kikuchi, Meneridez et al. 2007), 
bioluminescence imaging (Ray 2007) were all studied in the literature. After virion adsorption 
to cell surface proteoglycans, gD binds to one of its receptors, herpesvirus entry mediator 
(HVEM), nectin-1 (HveC), or 3-0-sulfated heparan sulfate (3-0-S HS) (Montgomery, Warner 
et al. 1996; Geraghty, Krummenacher et al. 1998; Shukla, Liu et al. 1999). Although HSV
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viruses have been shown to infect a wide range of human and animal tumour cells, but AY-27 
rat bladder tumour cells are rare exceptions in failing to support HSV entry and/or replication. 
To overcome this problem AY-27 cells were stably transfected with the herpesvirus entry 
receptor (HVEM). After the transfection our in vitro fusion assay results showed increased 
tumour cell killing with OncoVex^^^^^^ compared to the OncoVex^^^ control. AY-27 
HVEM cells were further tested in our prodrug assay. We can conclude from these in vitro 
experiments that expression of the FcyiFur gene within the OncoVex^^^^^^ promotes active 
metabolism of 5-FC into 5-FU and further into its metabolites, resulting in tumour cell killing 
in AY-27HVEM cells.
We planned to use QRT-PCR to demonstrate the presence of the HVEM receptor of the AY- 
27 rat bladder tumour cells as a marker for tumour load. However while we obtained positive 
signals on bladder tissue QRT-PCR, signals using urine samples were insignificant, therefore 
tumour groAvth was detectable by QRT-PCR only on bladder tissue samples. As another 
option we planed to use a bioluminescence imaging technique that has become a very popular 
tool for noninvasive monitoring of fundamental biological and molecular processes in small 
living subjects. The non-invasive IVIS camera can detect the luciferase activity of the 
implanted tumours. We have cloned a new AY-27 bladder tumour cell line that contains both 
HVEM receptor and luciferase activating gene. Unfortunately our experiments showed that 
the implanted AY-27 tumours expressing luciferase regress after a period growth. We think 
this tumour regress may be due to immune responses to the luciferase (insect) proteins. This 
view is support by the fact that the majority of IVIS bioluminescence imaging studies are 
carried out on nude mice which have a deletion of thymus function resulting greatly reduced 
number of T cells. Therefore nude mice are unable to mount most types of immune responses, 
which results them fail to reject xenograft tissue. Fischer F344 rats (inbred) on the other hand 
have a fully competent immune system, which do not reject wild type AY-27 cells due to the
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fact that the tumour cells are derived from the same strained of mice. But the Fischer F344 
rats must make specific immune responses to the insect luciferase protein leading to the 
regress of the tumours. Therefore the non-invasive IVIS bioluminescence imaging camera is 
not suitable to detect tumour growth in this rat orthotopic bladder tumour model. In the future 
we plan to use a non-invasive MRI scanner to detect the tumour development and the effect of 
the different treatment options. In conclusion we have set up a useful rat orthothopic bladder
tumour model to test the effectiveness of the O n c o v e x ^ ^ L V / C D  virus.
OncoVex^"^^^^^ has been found to be effective in treating various experimental cancers while 
maintaining an excellent safety profile. Simpson et al. have showed in vivo the effectiveness 
of OncoVex^"^^^^^ double approach with a significant improvement in a gliosarcoma rat 
flank model (Simpson, Han et al. 2006). Data from our current experiments in a well- 
accepted, orthotopic rat bladder model confirm safety, efficacy, and ease of delivery of 
oncolytic viral therapy for experimental treatment of bladder cancer. OncoVex^^^^^^ virus, 
when administered with prodrug weekly for 3 weeks by intravesical instillation, was clearly 
more effective than control or virus alone at reducing tumor burden. In these experiments, 
treated animals continued to groom themselves and behave normally, no adverse events were 
noted, and there were no treatment-related deaths. However, these oncolytic viruses will 
likely be more efficacious in vivo in humans because HSV are human viruses and human 
tumours are significantly more susceptible to their effects than murine tumours (Cozzi, 
Malhotra et al. 2001). Our results suggested that OncoVex^"^^^^^ intravesical therapy in the 
presence of 5-FC prodrug is suitable for further human phase I studies.
In conclusion our results on human bladder carcinoma cell lines and rat orthotopic bladder 
tumour model indicate that OncoVex^^^^^^ may improve local tumour control within the 
bladder and it can be used in combination with mitomycin. It is hoped that this will lead to 
new therapeutic option for bladder cancer.
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The current work has raised questions that would be the basis of our future work. In the in 
vitro part (fusion and prodrug assay) we plan to extend the number of tested cell lines and also 
test other histological type of bladder cancer than TCC. We plan to repeat our prodrug assay 
with more concentrations of administered 5-FC to be able to accurately evaluate the IC50 
levels for each cell line. Further combination therapy studies are needed Avith other 
chemotherapeutic agents (epirubicin, doxorubicin) and Avith immunotherapy (BCG) as we 
would plan to test OncoVex^^^^^^ as a potential treatment for NMIBC. We plan to further 
study the mechanism of the OncoVex^^^^^^ virus (presence of Pitl receptor in bladder 
cancer, proteomic study). Using the rat orthotopic bladder model we plan to use a non- 
invasive MRI or CT imaging technique in order to monitor tumour groAvth and prove 
therapeutic effect of OncoVex^^^^^^ during the treatment. With an immune-competent rat 
orthotopic bladder model it was necessary to use a non-human cell line, which required 
transfection of a viral receptor-encoding construct, and raises questions regarding immune 
response against luciferase transgene expression. In chapter 6 we discussed more in details 
why had chosen a rat immune-competent model (absecnce of pitl receptor in mice). 
Therefore we plan to study OncoVex^^^^^^ on an immune-deficient rat model as well to 
overcome these problems.
According to the literature gene therapy using viral vectors seems to be a promising tool in 
the field of oncotherapy. Several phase I-III ongoing studies shows that this is one of the 
burning issues in cancer therapy. In bladder cancer there are many published in vitro and in 
vivo studies using different vectors and different therapeutic genes, and all have pros and cons 
as we discussed in the introduction part of the thesis. Unfortunately, to date there have been 
few clinical trials of gene therapy for bladder cancer. It is also worth noting that a version of 
this virus expressing GM-CSF has shoAvn promising results in phase I and II (Hu, Coffin et al. 
2006; Senzer, Kaufman et al. 2009) Avith limited toxicity to patients and is currently in phase
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Ill clinical trials. Once we finish our in vitro and in vivo studies we plan to set up a phase I 
trial with OncoVex^^^^^^. The planned treated group would be medium risk NMIBC 
patients in combination with currently used chemotherapies and probably high risk patients in 
combination with BCG.
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